



## Review

## Antibiotic exposure and adverse long-term health outcomes in children: A systematic review and meta-analysis

Quynh A Duong<sup>a</sup>, Laure F Pittet<sup>b,c,d,e</sup>, Nigel Curtis<sup>b,c,d</sup>, Petra Zimmermann<sup>a,c,f,\*</sup><sup>a</sup> Department of Community Health, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland<sup>b</sup> Department of Paediatrics, The University of Melbourne, Parkville, Australia<sup>c</sup> Infectious Diseases Research Group, Murdoch Children's Research Institute, Parkville, Australia<sup>d</sup> Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, Australia<sup>e</sup> Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland<sup>f</sup> Department of Paediatrics, Fribourg Hospital, Fribourg, Switzerland

## ARTICLE INFO

## Article history:

Accepted 4 January 2022

Available online 10 January 2022

## Keywords:

Allergies

Asthma

Atopy

Eczema

Abdominal pain

Overweight

Obesity

Arthritis

Autism spectrum disorder

ADHD

Psoriasis

Inflammatory bowel disease

Celiac disease

Diabetes

## SUMMARY

**Background:** Antibiotics are amongst the most commonly used drugs in children. In addition to inducing antibiotic resistance, antibiotic exposure has been associated with adverse long-term health outcomes.

**Methods:** A systematic search using PRISMA guidelines to identify original studies reporting associations between antibiotic exposure and adverse long-term health outcomes in children. Overall pooled estimates of the odds ratios (ORs) were obtained using random-effects models.

**Results:** We identified 160 observational studies investigating 21 outcomes in 22,103,129 children. Antibiotic exposure was associated with an increased risk of atopic dermatitis (OR 1.40, 95% confidence interval (CI) 1.30–1.52,  $p < 0.01$ ), allergic symptoms (OR 1.93, 95%CI 1.66–2.26,  $p < 0.01$ ), food allergies (OR 1.35, 95%CI 1.20–1.52,  $p < 0.01$ ), allergic rhinoconjunctivitis (OR 1.66, 95%CI 1.51–1.83,  $p < 0.01$ ), wheezing (OR 1.81, 95%CI 1.65–1.97,  $p < 0.01$ ), asthma (OR 1.96, 95%CI 1.76–2.17,  $p < 0.01$ ), increased weight gain or overweight (OR 1.18, 95%CI 1.11–1.26,  $p < 0.01$ ), obesity (OR 1.21, 95%CI 1.05–1.40,  $p < 0.01$ ), juvenile idiopathic arthritis (OR 1.74, 95%CI 1.21–2.52,  $p < 0.01$ ), psoriasis (OR 1.75, 95%CI 1.44–2.11,  $p < 0.01$ ), autism spectrum disorders (OR 1.19, 95%CI 1.04–1.36,  $p = 0.01$ ) and neurodevelopment disorders (OR 1.29, 95%CI 1.09–1.53,  $p < 0.01$ ). Dose-response effects and stronger effects with broad-spectrum antibiotic were often reported. Antibiotic exposure was not associated with an altered risk of allergic sensitisation, infantile colic, abdominal pain, inflammatory bowel disease, celiac disease, type 1 diabetes, fluorosis, and attention deficit hyperactivity disorder.

**Conclusion:** Although a causal association cannot be determined from these studies, the results support the meticulous application of sound antibiotic stewardship to avoid potential adverse long-term health outcomes.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.

This is an open access article under the CC BY-NC-ND license

<http://creativecommons.org/licenses/by-nc-nd/4.0/>

## Introduction

Antibiotics belong to the greatest discoveries in medicine and amongst the most life-saving medical interventions. Their efficacy and presumed safety have led to their widespread use, which sometimes is irrational or even inappropriate.<sup>1–3</sup> In infants and children, antibiotics are amongst the most commonly used drugs. In many settings, more than two-thirds of children receive

antibiotics before reaching the age of two years and, on average, more than half of all children receive at least one antibiotic each year with the highest rate in the second year of life.<sup>4,5</sup>

The reduction in the incidence of infectious diseases in many countries over the last few decades has been paralleled by a dramatic rise in the prevalence of immune-mediated diseases, including allergic diseases, inflammatory bowel diseases (IBD), rheumatological diseases and diabetes mellitus.<sup>6–8</sup> The 'hygiene hypothesis' proposes that decreased microbial exposure explains the rise in immune-mediated diseases.<sup>9</sup> It is likely that the overuse of antibiotics contributes to this.<sup>10</sup>

\* Corresponding author at: Department of Community Health, Faculty of Science and Medicine, University of Fribourg, Fribourg, Route des Arsenaux 41, Fribourg 1700, Switzerland.

E-mail address: [petra.zimmermann@unifr.ch](mailto:petra.zimmermann@unifr.ch) (P. Zimmermann).

In this systematic review and meta-analysis, we summarise studies that have investigated the association between antibiotic exposure and adverse long-term health outcomes in children.

### Systematic review methods

To identify original studies investigating the association between antibiotic exposure and adverse long-term health outcomes in children and adolescents (less than 18 years of age) MEDLINE (1946 to present) was searched in April 2021 using the Ovid interface with the search terms detailed in the supplementary data. Exclusion criteria were studies in which: (i) the effect of prenatal antibiotics was investigated; (ii) the timing of antibiotic exposure was not specified; (iii) antibiotic exposure occurred after the onset of the adverse health outcome and (iv) included preterm infants without adjusting values for prematurity. References of retrieved articles were hand-searched for additional publications. The following variables were extracted from the included studies: author, country, publication year, study design, cohort size, time of antibiotic exposure, specification of antibiotic treatment, age at outcome measure, number of cases, outcome definition and key findings. Review Manager (version 5.3) was used for the calculation of the odds ratios and the meta-analyses. If studies evaluated several time points, only the latest was included in the meta-analysis. Diversity in study design and reporting, which might result in selection and reporting bias, precluded quality evaluation according to the PRISMA guidelines. The ROBINS-1 tool was used to assess risk of bias.<sup>11</sup>

### Systematic review results

Our search identified 23,225 studies. Of these, 150 fulfilled the inclusion criteria.<sup>12–161</sup> An additional 10 relevant studies were identified by hand searching of references.<sup>162–171</sup> The selection of studies is summarised in Fig. 1. The 160 studies included in this review investigated 21 outcomes in 22,103,129 children; 159 were observational studies (23 registry-based studies, 69 cohort studies, 34 cross-sectional studies, 11 case-control studies, and 22 retrospective studies) and one was a secondary analysis of data from a randomised control trial;<sup>45</sup> 145 of the studies were done in industrialised countries. The number of participants in each study ranged from 50 to 9,400,000 (median 3944, mean 138,146). Exposure to antibiotics was captured through registries, medical and prescription records or parent questionnaires; studies included any course of antibiotic received, antibiotic exposure during an early-life period (e.g. first week, months or first years of life) or during a certain time before diagnosis. Outcomes were defined by validated questionnaires, diagnostic codes, parent-reported symptoms, or diagnosis, or clinical or laboratory evaluation. The results of these studies are summarised in Table 1. In addition to the overall antibiotic exposure, 17 studies investigated the effect of the number of antibiotic courses received, 17 studies compared the effect of different types of antibiotics and 41 studies both. The risk of bias summary of studies included in the review can be found in Supplementary Table 2.

#### Atopic dermatitis

Forty studies in 1,602,639 children (183,244 cases with one study not reporting number of cases) investigated the association between antibiotic exposure and the risk of developing atopic dermatitis, evaluated by the International Study of Allergy and Asthma in Childhood (ISAAC) questionnaire, international classification of disease (ICD) codes, parent-reported symptoms or physician's diagnosis, the Criteria by the American Academy

of Dermatology, Hanifin and Rajka criteria or William's criteria (Table 1).<sup>32,37,40,43,48–51,53,62,79,80,82,93,96,98,103,105,114,120,123,129,135,150,153–155,157,161,162,172–181</sup> Of the 40 studies, 38 (95%) investigated the effect of antibiotic exposure in the first five years of life (36 (90%) in the first two years of life).<sup>32,37,40,43,48–51,53,62,79,80,82,93,96,98,103,105,114,120,123,129,135,150,153,157,161,162,172–181</sup> Overall, 26 (65%) studies reported a significantly increased incidence of atopic dermatitis in children who were exposed to antibiotics.<sup>37,40,48–51,53,62,82,93,96,103,120,123,129,150,153,157,161,172,173,175,176,179–181</sup>; However, in two studies the incidence atopic dermatitis was higher only if exposed to two or more courses of antibiotics.<sup>123,180</sup> In contrast, two studies (5%) reported a decreased incidence in children who were exposed to antibiotics.<sup>40,51</sup> Five studies reported that the risk of atopic dermatitis increased with the number of antibiotic courses.<sup>32,93,103,123,176</sup> One study, however, did not find an association between the number of antibiotic courses and the risk of atopic dermatitis.<sup>182</sup> Four studies compared the effect of different antibiotic classes.<sup>123,157,172,182</sup> One study reported that the risk of atopic dermatitis increased after exposure to cephalosporins and macrolides, but not after exposure to penicillins<sup>123</sup>; one study after amoxicillin but not penicillin, amoxicillin/clavulanic acid, macrolides or cephalosporins,<sup>182</sup> one study after macrolides<sup>157</sup> and the last study reported an increased risk in girls after exposure to cephalosporins but a decreased risk after exposure to macrolides.<sup>172</sup>

Of the 40 studies, 32 (80%) provided sufficient data to be included in the meta-analysis (supplementary Fig. 1).<sup>32,37,40,43,48,49,51,53,62,79,80,82,93,96,103,105,114,120,123,135,153,154,157,161,162,172–174,176,178,180,181</sup> Of the 309,828 children exposed to antibiotics 51,543 (17%) developed atopic dermatitis compared to 105,587 (14%) of 766,331 children not exposed to antibiotics. The overall odds ratio (OR) for developing atopic dermatitis after antibiotic exposure was 1.40, 95% confidence interval (CI) 1.30 to 1.52,  $p < 0.01$  (Fig. 2).

#### Allergic sensitisation

Twenty-three studies in 34,806 children (8952 cases) investigated the association between antibiotic exposure and the risk of developing allergic sensitisation diagnosed by skin prick test or serum immunoglobulin (Ig) E levels (Table 1).<sup>24,40,43,49,60,70,79,80,82,87,93,105,116,126,135,153,175–178,181,183,184</sup> Of the studies, 21 (91%) investigated the effect of antibiotic exposure in the first five years of life (18 (78%) in the first two years of life).<sup>24,40,43,49,60,70,79,80,82,93,105,116,126,135,153,175–178,181,183</sup> Four (17%) reported a significant increased incidence of allergic sensitisation in children who were exposed to antibiotics.<sup>87,116,181,183</sup> In contrast, one study (4%) reported a decreased incidence of allergic sensitisation in children who were exposed to antibiotics.<sup>40</sup> The one study which investigated if the risk of allergic sensitisation correlated with the number of antibiotic courses found no association.<sup>176</sup>

Of the 23 studies, 18 (78%) provided sufficient data to be included in the meta-analysis (supplementary Fig. 2).<sup>24,40,43,49,70,79,80,82,87,93,105,116,135,153,176,178,181,183</sup> Of the 12,502 children exposed to antibiotics 2582 (21%) developed allergic sensitisation compared to 3642 (22%) of the 16,731 children not exposed to antibiotics. Overall, the evidence did not support an association between antibiotic exposure and developing allergic sensitisation (OR 1.11, 95%CI 0.98–1.26,  $p = 0.05$ ) (Fig. 2).

#### Food allergies

Fifteen studies investigated the association between antibiotic exposure and the risk of developing food allergies







Fig. 1. Selection of studies.



CI – confidence interval H-M – Mantel-Haenszel

Fig. 2. Comparison of incidence of adverse health outcomes in children exposed and not exposed to antibiotics (number of studies in brackets).

**Table 1**  
Summary of studies investigating the effect of antibiotic exposure on health outcomes in children. See Ref. 240

Author Country Publication year	Study type (Level of evidence)	No of cases; cohort size  No of cases in children with antibiotics; no of children with antibiotics  No of cases in children without antibiotics; no of children without antibiotics	Time of antibiotic exposure (age unless otherwise specified)  Antibiotic specified  Evaluation of antibiotic exposure	Age at outcome measure	Outcome definition	Main findings	Factors adjusted for
<b>Atopic dermatitis</b>							
Aversa et al. <sup>172</sup> USA 2021	Multicentre prospective cohort study (2b)	297; 14,572  231; 10,220 66; 4,352	< 2 y  Yes  Medical records	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aHR 1.47 (95%CI 1.12-1.94), p&lt;0.01</b>  Girls • penicillins: HR 1.27 (95%CI 0.87-1.87), p=0.22 • cephalosporins: <b>HR 1.69 (95%CI 1.14-2.52), p=0.01</b> • macrolides: <b>HR 0.59 (95%CI 0.37-0.92), p=0.02</b> • sulfonamides: HR 0.98 (95%CI 0.49-1.96), p=0.95  Boys • penicillins: HR 1.40 (95%CI 0.96-2.03), p=0.08 • cephalosporins: HR 1.29 (95%CI 0.90-1.84), p=0.17 • macrolides: HR 0.83 (95%CI 0.57-1.19), p=0.30 • sulfonamides: HR 1.37 (95%CI 0.75-2.51), p=0.30	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode
Zou et al. <sup>161</sup> China 2020	Multicentre cross-sectional study (3b)	2,752; 12,667  772; 3,049 1,980; 9,618	< 1 y  No  Parent questionnaire	4-6 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.17 (95%CI 1.05-1.31), p&lt;0.01</b>	Age, sex, living area, family history of atopy, breastfeeding, home decoration, pet, smoke and home dampness-related exposure

(continued on next page)

Table 1 (continued)

Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	301; 1,185	< 1 y	12-36 m	Criteria by American Academy of Dermatology	Exposure to AB in first y of life associated with increased risk in urban cohort.	
South-Africa		182; 654	No				
2020		119; 531					
		8; 398	Parent questionnaire				
		7; 347					
		1; 51					
Rutter et al. <sup>120</sup>	Multicentre cross-sectional study (3b)	15,152; 120,799	< 1 y	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Sex, maternal education and smoking; medication use, open fire cooking
UK		13,108*; 97,631	No				
2019		2,044*; 23,168	Parent questionnaire				
Metzler et al. <sup>93</sup>	Multicentre prospective cohort study (2b)	275; 1,019	< 1 y	< 6 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.	Sex, family history of atopy, number of siblings, living area, smoking and pet exposure during pregnancy; delivery mode, duration of breastfeeding, pet exposure
Switzerland		154; 419	No				
2019		121; 600	Parent questionnaire				
Gao et al. <sup>51</sup>	Single-centre prospective cohort study (2b)	226; 903	< 1 y	12 m	Parent-reported atopic dermatitis symptoms	Exposure to AB in first y of life associated with decreased risk.	Sex, family history of atopy, antibiotic use during pregnancy, season of birth, egg and milk consumption
China		26; 184	No				
2019		200; 719	Parent questionnaire				
Ho et al. <sup>62</sup>	Multicentre cross-sectional study (3b)	2,625; 23,908	< 1 y	6-8 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Sex, number of siblings, number of LRTIs, duration of breastfeeding, timing of solid food introduction, pet and home dampness-related exposure
Taiwan		562; 3,691	No				
2019		2,063; 20,217	Parent questionnaire				

(continued on next page)

Table 1 (continued)

Norbäck et al. <sup>103</sup>	Multicentre retrospective cohort study (2b)	9,573; 39,782 7,497; 29,303 2,076; 10,479	< 1 y No Parent questionnaire	3-6 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.20 (95%CI 1.11-1.30), p&lt;0.01</b>  • 1 AB course: <b>aOR 1.15 (95%CI 1.07-1.24), p&lt;0.01</b> • > 1 AB courses: <b>aOR 1.45 (95%CI 1.36-1.56), p&lt;0.01</b>	Living area, temperature in each city, time spend outdoors, air pollution
China 2019							
Oosterloo et al. <sup>105</sup>	Multicentre prospective cohort study (2b)	156; 436 57; 151 99; 285	< 1 w No Parent questionnaire	0-1 y	Parent-reported atopic dermatitis symptoms	Exposure to AB in first w of life not associated with increased risk.  • aOR 1.09 (95%CI 0.70-1.70), p=0.70	Family history of atopy, parental education, day care, number of siblings, smoking during pregnancy, delivery mode, duration of breastfeeding, household smoking
Netherlands 2018							
Mitre et al. <sup>96</sup>	Multicentre retrospective cohort study (2b)	112,608; 792,130 21,638; 131,708 90,970; 660,422	< 6 m No Registry	1-6 y	ICD-9-CM codes	Exposure to AB in first 6 m of life associated with increased risk.  • <b>aHR 1.18 (95%CI 1.16-1.19), p=nr</b>	Sex, prematurity, delivery mode, medication (incl. anti-reflux medication) use
USA 2018							
Singh et al. <sup>129</sup>	Multicentre cross-sectional study (3b)	1,249; 44,928 nr; nr nr; nr	< 1 y No Parent questionnaire	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.80 (95%CI 1.60-2.00), p&lt;0.01</b>	
India 2018							
Yamamoto-Hanada et al. <sup>157</sup>	Multicentre prospective cohort study (2b)	194; 902 107; 436 87; 466	< 2 y Yes Parent questionnaire	5 y	Questionnaire for atopic dermatitis symptoms (ISAAC) plus medical records	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aOR 1.40 (95%CI 1.01-1.94), p=0.04</b>  • penicillins: aOR 1.41 (95%CI 0.82-2.43), p=0.22 • cephem: aOR 1.37 (95%CI 0.94-1.99), p=0.10 • macrolides: <b>aOR 1.58 (95%CI 1.07-2.33), p=0.02</b>	Sex, maternal age, BMI education and history of atopy; parity, smoking during pregnancy, gestational age, delivery mode, number of LRTIs, day care
Japan 2017							
Park et al. <sup>174</sup>	Multicentre cross-sectional study (3b)	1,424; 4,003 607; 1585* 817; 2418* 981; 4,112 288; 1090* 693; 3022*	< 1 y No Parent questionnaire	6-7 y 12-13 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk.  • aOR 1.09 (95%CI 0.88-1.39), p=0.70  Exposure to AB in first y of life not associated with increased risk.  • aOR 1.04 (95%CI 0.86-1.34), p=0.70	Age, sex, family history of atopy, living area, atopy
Korea 2016							

(continued on next page)



Table 1 (continued)

Taylor-Robinson et al. <sup>173</sup>	Multicentre prospective cohort study (2b)	3,489; 12,917 1,909; 5,678 1,580; 7,239	< 1 y No Registry	5 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.28 (95%CI 1.16-1.42), p&lt;0.01</b>	Sex, ethnicity, maternal age, BMI, education and history of atopy; maternal smoking and alcohol consumption during pregnancy; day care, number of siblings, birth weight, delivery mode, breastfeeding, timing of solid food and cow's milk introduction, smoke and grime exposure
Loo et al. <sup>175</sup>	Multicentre prospective cohort study (2b)	43; 792 nr; nr nr; nr nr; nr nr; nr	< 6 m No Parent questionnaire	6 m-1 y 1-1.5 y	Parents-reported physician's diagnosis	Exposure to AB in first 6 m of life not associated with increased risk.  • <b>aOR 3.19 (95%CI 0.72-14.11), p=0.13</b>  Exposure to AB in first 6 m of life associated with increased risk.  • <b>aOR 3.11 (95%CI 1.10-8.76), p=0.03</b>	Sex, sibling history of atopy, living area, age of child at outcome
Hoskin-Parr et al. <sup>176</sup>	Single-centre prospective cohort study (2b)	994; 5,780 494*; 2,659 500*; 3,121	< 2 y No Parent questionnaire	7.5 y (mean)	Parents-reported physician's diagnosis	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aOR 1.20 (95%CI 1.02-1.41), p=nr</b>  • 1 AB course: aOR 1.05 (95%CI 0.85-1.29), p=nr • 2 AB courses: aOR 1.23 (95%CI 1.00-1.51), p=nr • 3 AB courses: aOR 1.17 (95%CI 0.93-1.47), p=nr • ≥ 4 AB courses: aOR 1.41 (95%CI 1.14-1.74), p=nr	Age, sex, maternal age and education; parental marital status, home ownership status, difficulty in paying for food, smoking and disinfectant use during pregnancy, gestational age, birth weight, delivery mode, age of child at outcome, breastfeeding, time spend outdoors, pet exposure

(continued on next page)

Table 1 (continued)

Wang et al. <sup>150</sup>	Multicentre prospective cohort study (2b)	19,015; 263,620 nr; 15,663 nr; 247,957	< 1 y Yes Medical records	2-6 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk.  • <b>aHR 1.61 (95%CI 1.53-1.70), p&lt;0.05</b>	Living area, socioeconomic status, healthcare use
Taiwan						Results according to antibiotic class nr	
2013							
Sandini et al. <sup>177</sup>	Single-centre prospective cohort study (2b)	270; 925 nr; nr nr; nr	< 6 m No Parent questionnaire	2 y 5 y	William's criteria	Exposure to AB in first 6 m of life not associated with increased risk.  • OR 1.18 (95%CI 0.77-1.81), p=0.44	
Finland						Exposure to AB in first 6 m of life not associated with increased risk.  • OR 1.20 (95%CI 0.79-1.81), p=0.39	
2011							
Schmitt et al. <sup>123</sup>	Multicentre prospective cohort study (2b)	44; 370 24; 155 20; 215	< 1 y Yes Registry	2 y	ICD-10 codes plus prescription records	Exposure to AB in first y of life associated with increased risk, significant only for ≥ 2 AB courses.  • OR 1.79 (95%CI 0.95-3.37), p=0.07*  • 1 AB course: RR 1.45 (95%CI 0.76-2.75), p=nr • ≥ 2 AB courses: <b>RR 2.11 (95%CI 1.05-4.22), p=nr</b>  • penicillins: RR 0.88 (95%CI 0.37-2.12), p=nr • cephalosporins: <b>RR 1.93 (95%CI 1.07-3.49), p=nr</b> • macrolides: <b>RR 2.15 (95%CI 1.18-3.91), p=nr</b>	
Germany							
2010							
Su et al. <sup>135</sup>	Single-centre prospective cohort study (2b)	134; 424 49; 136 85; 288	< 9 m No Parent questionnaire	1-5 y	Parent-reported physician's diagnosis	Exposure to AB in first 9 m of life not associated with increased risk.  • OR 1.35 (95%CI 0.87-2.07), p=0.18*	
USA							
2010							
Dom et al. <sup>40</sup>	Multicentre prospective cohort study (2b)	243; 670 192; 564 51; 106	< 4 y No Parent questionnaire	< 4 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first 4 y of life associated with decreased risk.  • <b>OR 0.56 (95%CI 0.37-0.85), p&lt;0.01*</b>  Exposure to AB in first y of life not associated with decreased risk. • aOR 0.61 (95%CI 0.36-1.01), p=0.05  Exposure to AB in second to fourth y of life with decreased risk.  • <b>aOR 0.11 (95%CI 0.05-0.23), p&lt;0.01</b>	Sex, maternal age, family history of atopy, day care, number of siblings, parental education, smoking and pet exposure during pregnancy, birth weight, number of LRTIs, breastfeeding, household smoking, pet exposure
Belgium							
2010							

(continued on next page)

Table 1 (continued)

Mai et al. <sup>178</sup>	Single-centre prospective cohort study (2b)	663; 3,306	< 1 y	4 y	Questionnaire for atopic dermatitis symptoms (BAMSE based on ISAAC)	Exposure to AB in first y of life associated with increased risk.	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding
Sweden		318; 1,420	No			• <b>aOR 1.30 (95%CI 1.10-1.50), p=nr</b>	
2010		523; 3,306	Parent questionnaire	8 y		Exposure to AB in first y of life associated with increased risk.	
		255; 1,420				• <b>aOR 1.30 (95%CI 1.10-1.60), p=nr</b>	
		268; 1,886					
Garcia-Marcos et al. <sup>53</sup>	Multicentre retrospective case-control study (3b)	922; 13,325	< 1 y	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Age, sex, number of siblings, living area, maternal education and smoking; pet and traffic exposure
Spain		589; 6,831	No			• <b>aOR 1.66 (95%CI 1.43-1.92), p&lt;0.01</b>	
2010		333; 6,494	Parent questionnaire				
Karimi et al. <sup>162</sup>	Multicentre cross-sectional study (3b)	90; 1,476	< 1 y	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk.	
Iran		63; 952*	No			• OR 1.30 (95%CI 0.79-2.13), p=0.20	
2009		27; 524*	nr				
Foljaki et al. <sup>50</sup>	Multicentre retrospective cross-sectional study (3b)	nr; 193,412	< 1 y	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Sex, language, living area, income
Sweden		nr; 135,775	No			• <b>aOR 1.58 (95%CI 1.33-1.51), p=nr</b>	
2009		nr; 57,637	Parent questionnaire				

(continued on next page)

Table 1 (continued)

Wickens et al. <sup>153</sup>	Multicentre prospective cohort study (2b)	398; 1,064 52*; 148 346*; 916	< 3 m No Parent questionnaire	15 m	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first 3 m of life not associated with increased risk.  • aOR 0.84 (95%CI 0.57-1.22), p=0.35	Number of LRTIs
New Zealand 2008		305; 1,011 242*; 722 63*; 289	< 15 m 4 y			Exposure to AB in first 15 m of life associated with increased risk.  • aOR 1.75 (95% CI, 1.03-2.96), p=0.04	
Kusel et al. <sup>80</sup>	Multicentre prospective cohort study (2b)	62; 198 37*; 107 25*; 91	< 1 y Yes Parent questionnaire	0-5 y	Hanifin and Rajka criteria	Exposure to AB in first y of life not associated with increased risk.  • aOR 1.50 (95%CI 0.70-3.30), p=nr  Results according to antibiotic class nr	Sex, day care, number of GP visits, pet exposure
Australia 2008							
Kummeling et al. <sup>79</sup>	Multicentre prospective cohort study (2b)	817; 2,462 145; 489 672; 1,973	< 6 m No Parent questionnaire	< 2 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first 6 m not associated with increased risk.  • aOR 0.94 (95%CI 0.75-1.18), p=nr	Sex, family history of atopy, day care, number of siblings, delivery mode, vaccination status, fever, breastfeeding, pet and smoke exposure
Netherlands 2007							
Mullooly et al. <sup>98</sup>	Single-centre retrospective case-control study (3b)	58; 844 nr; nr nr; nr	< 2 y No Medical records	10.3 y (mean)	Parent-reported physician's diagnosis	Exposure to AB in first 2 y of life not associated with increased risk.  • aOR 1.03 (95%CI 0.96-1.10), p=nr	Sex, ethnicity, maternal age, birth weight, age of child at time of outcome, breastfeeding, household smoking
USA 2007							
Floistrup et al. <sup>49</sup>	Multicentre cross-sectional study (3b)	520; 4,606 126*; 788 394*; 3,818	< 1 y No Parent questionnaire	7-11 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • aOR 1.63 (95%CI 1.22-2.17), p=nr	Age, sex, family history of atopy, number of siblings, country, parental education, measles infection, vaccination status, medication use, smoking during pregnancy, diet, household smoking, pet exposure
Netherlands, Austria, Germany, Sweden, Switzerland 2006							

(continued on next page)



Table 1 (continued)

Purvis et al. <sup>114</sup>	Multicentric, prospective case-control study (3b)	87; 550 57; 369 30; 181	< 1 y No Parent questionnaire	3.5-4 y	Questionnaire for atopic dermatitis symptoms (ISAAC) plus serum IgE (environmental allergens)	Exposure to AB in first y of life not associated with increased risk.  • OR 1.18 (95%CI, 0.61-2.26), p=0.62	
Cohet et al. <sup>37</sup>	Single-centre retrospective case-control study (3b)	1,549; 3,927 1,130; 2,684 419; 1,243	< 1 y No Parent questionnaire	6-7 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • OR 1.40 (95%CI 1.21-1.62), p=nr	
Celedon et al. <sup>32</sup>	Multicentre prospective cohort study (2b)	22; 448 16; 302 6; 146	< 1 y No Parent questionnaire	5 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life not associated with increased risk.  • 1 AB course: aOR 0.90 (95%CI 0.30-3.40), p=nr • ≥ 2 AB courses: aOR 1.10 (95%CI 0.40-3.10), p=nr	Sex, family history of atopy, income
Bohme et al. <sup>180</sup>	Multicentre prospective cohort study (2b)	952; 3,786 ≥ 2 AB courses: 450; 1,586 502; 2,200	1-2 y No Parent questionnaire	2 y	Questionnaire for atopic dermatitis symptoms (BAMSE)	Exposure to ≥ 2 AB courses in first 2 y of life associated with increased risk.  • aRP 1.29 (95%CI 1.07-1.56), p=nr	Sex, maternal age and smoking; family history of atopy, parental education, gestational age, age of child at outcome, breastfeeding duration
McKeever et al. <sup>182</sup>	Single-centre prospective cohort study (2b)	3,580; 19,133 nr; 12,497 nr; 6,636	< 1 y Yes Medical records	< 11 y 2.2 y (mean)	Oxford Medical Information System (OXMIS), ICD-8 or Read codes	Exposure to AB in first y of life associated with increased risk.  • 1 AB course: aHR 1.22 (95%CI 1.12-1.34), p=nr • 2 AB courses: aHR 1.21 (95%CI 1.09-1.35), p=nr • 3 AB courses: aHR 1.22 (95%CI 1.08-1.38), p=nr • 4 AB courses: aHR 1.11 (95%CI 0.95-1.28), p=nr • > 4 AB courses: aHR 1.01 (95%CI 0.88-1.17), p=nr	Number of GP visits

(continued on next page)

Table 1 (continued)

						<ul style="list-style-type: none"> <li>• penicillin: aHR 1.07 (95%CI 0.97-1.18), p=nr</li> <li>• amoxicillin: <b>aHR 1.09 (95%CI 1.01-1.17), p=nr</b></li> <li>• amoxicillin/clavulanic acid: aHR 1.16 (95%CI 0.98-1.38), p=nr</li> <li>• cephalosporins: aHR 0.90 (95%CI 0.80-1.02), p=nr</li> <li>• macrolides: aHR 0.96 (95%CI 0.89-1.04), p=nr</li> </ul>	
Wjst et al. <sup>155</sup>	Multicentre cross-sectional study (3b)	768; 2,512 nr; 2,025 nr; 487	< 5-14 y No Medical records	5-14 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB between the fifth and fourteenth y of life not associated with increased risk.  • aOR 1.30 (95%CI 0.80-2.20), p=0.27	Age, sex, family history of atopy, season, parental education
Droste et al. <sup>43</sup>	Multicentre retrospective cross-sectional study (3b)	233; 1,180 85; 375 148; 805	< 1 y No Parent questionnaire	7-8 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk in high-risk children.  • <b>aOR 1.30 (95%CI 1.00-1.80), p=0.05</b>	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, smoke exposure
Von Mutius et al. <sup>181</sup>	Single-centre cross-sectional study (3b)	812; 5,006 673; 3,904 139; 1,102 865; 5,267 701; 4006 164; 1261	< 3 y No Medical records	5-7 y 9-11 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first 3 y of life associated with increased risk.  • <b>OR 1.44 (95%CI 1.19-1.76), p&lt;0.01*</b>  Exposure to AB in first 3 y of life associated with increased risk.  • <b>OR 1.42 (95%CI 1.18-1.70), p&lt;0.01*</b>	
Wickens et al. <sup>154</sup>	Multicentre retrospective cross-sectional study (3b)	125; 447 98; 334 27; 113	< 10 y No Parent questionnaire	5-10 y	Questionnaire for atopic dermatitis symptoms (ISAAC)	Exposure to AB in first 10 y of life not associated with increased risk.  • aOR 1.23 (95%CI 0.71-2.13), p=nr	Age, sex, ethnicity, family history of atopy, household size, parental smoking
Farooqi et al. <sup>48</sup>	Single-centre retrospective cohort study (2b)	367; 1,855 287*; 1,237 80*; 618	< 2 y Yes Medical records	6-12 y	Physician's diagnosis	Exposure to AB in first 2 y of life associated with increased risk.  • <b>OR 2.04 (95%CI 1.53-2.73), p&lt;0.01</b>  Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Allergic sensitisation							
Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	107; 1,185	< 1 y	12-36 m	SPT (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk.	
South-Africa		64; 654	No				• OR 1.23 (95%CI 0.82-1.85), p=0.31*
2020		11; 398	Parent questionnaire			Exposure to AB in first y of life not associated with increased risk in rural cohort.	
		11; 347					• OR 3.52 (95%CI 0.20-60.65), p=0.39*
		0; 51					
Metzler et al. <sup>93</sup>	Multicentre prospective cohort study (2b)	388; 1,019	< 1 y	< 6 y	Serum IgE (seasonal, perennial and food allergens)	Exposure to AB in first y of life not associated with increased risk.	Sex, family history of atopy, number of siblings, living area, smoking and pet exposure during pregnancy; delivery mode, duration of breastfeeding, pet exposure
Switzerland		167; 419	No				• aOR 1.06 (95%CI 0.70-1.60), p=nr
2019		221; 600	Parent questionnaire				
Oosterloo et al. <sup>105</sup>	Multicentre prospective cohort study (2b)	18; 205	< 1 w	0-1 y	Serum IgE (food and inhalant allergens)	Exposure to AB in first w of life not associated with increased risk.	Family history of atopy, parental education, day care, number of siblings, smoking during pregnancy, delivery mode, duration of breastfeeding, household smoking
Netherlands		9; 77	No				• aOR 3.26 (95%CI 0.95-11.13), p=0.06
2018		9; 128	Parent questionnaire				
Batool et al. <sup>183</sup>	Multicentre prospective cohort study (2b)	141; 576	< 1 y	1 y	SPT (food and inhalant allergens)	Exposure to AB in first y of life associated with increased risk.	
Canada		63; 205	No				• OR 1.67 (95%CI 1-13-2.46), p<0.01*
2016		78; 371	Parent questionnaire				
Azad et al. <sup>24</sup>	Multicentre prospective cohort study (2b)	12; 166	< 3 m	1 y	SPT (food allergens)	Exposure to AB in first 3 m of life not associated with increased risk.	
Canada		6; 78	No				• OR 1.14 (95%CI 0.35-3.69), p=0.83*
2015		6; 88	Medical records				
		12; 166	< 1 y			Exposure to AB in first y of life not associated with increased risk.	
		9; 105	No				• OR 1.81 (95%CI 0.47-6.97), p=0.39*
		3; 61	Medical records				

(continued on next page)

Table 1 (continued)

Loo et al. <sup>175</sup> Singapore 2015	Multicentre prospective cohort study (2b)	94; 696 nr; nr nr; nr	< 6 m No Parent questionnaire	1.5 y	SPT (food and inhalant allergens)	Exposure to AB in first 6 m of life not associated with increased risk. • aOR 11.44 (95%CI 0.50-260.29), p=0.13	Sex, living area, family history of atopy, age of child at time of outcome
Semic-Jusufagic et al. <sup>126</sup> UK 2014	Multicentre prospective cohort study (2b)	209; 800 nr; 564 nr; 236	< 1 y No Parent questionnaire	1-11 y	SPT (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk. • HR 1.02 (95%CI 0.60-1.78), p=0.92	
Hoskin-Parr et al. <sup>176</sup> UK 2013	Single-centre prospective cohort study (2b)	830; 5,780 386*; 2,659 444*; 3,121	< 2 y No Parent questionnaire	7.5 y (mean)	SPT (inhalant allergens)	Exposure to AB in first 2 y of life not associated with increased risk. • aOR 1.02 (95%CI 0.85-1.22), p=nr • 1 AB course: aOR 1.00 (95%CI 0.80-1.25), p=nr • 2 AB courses: aOR 1.10 (95%CI 0.89-1.39), p=nr • 3 AB courses: aOR 0.96 (95%CI 0.74-1.24), p=nr • ≥ 4 AB courses: aOR 1.00 (95%CI 0.79-1.27), p=nr	Age, sex, maternal age and education; parental marital status, home ownership status, degree of difficulty in paying for food, smoking during pregnancy, disinfectant use during pregnancy, gestational age, birth weight, delivery mode, age of child at outcome, breastfeeding, time spend outdoors, pet exposure

(continued on next page)



Table 1 (continued)

Risnes et al. <sup>116</sup>	Multicentric prospective cohort study (2b)	151; 1,401 71*; 464 80*; 937	< 6 m No Parent questionnaire	6 y	SPT (food and inhalant allergens)	Exposure to AB in first 6 m of life associated with increased risk.  • aOR 1.59 (95% CI, 1.10-2.28), p=nr	Maternal age, family history of atopy, number of LRTIs
Sandini et al. <sup>177</sup>	Single-centre prospective cohort study (2b)	271; 916 nr; nr nr; nr 367; 889 nr; nr nr; nr	< 6 m No Parent questionnaire	2 y 5 y	SPT or serum IgE (food and inhalant allergens)	Exposure to AB in first 6 m of life not associated with increased risk.  • OR 1.22 (95%CI 0.79-1.88), p=0.37  Exposure to AB in first 6 m of life not associated with increased risk.  • OR 0.82 (95%CI 0.54-1.25), p=0.35	
Dom et al. <sup>40</sup>	Multicentric prospective cohort study (2b)	160; 450 121; 384 39; 66	< 4 y No Parent questionnaire	< 4 y	Serum IgE (food and inhalant allergens)	Exposure to AB before first 4 y of life associated with decreased risk.  • OR 0.32 (95%CI 0.19-0.54), p<0.01*	Sex, maternal age, family history of atopy, day care, number of siblings, parental education, smoking and pet exposure during pregnancy, birth weight, number of LRTIs, breastfeeding, household smoking, pet exposure
Mai et al. <sup>178</sup>	Single-centre prospective cohort study (2b)	579; 3,306 244; 1,420 335; 1,886 828; 3,306 358; 1,420 470; 1,886	< 1 y No Parent questionnaire	4 y 8 y	Serum IgE (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk.  • aOR 0.90 (95%CI 0.70-1.10), p=nr  Exposure to AB in first y of life not associated with increased risk.  • aOR 1.00 (95%CI 0.80-1.20), p=nr	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding
Su et al. <sup>135</sup>	Single-centre prospective cohort study (2b)	202; 398 65; 136 137; 262	< 9 m No Parent questionnaire	1-5 y	Serum IgE (food and inhalant allergens)	Exposure to AB in first 9 m of life not associated with increased risk.  • OR 0.84 (95%CI 0.55-1.26), p=0.39*	

(continued on next page)

Table 1 (continued)

Kusel et al. <sup>80</sup> Australia 2008	Multicentre prospective cohort study (2b)	67; 198 36*; 107 31*; 91	< 1 y Yes Parent questionnaire	0-5 y	SPT plus serum IgE (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk. • aOR 1.00 (95%CI 0.50-2.10), p=nr Results according to antibiotic class nr	Sex, day care, number of GP visits, pet exposure
Wickens et al. <sup>153</sup> New Zealand 2008	Multicentre prospective cohort study (2b)	249; 1,064 44*; 148 205*; 916	< 3 m No Parent questionnaire	15 m	SPT (food and inhalant allergens)	Exposure to AB before 3 m of life not associated with increased risk. • aOR 1.36 (95% CI, 0.91-2.05), p=0.14	Number of LRTIs
Harris et al. <sup>60</sup> UK 2007	Single-centre prospective cohort study (2b)	104; 490 27; nr 77; nr	< 5 y No Medical records	8 y	SPT (inhalant allergens)	Exposure to AB in first 5 y of life not associated with increased risk. • aOR 1.00 (95%CI 0.97-1.03), p=0.86	Family history of atopy, birth order, smoke exposure
Majkowska-Wojciechowska et al. <sup>87</sup> Poland 2007	Multicentre prospective cohort study (2b)	128; 201 8*; 10 120*; 191	nr No Parent questionnaire	12-16 y	SPT	Early-life exposure to AB associated with increased risk. • <b>OR 2.12 (95%CI 1.16-3.85), p=0.02</b>	
Kummeling et al. <sup>79</sup> Netherlands 2007	Multicentre prospective cohort study (2b)	223; 2,462 44; 489 179; 1,973	< 6 m No Parent questionnaire	2 y	Serum IgE (food and inhalant allergens)	Exposure to AB in first 6 m of life not associated with increased risk. • aOR 1.32 (95%CI 0.86-2.02), p=nr	Sex, family history of atopy, day care, number of siblings, delivery mode, vaccination status, fever, breastfeeding, pet and smoke exposure

(continued on next page)

Table 1 (continued)

Floistrup et al. <sup>49</sup>	Multicentre cross-sectional study (3b)	1,487; 4,606 264*; 788 1,223*; 3,818	< 1 y No Parent questionnaire	7-11 y	Serum IgE (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk. • aOR 0.91 (95%CI 0.60-1.37), p=nr	Age, sex, family history of atopy, number of siblings, country, parental education, measles infection, vaccination status, medication use, smoking during pregnancy, diet, parental smoking, pet exposure
Netherlands, Austria, Germany, Sweden, Switzerland							
2006							
Johnson et al. <sup>70</sup>	Multicentre prospective cohort study (2b)	157; 448 83*; 221 74*; 227	< 6 m No Medical records	6-7 y	Clinical evaluation plus SPT	Exposure to AB in first 6 m of life not associated with increased risk. • aOR 1.48 (95%CI 0.94-2.34), p=0.09	Family history of atopy, number of LRTIs, duration of breastfeeding, pet exposure
USA							
2005							
Wjst et al. <sup>155</sup>	Multicentre cross-sectional study (3b)	1,944; 2,512 nr; 2,025 nr; 487	< 5-14 y No Medical records	5-14 y	SPT (food and inhalant allergens)	Exposure to AB in first y of life not associated with increased risk. • aOR 0.90 (95%CI 0.60-1.40), p=0.71	Age, sex, family history of atopy, season, parental education
Germany							
2001							
Droste et al. <sup>43</sup>	Multicentre cross-sectional study (3b)	130; 660 45; 210 85; 450	< 1 y No Parent questionnaire	7-8 y	SPT (inhalant allergens)	Exposure to AB in first y of life not associated with increased risk in high-risk children. • aOR 1.10 (95%CI 0.70-1.70), p=0.10	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, smoke exposure
Belgium							
2000							
Von Mutius et al. <sup>181</sup>	Single-centre cross-sectional study (3b)	222; 5,006 168; 3,904 54; 1,102 946; 5,267 745; 4,006 201; 1,261	< 3 y No Medical records	5-7 y 9-11 y	Serum IgE (inhalant allergens) plus SPT	Exposure to AB in first 3 y of life not associated with increased risk. • OR 0.87 (95%CI 0.64-1.19), p=0.40* Exposure to AB in first 3 y of life associated with increased risk. • <b>OR 1.20 (95%CI 1.02-1.43), p=0.03*</b>	
Germany							
1999							

(continued on next page)

Table 1 (continued)

Food allergies							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study (2b)	261; 14,572 201; 10,220 60; 4,352	< 2 y Yes Medical records	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life not associated with increased risk.  • aHR 1.33 (95%CI 0.99-1.77), p=0.05  Girls • penicillins: HR 0.74 (95%CI 0.47-1.15), p=0.18 • cephalosporins: <b>HR 2.73 (95%CI 1.74-4.28), p&lt;0.01</b> • macrolides: HR 1.00 (95%CI 0.62-1.59), p=0.99 • sulfonamides: HR 1.27 (95%CI 0.65-2.49), p=0.49  Boys • penicillins: HR 1.06 (95%CI 0.73-1.53), p=0.77 • cephalosporins: <b>HR 1.96 (95%CI 1.39-2.76), p&lt;0.01</b> • macrolides: HR 0.99 (95%CI 0.69-1.41), p=0.94 • sulfonamides: HR 0.67 (95%CI 0.31-1.43), p=0.30	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode,
Zou et al. <sup>161</sup>	Multicentre cross-sectional study (3b)	1,938; 12,667 560; 3,049 1,378; 9,618	< 1 y No Parent questionnaire	4-6 y	Questionnaire for allergic symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • aOR 1.29 (95%CI 1.13-1.46), p<0.01	Age, sex, living area, family history of atopy, breastfeeding, home decoration, pet, smoke and home dampness-related exposure
Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	27; 1,185 18; 654 9; 531 2; 398 2; 347 0; 51	< 1 y No Parent questionnaire	12-36 m	Questionnaire for allergic symptoms (based on ISAAC)	Exposure to AB in first y of life not associated with increased risk in urban cohort.  • OR 1.64 (95%CI 0.73-3.68), p=0.23*  Exposure to AB in first y of life not associated with increased risk in rural cohort.  • OR 0.75 (95%CI 0.04-15.75), p=0.19*	
Metzler et al. <sup>93</sup>	Multicentre prospective cohort study (2b)	75; 1,019 37; 419 38; 600	< 1 y No Parent questionnaire	< 6 y	Questionnaire for allergic symptoms (based on ISAAC) plus parent-reported physician's diagnosis	Exposure to AB in first y of life not associated with increased risk.  • aOR 1.47 (95%CI 0.73-2.98), p=nr	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, pet exposure during pregnancy, delivery mode, duration of breastfeeding, pet exposure

(continued on next page)



Table 1 (continued)

Gao et al. <sup>51</sup> China 2019	Single-centre prospective cohort study (2b)	200; 903 43; 201 157; 702	< 1 y No Parent questionnaire	12 m	Parent-reported	Exposure to AB in first y of life not associated with increased risk.  • OR 0.94 (95%CI 0.65-1.38), p=0.77*	Sex, family history of atopy, antibiotic use during pregnancy, season of birth, egg and milk consumption
Li et al. <sup>185</sup> USA 2019	Multicentre prospective cohort study (2b)	14,812; 1,001,294 9,193; 500,647 5,619; 500,647	< 1 y No Registry	< 4 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk.  • aHR 1.40 (95%CI 1.34-1.45), p=nr	Day care, living area, prematurity, birth weight, delivery mode, neonatal intensive-care unit admission, State Children's Health Insurance Program, atopy
Mitre et al. <sup>96</sup> USA 2018	Multicentre retrospective cohort study (2b)	24,514; 792,130 4,753; 131,708 19,761; 660,422	< 6 m No Registry	1-6 y	ICD-9-CM codes	Exposure to AB in first 6 m of life associated with increased risk.  • aHR 1.14 (95%CI 1.10-1.18), p=nr	Sex, prematurity, delivery mode, medication (incl. anti-reflux medication) use
Hirsch et al. <sup>61</sup> USA 2017	Multicentre case-control study (3b)	484; 2,904 210; 1,074 274; 1,830  598; 3,588  445; 2,496 153; 1,092	>1-2 m before diagnosis Yes Medical records	< 7 y	Cow's milk allergy ICD-9 codes plus medical or prescription records  Non-milk food allergy ICD-9 codes plus medical or prescription records	Exposure to AB until 2 m before diagnosis associated with increased risk.  • aOR 1.58 (95%CI 1.24-2.02), p=nr  • ≤ 2 AB courses: aOR 1.49 (95%CI 1.15-1.96), p=nr • ≥ 3 AB courses: aOR 1.78 (95%CI 1.28-2.48), p=nr  • penicillins: aOR 1.58 (95%CI 1.24-2.02), p=nr • cephalosporins: aOR 1.40 (95%CI 1.02-1.93), p=nr • macrolides: aOR 1.68 (95%CI 1.19-2.37), p=nr  Exposure to AB until 2 m before diagnosis associated with increased risk.  • aOR 1.49 (95%CI 1.18-1.87), p=nr  • ≤ 2 AB courses: aOR 1.38 (95%CI 1.08-1.77), p=nr • ≥ 3 AB courses: aOR 1.65 (95%CI 1.27-2.14), p=nr • penicillins: aOR 1.29 (95%CI 1.04-1.59), p=nr • cephalosporins: aOR 1.57 (95%CI 1.29-1.93), p=nr • macrolides: aOR 1.58 (95%CI 1.28-1.96), p=nr	Ethnicity, healthcare use

(continued on next page)

Table 1 (continued)

Batool et al. <sup>183</sup>	Multicentre prospective cohort study (2b)	143; 818 62; 285 81; 533	< 1 y No Parent questionnaire	1 y	Parent-reported food allergies or SPT	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.55 (95%CI 1.07-2.24), p=0.02*</b>	
Canada 2016							
Love et al. <sup>163</sup>	Multicentre retrospective case-control study (3b)	1,504; 7,499 722; 3,324 782; 4,175	< 1 y Yes Prescription records	0-3 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.21 (95%CI 1.06-1.39), p&lt;0.01</b>  • penicillins: <b>aOR 1.19 (95%CI 1.04-1.36), p=0.01</b> • cephalosporins: <b>aOR 1.50 (95%CI 1.27-1.77), p&lt;0.01</b> • macrolides: <b>aOR 1.36 (95%CI 1.13-1.63), p&lt;0.01</b> • sulfonamides: <b>aOR 1.54 (95%CI 1.19-2.01), p&lt;0.01</b>	Maternal age and smoking, pre-pregnancy diabetes, living area, smoking during pregnancy, gestational age, delivery mode, atopy, breastfeeding,
USA 2016							
Metsälä et al. <sup>91</sup>	Multicentre case-control study (3b)	533; 15,672 162*; 3,292 371*; 12,380	< 1 m before diagnosis Yes Registry	1 m-8 y	Cow's milk allergy ICD-10 codes plus SPT plus serum IgE	Exposure to AB within 1 m before diagnosis associated with increased risk.  • <b>aOR 1.71 (95%CI 1.59-1.84), p=nr</b>  • penicillin: <b>aOR 1.97 (95%CI 1.50-2.58), p=nr</b> • amoxicillin: <b>aOR 1.39 (95%CI 1.29-1.51), p=nr</b> • cephalosporins: <b>aOR 2.43 (95%CI 2.14-2.77), p=nr</b> • macrolides: <b>aOR 1.65 (95%CI 1.49-1.82), p=nr</b> • trimethoprim/sulfamethoxazole: <b>aOR 1.60 (95%CI 1.27-2.02), p=nr</b>	Maternal age, parity, maternal smoking during pregnancy, birth weight, delivery mode
Finland 2013							
Dowhower Karpa et al. <sup>42</sup>	Single-centre retrospective case-control study (4)	99; 291 16; 40 83; 251	< 1 m No Medical	0-18 y	ICD-9-CM codes plus serum IgE or SPT or physician's	Early exposure to AB not associated with increased risk.  • OR 1.35 (95%CI 0.68-2.68), p=0.39	
USA							

(continued on next page)

Table 1 (continued)

Raciborski et al. <sup>115</sup>	Multicentre retrospective cohort study (2b)	307; 1,330 211; 820 96; 510	< 1 y No Parent questionnaire	6-8 y	Questionnaire for allergic symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.49 (95%CI 1.14-1.96), p&lt;0.01*</b>  • 1 AB course: OR 1.23 (95%CI nr), p=0.22 • 2-3 AB courses: OR 1.30 (95%CI nr), p=0.18 • > 3 AB courses: <b>OR 1.52 (95%CI nr), p=0.05</b>	
Poland		307; 1,321	1-3 y			Exposure to AB in first to third y of life not associated with increased risk.  • OR 1.31 (95%CI 0.88-1.95), p=0.19	
2012		273; 1,145 34; 176	No Parent questionnaire			• 1-2 AB courses: OR 1.12 (95%CI nr), p=0.62 • 3-4 AB courses: OR 1.32 (95%CI nr), p=0.23 • > 4 AB courses: OR 1.32 (95%CI nr), p=0.24	
Mai et al. <sup>178</sup>	Single-centre prospective cohort study (2b)	354; 3,306 181; 1,420 173; 1,886	< 1 y No Parent questionnaire	4 y 8 y	Questionnaire for allergic symptoms (BAMSE based on ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.40 (95%CI 1.10-1.70), p=nr</b>	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding,
Sweden		436; 3,306				Exposure to AB in first y of life not associated with increased risk.  • aOR 1.20 (95%CI 0.90-1.40), p=nr	
2010		206; 1,420 230; 1,886					
Eggesbo et al. <sup>46</sup>	Single-centre retrospective cohort study (2b)	32; 2,759 12; 963 20; 1,796	< 6 m No Parent questionnaire	2.5 y	Parent-reported immediate reaction plus serum IgE	Exposure to AB in first 6 m of life not associated with increased risk.  • aOR 1.50 (95% CI, 0.60-3.70), p=0.40	Maternal age, education and smoking; number of siblings, restricted growth in pregnancy, pregnancy complications, gestational age, birth weight
Norway							
2003							
<b>Allergic rhinoconjunctivitis</b>							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study (2b)	971; 14,572 760; 10,220 211; 4,352	< 2 y Yes Medical records	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aHR 1.36 (95%CI 1.17-1.59), p&lt;0.01</b>	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode,
USA							
2021							

(continued on next page)

Table 1 (continued)

						<p>Girls</p> <ul style="list-style-type: none"> <li>• penicillins: HR 1.15 (95%CI 0.91-1.46), p=0.25</li> <li>• cephalosporins: <b>HR 1.83 (95%CI 1.46-2.30), p&lt;0.01</b></li> <li>• macrolides: HR 1.11 (95%CI 0.88-1.40), p=0.36</li> <li>• sulfonamides: HR 1.16 (95%CI 0.81-1.66), p=0.41</li> </ul> <p>Boys</p> <ul style="list-style-type: none"> <li>• penicillins: HR 1.16 (95%CI 0.95-1.41), p=0.15</li> <li>• cephalosporins: <b>HR 1.29 (95%CI 1.07-1.55), p&lt;0.01</b></li> <li>• macrolides: <b>HR 1.39 (95%CI 1.16-1.66), p&lt;0.01</b></li> <li>• sulfonamides: HR 1.10 (95%CI 0.80-1.52), p=0.56</li> </ul>	
Zou et al. <sup>161</sup>	Multicentre cross-sectional study (3b)	1,579; 12,667	< 1 y	4-6 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Age, sex, living area, family history of atopy, breastfeeding, home decoration, pet, smoke and home dampness-related exposure
China		479; 3,049	No				
2020		1,100; 9,618	Parent questionnaire			<b>• aOR 1.23 (95%CI 1.07-1.41), p&lt;0.01</b>	
Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	295; 1,185	< 1 y	12-36 m	Questionnaire for allergic rhinitis symptoms (based on ISAAC)	Exposure to AB in first y of life associated with increased risk in urban cohort.	
South-Africa		187; 654	No				
2020		108; 531	Parent questionnaire			<b>• OR 1.57 (95%CI 1.20-2.06), p&lt;0.01*</b>	
		13; 398				Exposure to AB in first y of life not associated with increased risk in rural cohort.	
		12; 347				<b>• OR 1.79 (95%CI 0.23-14.07), p=0.58*</b>	
		1; 51					
Chinratanapit et al. <sup>35</sup>	Multicentre cross-sectional study (3b)	462; 3,074	< 1 y	6-7 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Age, sex, family history of atopy, number of siblings, migration, birth weight, BMI, medication use, parental smoking, diet, pet, farm animal, air pollution, cooking fuels, and traffic exposure
Thailand		237; 1,138	No				
2019		225; 1,936	Parent questionnaire			<b>• OR 2.00 (95%CI 1.64-2.44), p&lt;0.01*</b>	
Ni et al. <sup>102</sup>	Single-centre retrospective cohort study (4)	233; 2,398	< 1 y	1-10 y	ICD-9 and ICD-10 codes	Exposure to AB in first y of life not associated with increased risk.	Age, sex, ethnicity, socioeconomic status, prematurity, birth weight, delivery mode, neonatal intensive-care unit admission
USA		130*; 1,060	Yes				
2019		103*; 1,338	Medical records			<b>• aOR 1.41 (95%CI 0.48-4.14), p=0.53</b>	
		215; 2,398	< 10 y			Results according to antibiotic class nr	
		198*; 1,755	Yes			Exposure to AB in first 10 y of life associated with increased risk.	
		17*; 643	Medical records			<b>• aOR 2.43 (95%CI 1.43-4.11), p&lt;0.01</b>	
						Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Norbäck et al. <sup>103</sup>	Multicentre retrospective cohort study (2b)	3,463; 39,782 3,000; 29,303 463; 10,479	< 1 y No Parent questionnaire	3-6 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.77 (95%CI 1.54-2.03), p&lt;0.01</b>  • 1 AB course: <b>aOR 1.19 (95%CI 1.06-1.34), p&lt;0.01</b> • > 1 AB courses: <b>aOR 1.51 (95%CI 1.36-1.68), p&lt;0.01</b>	Living area, time spend outdoors, air pollution, temperature in each city
China 2019							
Metzler et al. <sup>93</sup>	Multicentre prospective cohort study (2b)	59; 1,019 21; 419 38; 600	< 1 y No Parent questionnaire	< 6 y	Questionnaire for allergic symptoms (based on ISAAC) plus parent-reported physician's diagnosis	Exposure to AB in first y of life not associated with increased risk.  • aOR 0.70 (95%CI 0.33-1.51), p=nr	Sex, family history of atopy, number of siblings, living area, smoking during and pet exposure during pregnancy; delivery mode, duration of breastfeeding, pet exposure
Switzerland 2019							
Mitre et al. <sup>96</sup>	Multicentre retrospective cohort study (2b)	24,585; 792,130 5,047; 131,708 19,538; 660,422 248,232; 792,130 52,135; 131,708 196,097; 660,422	< 6 m No Registry	1-6 y	Allergic conjunctivitis ICD-9-CM codes  Allergic rhinitis ICD-9-CM codes	Exposure to AB in first 6 m of life associated with increased risk.  • <b>aHR 1.42 (95%CI 1.34-1.50), p=nr</b>  Exposure to AB in first 6 m of life associated with increased risk.  • <b>aHR 1.75 (95%CI 1.72-1.78), p=nr</b>	Sex, prematurity, delivery mode, medication (incl. anti-reflux medication) use
USA 2018							

(continued on next page)

Table 1 (continued)

Singh et al. <sup>129</sup>	Multicentre cross-sectional study (3b)	1,753; 44,928 nr; nr	< 1 y No	6-7 y	Questionnaire for allergic rhinoconjunctivitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>OR 1.90 (95%CI 1.70-2.20), p&lt;0.01</b>	
India		5,100; 44,928 nr; nr nr; nr	Parent questionnaire		Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>OR 1.90 (95%CI 1.70-2.00), p&lt;0.01</b>	
2018							
Han et al. <sup>59</sup>	Multicentre cross-sectional study (3b)	207; 1,517 155; 921 52; 596	< 1 y No	6-7 y	Questionnaire for allergic rhinoconjunctivitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.90 (95%CI 1.30-2.70), p&lt;0.01</b>	Number of LRTIs, medication use
Argentina			Parent questionnaire				
2017							
Yamamoto-Hanada et al. <sup>157</sup>	Multicentre prospective cohort study (2b)	96; 902 59; 436 37; 466	< 2 y Yes	5 y	Questionnaire for allergic rhinitis (ISAAC) symptoms plus medical records	Exposure to AB in first 2 y of life associated with increased risk. • <b>aOR 1.65 (95%CI 1.05-2.58), p=0.03</b> • penicillins: aOR 0.58 (95%CI 0.22-1.51), p=0.26 • cephem: <b>aOR 1.82 (95%CI 1.12-2.93), p=0.02</b> • macrolides: aOR 1.50 (95%CI 0.902.49), p=0.12	Sex, maternal age, BMI, education and history of atopy; parity, day care, , smoking during pregnancy, gestational age, delivery mode, number of LRTIs
Japan			Parent questionnaire				
2017							
Wang et al. <sup>186</sup>	Multicentre cross-sectional study (3b)	1,624; 13,335 nr; nr nr; nr	< 1 y No	4-6 y	Questionnaire for allergic rhinitis (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.23 (95%CI 1.09–1.40), p=nr</b>	Age, sex, family history of atopy
China			Parent questionnaire				
2016							
Yang et al. <sup>158</sup>	Multicentre cross-sectional study (3b)	1,768; 6,435 1,258; 1,947 2,629; 4,488	< 1 y No	15 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.25 (95%CI 1.04-1.50), p=0.02</b>	Age, sex, study centre, family history of atopy, income, BMI
Korea			Parent questionnaire				
2014							

(continued on next page)

Table 1 (continued)

Alm et al. <sup>16</sup> Sweden 2014	Multicentre prospective cohort study (2b)	564; 4,051 40*; 187 524*; 3,864	< 1 w No Parent questionnaire	8 y	Questionnaire for allergic rhinitis symptoms (ISAAC and BAMSE)	Exposure to AB in first w of life associated with increased risk.  • <b>aOR 1.75 (95%CI 1.03-2.97), p=nr</b>	Sex, maternal age, family history of atopy, living area, paternal education, maternal medication during pregnancy, weight for gestational age, atopy, diet, pacifier use, time spend outdoors, pet exposure
Tamay et al. <sup>187</sup> Turkey 2014	Multicentre prospective cohort study (2b)	803; 9,875 nr; nr nr; nr	< 1 y No Parent questionnaire	6-7 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.41 (95%CI 1.15-1.73), p&lt;0.05</b>	Number of LRTIs, perianal redness, adenotonsillectomy, medication use, pet exposure, environmental factors
Hoskin-Parr et al. <sup>176</sup> UK 2013	Single-centre prospective cohort study (2b)	503; 5,780 260*; 2,659 243*; 3,121	< 2 y No Parent questionnaire	7.5 y (mean)	Parents-reported physician's diagnosis	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aOR 1.28 (95%CI 1.03-1.60), p=nr</b>  • 1 AB course: aOR 1.17 (95%CI 0.88-1.54), p=nr • 2 AB courses: aOR 1.21 (95%CI 0.90-1.61), p=nr • 3 AB courses: aOR 1.18 (95%CI 0.86-1.61), p=nr • ≥ 4 AB courses: aOR 1.60 (95%CI 1.21-2.10), p=nr	Age, sex, maternal age and education; parental marital status, home ownership status, degree of difficulty in paying for food, smoking during pregnancy, disinfectant use during pregnancy, gestational age, birth weight, delivery mode, age of child at outcome, breastfeeding, time spend outdoors, pet exposure
Muc et al. <sup>97</sup> Portugal 2013	Multicentre cross-sectional study (3b)	14; 1,037 5*; 237 9*; 800	< 1 y No Parent questionnaire	6-9 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.84 (95%CI 1.30-2.59), p&lt;0.01</b>	Age, sex, prematurity, atopy

(continued on next page)

Table 1 (continued)

Wang et al. <sup>150</sup>	Multicentre prospective cohort study (2b)	82,292; 263,620 nr; 15,663 nr; 247,957	< 1 y Yes Medical records	2-6 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk.  • <b>aHR 1.41 (95%CI 1.35-1.47), p&lt;0.05</b>  Results according to antibiotic class nr	Sex, living area, socioeconomic status, healthcare use
Kim et al. <sup>74</sup>	Multicentre cross-sectional study (3b)	1,550; 4,436 748*; 1,528 802*; 2,908	< 1 y No Parent questionnaire	9.5 y (mean)	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.95 (95%CI 1.61-2.36), p&lt;0.01</b>  Strongest risk of children with atopic parents • <b>aOR 6.00 (95%CI 4.63-7.80), p=nr</b>	Age, sex, study centre, family history of atopy, maternal education, BMI, smoke exposure
Peñaranda et al. <sup>110</sup>	Multicentre cross-sectional study (3b)	588; 3,256 401; nr 163; nr	< 1 y No Parent questionnaire	6-7 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.30 (1.10-1.70), p=0.01</b>	Maternal education, delivery mode, atopy, medication use, household smoking
Sandini et al. <sup>177</sup>	Single-centre prospective cohort study (2b)	177; 891 nr; nr nr; nr	< 6 m No Parent questionnaire	5 y	Parent-reported allergic rhinitis symptoms	Exposure to AB in first 6 m of life not associated with increased risk.  • OR 0.92 (95%CI 0.54-1.56), p=0.75	
Mai et al. <sup>178</sup>	Single-centre prospective cohort study (2b)	369; 3,306 176; 1,420 193; 1,886 447; 3,306 202; 1,420 245; 1,886	< 1 y No Parent questionnaire	4 y 8 y	Questionnaire for allergic rhinitis symptoms (BAMSE based on ISAAC)	Exposure to AB in first y of life not associated with increased risk.  • aOR 1.20 (95%CI 0.90-1.50), p=nr  Exposure to AB in first y of life not associated with increased risk.  • aOR 1.10 (95%CI 0.90-1.30), p=nr	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding,
Sultesz et al. <sup>188</sup>	Single-centre case-control study (3b)	883; 3,322 473; 1,495 410; 1,827	< 1 y No Parent questionnaire	6-12 y	Questionnaire for allergic rhinitis symptoms (based on ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.60 (95%CI 1.37-1.87), p&lt;0.01</b>	

(continued on next page)



Table 1 (continued)

Foljaki et al. <sup>50</sup>	Multicentre retrospective cross-sectional study (3b)	nr; 193,412 nr; 135,775 nr; 57,637	< 1 y No Parent questionnaire	6-7 y	Questionnaire for rhinoconjunctivitis (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • aOR 1.56 (95%CI 1.46-1.66), p=nr	Sex, language, living area, income
Sweden 2009							
Karimi et al. <sup>162</sup>	Multicentre cross-sectional study (3b)	195; 1,476 134; 958* 61; 518*	< 1 y No nr	6-7 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk.  • OR 1.22 (95%CI 0.87-1.72), p=0.20	
Iran 2009							
Harris et al. <sup>90</sup>	Single-centre prospective cohort study (2b)	124; 523 43; nr 81; nr	< 5 y No Medical records	8 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first 5 y of life associated with increased risk.  • aOR 1.06 (95%CI 1.03-1.09), p<0.01	Family history of atopy, birth order, smoke exposure
UK 2007							
Mullooly et al. <sup>98</sup>	Single-centre case-control study (3b)	660; 844 nr; nr nr; nr	< 2 y No Medical records	10.3 y (mean)	Parent-reported physician's diagnosis	Exposure to AB in first 2 y of life not associated with increased risk.  • aOR 1.03 (95%CI 0.99-1.08), p=nr	Sex, ethnicity, maternal age, birth weight, age of child at time of outcome, breastfeeding, household smoking
USA 2007							
Tamay et al. <sup>189</sup>	Multicentre prospective cohort study (2b)	671; 2,500 430; nr 241; nr	< 1 y No Parent questionnaire	6-12 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • aOR 1.26 (1.01-1.57), p=nr	Family history of atopy, number of LRTIs and sinusitis, atopy, adenotonsillectomy, perianal redness, medication use, pet, home-dampness and diesel truck exposure
Turkey 2007							
Flojstrup et al. <sup>49</sup>	Multicentre cross-sectional study (3b)	216; 4,606 67*; 788 149*; 3,818	< 1 y No Parent questionnaire	7-11 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • aOR 1.97 (95%CI 1.26-3.08), p=nr	Age, sex, family history of atopy, number of siblings, country, parental education, measles infection, vaccination status, medication use, smoking during pregnancy, diet, household smoking, pet exposure
Netherlands, Austria, Germany, Sweden, Switzerland 2006							

(continued on next page)

Table 1 (continued)

Thomsen et al. <sup>190</sup>	Single-centre case-control study (4)	44; 470 12*; 152 32*; 318	< 2 y No Parent questionnaire	7-17 y	Parent-reported physician's diagnosis	Exposure to AB in first 2 y of life not associated with increased risk. • OR 0.77 (95%CI 0.38-1.53), p=0.45*
Denmark 2006						
Cohet et al. <sup>37</sup>	Single-centre case-control study (3b)	699; 3,927 534; 2,684 165; 1,243	< 1 y No Parent questionnaire	6-7 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • OR 1.52 (95%CI 1.25-1.85), p=nr
New Zealand 2004						
Bremner et al. <sup>29</sup>	Multicentre nested case-control study (3b)	2,902; 40,183 nr; nr nr; nr	< 3 y Yes Medical records	5.1 y (mean)	Read codes	Exposure to AB in first 3 y of life associated with increased risk. • AB first y: OR 1.15 (95%CI, 1.03-1.29), p=0.02 • AB in second y: OR 1.29 (95%CI, 1.15-1.46), p<0.01 • AB in third y: OR 1.32 (95%CI, 1.17-1.48), p<0.01
UK 2003						
		4,196; 76,310 nr; nr nr; nr	< 1 y Yes Medical records	4.6 y (mean)	Oxford Medical Information System (OXMIS) or Read codes	Results according to antibiotic class nr Exposure to AB in first y of life not associated with increased risk. • AB first y: OR 1.08 (95%CI, 0.98-1.20), p=0.13 • 1 AB course: aOR 1.11 (95%CI 1.02-1.22), p=0.02 • 2 AB courses: aOR 1.26 (95%CI 1.14-1.41), p<0.01 • ≥ 3 AB courses: aOR 1.36 (95%CI 1.23-1.50), p<0.01

(continued on next page)

Table 1 (continued)

						<ul style="list-style-type: none"> <li>• penicillins: aOR 0.97 (95%CI 0.92-1.03), p=0.35</li> <li>• cephalosporins: aOR 0.95 (95%CI 0.86-1.06), p=0.34</li> <li>• macrolides: aOR 0.97 (95%CI 0.91-1.04), p=0.46</li> <li>• trimethoprim/sulfamethoxazole: aOR 0.92 (95%CI 0.82-1.02), p=0.12</li> </ul>	
			1-2 y			Exposure to AB in second y of life associated with increased risk.	
			Yes				
			Medical records				
			2-3 y			Exposure to AB in third y of life associated with increased risk.	
			Yes				
			Medical records				
Celedon et al. <sup>32</sup>	Multicentre prospective cohort study (2b)	45; 448 30; 302 15; 146	< 1 y	5 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life not associated with increased risk.	Sex, family history of atopy, income
USA			No				
2002			Parent questionnaire			<ul style="list-style-type: none"> <li>• OR 0.96 (95%CI 0.50-1.85), p=0.91*</li> <li>• 1 AB course: aOR 0.90 (95%CI 0.40-2.20), p=nr</li> <li>• ≥ 2 AB courses: aOR 0.70 (95%CI 0.30-1.50), p=nr</li> </ul>	
McKeever et al. <sup>182</sup>	Single-centre prospective cohort study (2b)	2,948; 23,604 nr; 15,775 nr; 7,829	< 1 y	< 11 y	Oxford Medical Information System (OXMIS), ICD-8 or Read codes	Exposure to AB in first y of life not associated with increased risk.	Number of GP visits
UK			Yes	3.5 (mean)		<ul style="list-style-type: none"> <li>• 1 AB course: aHR 1.14 (95%CI 0.94-1.38), p=nr</li> <li>• 2 AB courses: aHR 1.13 (95%CI 0.92-1.40), p=nr</li> <li>• 3 AB courses: aHR 0.95 (95%CI 0.74-1.22), p=nr</li> <li>• 4 AB courses: aHR 1.29 (95%CI 0.99-1.69), p=nr</li> <li>• &gt; 4 AB courses: aHR 1.14 (95%CI 0.88-1.47), p=nr</li> </ul>	
2002			Medical records			<ul style="list-style-type: none"> <li>• penicillin: aHR 1.05 (95%CI 0.87-1.26), p=nr</li> <li>• amoxicillin: aHR 1.05 (95%CI 0.91-1.21), p=nr</li> <li>• amoxicillin/clavulanic acid: aHR 0.94 (95%CI 0.67-1.32) p=nr</li> <li>• cephalosporins: aHR 1.01 (95%CI 0.81-1.26), p=nr</li> <li>• macrolides: aHR 1.09 (95%CI 0.94-1.27), p=nr</li> </ul>	

(continued on next page)

Table 1 (continued)

Wjst et al. <sup>155</sup> Germany 2001	Multicentre cross-sectional study (3b)	180; 2,512 nr; 2,025 nr; 487	< 5-14 y No Medical records	5-14 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk. • aOR 2.30 (95%CI 0.80-6.50), p=0.13	Age, sex, family history of atopy, season, parental education
Droste et al. <sup>43</sup> Belgium 2000	Multicentre cross-sectional study (3b)	67; 1,180 34; 375 33; 805	< 1 y No Parent questionnaire	7-8 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk in high-risk children. • aOR 2.30 (95%CI 1.30-3.80) p<0.01	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, smoke exposure
Ponsonby et al. <sup>112</sup> Australia 1999	Multicentre prospective cohort study (2b)	162; 864 24; 117 138; 747	< 1 m No Parent questionnaire	2.1 y (mean)	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first m of life not associated with increased risk. • aRR 0.95 (95%CI 0.62-1.44), p=nr	Age, prematurity, birth weight, smoking family history of atopy, breastfeeding, household size, gas heater in living room
Von Mutius et al. <sup>181</sup> Germany 1999	Single-centre cross-sectional study (3b)	222; 5,006 179; 3,904 43; 1,102 487; 5,267 403; 4,006 84; 1,261	< 3 y No Medical records	5-7 y 9-11 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first 3 y of life not associated with increased risk. • OR 1.18 (95%CI 0.84-1.66), p=0.33* Exposure to AB in first 3 y of life associated with increased risk. • OR 1.57 (95%CI 1.23-2.00), p<0.01*	
Wickens et al. <sup>154</sup> New Zealand 1999	Multicentre retrospective cross-sectional study (3b)	81; 447 70; 334 11; 113	< 10 y No Parent questionnaire	5-10 y	Questionnaire for allergic rhinitis symptoms (ISAAC)	Exposure to AB in first 10 y of life not associated with increased risk. • aOR 1.99 (95%CI 0.93-4.26), p=nr	Age, sex, ethnicity, family history of atopy, household size, parental smoking
Farooqi et al. <sup>48</sup> UK 1998	Single-centre retrospective cohort study (2b)	484; 1,855 374*; 1,237 110*; 618	< 2 y Yes Medical records	6-12 y	Physician's diagnosis of seasonal nasal or ocular irritation	Exposure to AB in first 2 y of life associated with increased risk. • OR 2.04 (95%CI 1.59-2.62), p<0.01 Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Wheezing							
Zou et al. <sup>161</sup>	Multicentre cross-sectional study (3b)	3,584; 12,667	< 1 y	4-6 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.44 (95%CI 1.30-1.60), p&lt;0.01</b>	Age, sex, living area, family history of atopy, breastfeeding, home decoration, pet, smoke and home dampness-related exposure
China		1,082; 3,049	No				
2020		2,502; 9,618	Parent questionnaire				
Norbäck et al. <sup>103</sup>	Multicentre retrospective cohort study (2b)	7,831; 39,782	< 1 y	3-6 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.66 (95%CI 1.52-1.82), p&lt;0.01</b>	Living city, time spend outdoors, air pollution, temperature in each city
China		6,442; 29,303	No				
2019		1,389; 10,479	Parent questionnaire			• 1 AB course: <b>aOR 1.24 (95%CI 1.14-1.34), p&lt;0.01</b> • > 1 AB courses: <b>aOR 1.57 (95%CI 1.46-1.69), p&lt;0.01</b>	
Oosterloo et al. <sup>105</sup>	Multicentre prospective cohort study (2b)	149; 436	< 1 w	0-1 y	Parent-reported wheezing	Exposure to AB in first w of life not associated with increased risk. • aOR 1.56 (95%CI 0.99-2.46), p=0.06	Family history of atopy, parental education, day care, number of siblings, smoking during pregnancy, delivery mode, duration of breastfeeding, household smoking
Netherlands		62; 151	No				
2018		87; 285	Parent questionnaire				
Yamamoto-Hanada et al. <sup>157</sup>	Multicentre prospective cohort study (2b)	148; 902	< 2 y	5 y	Questionnaire for wheezing symptoms (ISAAC) plus medical records	Exposure to AB in first 2 y of life not associated with increased risk. • aOR 1.24 (95%CI 0.86-1.78), p=0.26 • penicillins: aOR 1.16 (95%CI 0.61-2.18), p=0.65 • cephem: aOR 1.39 (95%CI 0.92-2.09), p=0.12 • macrolides: aOR 1.04 (95%CI 0.66-1.64), p=0.86	Sex, maternal age, BMI, education, history of atopy; parity, day care, smoking during pregnancy, gestational age, delivery mode, number of LRTIs
Japan		81; 436	Yes				
2017		67; 466	Parent questionnaire				
Han et al. <sup>59</sup>	Multicentre cross-sectional study (3b)	224; 1,517	< 1 y	6-7 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.80 (95%CI 1.30-2.60), p&lt;0.01</b>	Number of LRTIs, paracetamol use
Argentina		175; 921	No				
2017		49; 596	Parent questionnaire				

(continued on next page)

Table 1 (continued)

Eldeirawi et al. <sup>191</sup>	Multicentre cross-sectional study (3b)	107; 1,789 63; 803 44; 986	< 1 y No Parent questionnaire	1 y	Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.64 (95% CI, 1.53-3.55), p=0.04</b>  • 1-2 AB courses: aOR 1.24 (95%CI 0.73-2.12), p=42 • ≥ 3 AB courses: <b>aOR 2.47 (95%CI 1.39-4.38), p&lt;0.01</b>	Age, sex, country of birth, family history of atopy, having a regular doctor or clinic, number of ear infections
Sun et al. <sup>137</sup>	Multicentre prospective cohort study (2b)	29; 606 nr; 142 nr; 464	< 3 y Yes Parent questionnaire	6 m-3 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first 3 y of life associated with increased risk in children with high atopic risk factors.  • <b>aRR 1.09 (95%CI 1.05-1.13), p&lt;0.05</b>  • penicillin: aRR 1.00 (95%CI 0.94-1.05), p=nr • ampicillin: aRR 0.99 (95%CI 0.94-1.03), p=nr • cephalosporins: aRR 1.02 (95%CI 1.00-1.05), p=nr • macrolides: <b>aRR 1.09 (95%CI 1.05-1.13), p&lt;0.05</b> • trimethoprim: aRR 0.98 (95%CI 0.88-1.09), p=nr • broad-spectrum AB: aRR 1.02 (95%CI 0.98-1.06), p=nr	Family history of atopy, country, maternal education, birth order
Lapin et al. <sup>164</sup>	Multicentre prospective cohort study (2b)	65; 295 nr; 162 nr; 133	< 1 y No nr	2-3 y	Parent-reported wheezing	Exposure to AB in first y of life associated with increased risk in high-risk children.  • <b>aOR 1.29 (95%CI 1.07-1.55), p=nr</b>	Ethnicity, smoking during pregnancy, antibiotic and medication use during pregnancy, maternal asthma, birth weight, breastfeeding, household smoking
Ong et al. <sup>104</sup>	Multicentre retrospective cohort study (2b)	5,460; 62,576 3,190* 26,693 2,270*; 35,883	< 1 y No Registry	< 3 y	ICD-9 codes	Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.00 (95%CI 1.90-2.20), p&lt;0.01</b>	
Semic-Jusufagic et al. <sup>126</sup>	Multicentre prospective cohort study (2b)	199; 684 nr; nr nr; nr	< 1 y No Parent questionnaire	1-11 y	Parent-reported plus medical records	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.91 (95%CI, 1.29-2.83), p&lt;0.01</b>	

(continued on next page)

Table 1 (continued)

Muc et al. <sup>97</sup>	Multicentre cross-sectional study (3b)	357; 1,037	< 1 y	6-9 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 2.33 (95%CI 1.70-3.18), p&lt;0.01</b>	Age, sex, prematurity, atopy
Portugal 2013		117*; 237 240*; 800	No		Parent questionnaire		
Raciborski et al. <sup>115</sup>	Multicentre retrospective cohort study (2b)	197; 1,330	< 1 y	6-8 y	Questionnaire for wheezing symptoms (ISAAC and ECRHS II)	Exposure to AB in first y of life associated with increased risk. • <b>OR 2.21 (95%CI 1.56-3.12), p&lt;0.01*</b>	
Poland 2012		150; 820 47; 510	No		Parent questionnaire	• 1 AB course: OR 1.12 (95%CI nr), p=0.61 • 2-3 AB courses: <b>OR 1.93 (95%CI nr), p&lt;0.01</b> • > 3 AB courses: <b>OR 4.68 (95%CI 2.60-12.01), p&lt;0.01</b>	
		197; 1,321	1-3 y			Exposure to AB in first to third y of life associated with increased risk.	
		185; 1,145 12; 176	No		Parent questionnaire	• <b>OR 2.63 (95%CI 1.44-4.83), p&lt;0.01*</b> • 1-2 AB courses: OR 1.41 (95%CI nr), p=0.31 • 3-4 AB courses: <b>OR 1.89 (95%CI nr), p=0.06</b> • > 4 AB courses: <b>OR 4.73 (95%CI 1.41-15.90), p&lt;0.01</b>	
Kwon et al. <sup>165</sup>	Multicentre cross-sectional study (3b)	442; 3,765	< 1 y	9.5 y (mean)	Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.88 (95%CI 1.35-2.62), p&lt;0.01</b>	Age, sex, parental asthma, maternal education and BMI; smoke exposure
Korea 2011		nr; nr nr; nr	No		Parent questionnaire		
Rusconi et al. <sup>119</sup>	Multicentre cross-sectional study (3b)	1,598; 16,933	< 1 y	< 2 y	Early transient wheezing Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 3.76 (95%CI 3.31-4.27), p=nr</b>	Age, sex, study centre, person who completed the questionnaire, maternal age, family history of atopy, day care, number of siblings,
Italy		1,114; 5,863 484; 11,070	No				

(continued on next page)

Table 1 (continued)

2011		910; 16,933	Parent questionnaire	< 4-5 y	Persistent wheezing Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 3.06 (95%CI 2.60-3.60), p=nr</b>	sharing a bedroom, parental education, smoking during pregnancy, prematurity, season, breastfeeding, dampness-related exposure
		596; 5,345 314; 11,588					
		1,011; 16,933		4-5 until 6-7 y	Late-onset wheezing Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.18 (95%CI 1.02-1.38), p=nr</b>	
		412; 5,161 599; 11,772					
Goksoer et al. <sup>56</sup>	Multicentre prospective cohort study (2b)	245; 4,495 26; 203 219; 4,292	< 1 w No Parent questionnaire	4.5 y	Questionnaire for wheezing symptoms (ISAAC and BAMSE)	Exposure to AB in first w of life associated with increased risk. • <b>aOR 2.20 (95%CI 1.30-3.80), p&lt;0.05</b>	Prematurity, delivery mode
Sweden							
2011							
Dom et al. <sup>40</sup>	Multicentre prospective cohort study (2b)	235; 667 210; 586 25; 81	< 4 y No Parent questionnaire	6 m-4 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB before first y of life not associated with increased risk. • OR 1.25 (95%CI 0.76-2.06), p=0.38*	Sex, maternal age, family history of atopy, day care, number of siblings, parental education, smoking during pregnancy, pet exposure during pregnancy, birth weight, number of LRTIs, breastfeeding, household smoking, pet exposure
Belgium							
2010							
Mai et al. <sup>178</sup>	Single-centre prospective cohort study (2b)	482; 3,306 254; 1,420 228; 1,886	< 1 y No Parent questionnaire	4 y	Questionnaire for wheezing symptoms (BAMSE based on ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.40 (95%CI 1.20-1.80), p=nr</b> • <b>≥ 2 AB courses: aOR 1.60 (95%CI 1.10-2.20), p&lt;0.01</b>	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding
Sweden							
2010							
		330; 3,306		8 y		Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.40 (95%CI 1.10-1.70), p=nr</b>	
		170; 1,420 160; 1,886					

(continued on next page)



Table 1 (continued)

Karimi et al. <sup>162</sup> Iran 2009	Multicentre cross-sectional study (3b)	141; 1,476 95; 953* 46; 523*	< 1 y No nr	6-7 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk. • OR 1.13 (95%CI 0.77-1.67), p=0.50	
Mitchell et al. <sup>95</sup> New Zealand 2009	Multicentre cross-sectional study (3b)	2,315; 10,423 1,764; 6,476 551; 3,947	< 1 y No Parent questionnaire	6-7 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • aOR 1.78 (95%CI 1.56-2.04), p<0.01	Sex, ethnicity, country of birth, number of siblings, socioeconomic status, medication use, maternal smoking
Alm et al. <sup>15</sup> Sweden 2008	Multicentre prospective cohort study (2b)	994, 4,921 67; 219 927; 4,702	< 1 m No Parent questionnaire	1 y	Questionnaire for wheezing (BAMSE study)	Exposure to AB in first m of life associated with increased risk. • aOR 1.60 (95%CI 1.00–2.50), p=0.04	Sex, prematurity, neonatal intensive-care unit admission, smoking during pregnancy, family history of atopy, light sleep at 12 months, breastfeeding, pacifier use
Kusel et al. <sup>80</sup> Australia 2008	Multicentre prospective cohort study (2b)	56; 198 34*; 107 22*; 91	< 1 y Yes Parent questionnaire	0-5 y	Parent-reported current wheeze	Exposure to AB in first y of life not associated with increased risk. • aOR 1.00 (95%CI 0.50-2.20), p=nr Results according to antibiotic class nr	Sex, day care, number of GP visits, pet exposure
Simon et al. <sup>192</sup> USA 2008	Multicentre prospective cohort study (2b)	117; 239 67; 142 50; 97	< 6 m No Medical records	1-4 y	Parent-reported	Exposure to AB in first 6 m of life associated with increased risk. • aRR 1.60 (95%CI 1.00-2.60), p=0.05	Sex, family history of atopy, day care, birth order, fever, breastfeeding, pet exposure
Verhulst et al. <sup>193</sup> Belgium 2008	Multicentre prospective cohort study (2b)	36; 154 25*; 76 11*; 78	< 1 y No Parent questionnaire	1 y	Questionnaire for wheezing (ISAAC)	Exposure to AB in first y of life associated with increased risk. • OR 2.94 (95%CI 1.59-5.43), p<0.01	

(continued on next page)

Table 1 (continued)

Harris et al. <sup>60</sup> UK 2007	Single-centre prospective cohort study (2b)	79; 523 30; nr 49; nr	< 5 y No Medical records	8 y	Questionnaire for wheezing (ISAAC)	Exposure to AB in first 5 y of life associated with increased risk.  • <b>aOR 1.07 (95%CI 1.03-1.10), p&lt;0.01</b>	Family history of atopy, birth order, smoke exposure
Sharma et al. <sup>166</sup> India 2007	Multicentre prospective cohort study (2b)	300; 8,470 147*; 3,260 153*; 5,210	5-13 y No Parent questionnaire	6-14 y	Questionnaire for wheezing (ISAAC)	Exposure to AB in infancy associated with increased risk.  • <b>OR 1.60 (95%CI 1.10-2.10), p&lt;0.01</b>	
Kummeling et al. <sup>79</sup> Netherlands 2007	Multicentre prospective cohort study (2b)	265; 2,462 93; 489 172; 1,973	< 6 m No Parent questionnaire	2 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first 6 m of life associated with increased risk.  • <b>aOR 2.65 (95%CI, 1.95-3.60), p=nr</b>	Sex, family history of atopy, day care, number of siblings, delivery mode, vaccination status, fever, breastfeeding, pet and smoke exposure
Flojstrup et al. <sup>49</sup> Netherlands, Austria, Germany, Sweden, Switzerland 2006	Multicentre cross-sectional study (3b)	396; 4,606 113*; 788 283*; 3,818	< 1 y No Parent questionnaire	7-11 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 2.05 (95%CI 1.48-2.85), p=nr</b>	Age, sex, family history of atopy, number of siblings, country, parental education, measles infection, vaccination status, medication use, smoking during pregnancy, diet, household smoking, pet exposure
Ahn et al. <sup>13</sup> Korea 2005	Multicentre cross-sectional study (3b)	1,352; 25,787 480*; 6,273 872*; 19,514	< 1 y No Parent questionnaire	7-12 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.52 (95%CI 1.32-1.75), p&lt;0.01</b>  • 1-2 AB courses: <b>aOR 1.31 (95%CI 1.11-1.56), p&lt;0.01</b> • 3-4 AB courses: aOR 1.23 (95%CI 0.94-1.61), p=nr	Episodes of fever or acute gastroenteritis

(continued on next page)

Table 1 (continued)

Awasthi et al. <sup>194</sup>	Multicentre cross-sectional study (3b)	188; 1,492 46; 142 142; 1,350	< 1 y No Parent questionnaire	6-7 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 3.06 (95%CI 1.92-4.88), p=nr</b>	Maternal education, diet, exercise
India 2004							
Cohet et al. <sup>37</sup>	Single-centre case-control study (3b)	938; 3,927 738; 2,684 200; 1,243	< 1 y No Parent questionnaire	6-7 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.78 (95%CI 1.49-2.14), p=nr</b>	
New Zealand 2004							
Wjst et al. <sup>155</sup>	Multicentre cross-sectional study (3b)	562; 2,512 171; 2,025 391; 487	< 5-14 y No Parent questionnaire	5-14 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.90 (95%CI 1.20-3.30), p=0.01</b>	Age, sex, family history of atopy, season, parental education
Germany 2001							
Wickens et al. <sup>154</sup>	Multicentre retrospective cross-sectional study (3b)	138; 447 117; 334 21; 113	< 10 y No Parent questionnaire	5-10 y	Questionnaire for wheezing symptoms (ISAAC)	Exposure to AB in first 10 y of life associated with increased risk.  • <b>aOR 1.86 (95%CI 1.06-3.26), p=nr</b>	Age, sex, ethnicity, family history of atopy, household size, parental smoking
New Zealand 1999							
<b>Asthma</b>							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study (2b)	1,176; 14,572 964; 10,220 212; 4,352	< 2 y Yes Medical records	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aHR 1.90 (95%CI 1.63-2.20), p&lt;0.01</b>	Sex, ethnicity, maternal age and education, antibiotic use during pregnancy, birth weight, delivery mode, maternal smoking
USA 2021							

(continued on next page)

Table 1 (continued)

						<p>Girls</p> <ul style="list-style-type: none"> <li>• penicillins: <b>HR 1.50 (95%CI 1.21-1.87), p&lt;0.01</b></li> <li>• cephalosporins: <b>HR 1.39 (95%CI 1.13-1.71), p&lt;0.01</b></li> <li>• macrolides: <b>HR 1.33 (95%CI 1.08-1.62), p&lt;0.01</b></li> <li>• sulfonamides: HR 1.27 (95%CI 0.93-1.74), p=0.13</li> </ul> <p>Boys</p> <ul style="list-style-type: none"> <li>• penicillins: <b>HR 1.35 (95%CI 1.12-1.62), p&lt;0.01</b></li> <li>• cephalosporins: <b>HR 1.29 (95%CI 1.09-1.53), p&lt;0.01</b></li> <li>• macrolides: <b>HR 1.34 (95%CI 1.14-1.58), p&lt;0.01</b></li> <li>• sulfonamides: HR 0.92 (95%CI 0.66-1.27), p=0.60</li> </ul>	
Neto et al. <sup>101</sup>	Multicentre cross-sectional study (3b)	339; 850	< 6 m	9-12 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first 6 m of life associated with increased risk.	Maternal asthma, shared bedroom, number of LRTIs, atopy, medication use, pet exposure
Brazil		180*; 368	No				
2020		159*; 482	Parent questionnaire			• <b>aOR 1.57 (95%CI 1.13-2.17), p&lt;0.01</b>	
Donovan et al. <sup>41</sup>	Single-centre retrospective cohort study (4)	20,984; 152,622	< 1 y	4.5-6 y	ICD-9-CM codes plus prescription records	Exposure to AB in first y of life associated with increased risk.	Age, sex, ethnicity, maternal age and education; household size, living area, marital status, smoking during pregnancy, gestational age, birth weight, season of birth, delivery mode, medication use, pet exposure
USA		18,233; 120,973	Yes			• <b>aOR 1.88 (95%CI 1.80-1.96), p=nr</b>	
2020		2,751; 31,649	Medical records			Results according to antibiotic class nr	
Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	106; 1,185	< 1 y	12-36 m	Questionnaire for asthma symptoms (based on ISAAC)	Exposure to AB in first y of life associated with increased risk in urban cohort.	
South Africa		83; 654	No			• <b>OR 3.21 (95%CI 1.99-5.17), p&lt;0.01*</b>	
2020		23; 531	Parent questionnaire			Exposure to AB in first y of life not associated with increased risk in rural cohort.	
		4; 398				• <b>OR 1.35 (95%CI 0.07-25.43), p=0.84*</b>	
		4; 347					
		0; 51					

(continued on next page)

Table 1 (continued)

Patrick et al. <sup>109</sup>	Multicentre prospective cohort study	118; 1,947 29; 289	< 1 y Yes	5 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 2.15 (95%CI 1.37-3.39), p&lt;0.01</b>  • 1 AB course: <b>aOR 1.93 (95%CI 1.15-3.26), p=0.01</b> • 2 AB courses: aOR 2.66 (95%CI 0.99-7.18), p=0.05 • ≥ 3 AB courses: <b>aOR 3.25 (95%CI 1.05-10.08), p=0.04</b>  Results according to antibiotic class nr	Sex, ethnicity, study centre, family history of atopy, number of siblings, birth weight, season of birth, delivery mode, breastfeeding, smoke and environmental nitrogen dioxide exposure
Canada 2020	(2b)	89; 1,658	Registry				
Zou et al. <sup>161</sup>	Multicentre cross-sectional study (3b)	1,285; 12,667 412; 3,049 873; 9,618	< 1 y No Parent questionnaire	4-6 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.38 (95%CI 1.19-1.61), p&lt;0.01</b>	Age, sex, living area, family history of atopy, breastfeeding, home decoration, pet, smoke and home dampness-related exposure
China 2020							
Ni et al. <sup>102</sup>	Single-centre retrospective cohort study (4)	177; 2,398 128*; 1,060 49*; 1,338	< 1 y Yes Medical records	1-10 y	ICD-9 and ICD-10 codes	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 2.66 (95%CI 1.11-6.40), p=0.03</b>  Results according to antibiotic class nr	Age, sex, ethnicity, socioeconomic status, prematurity, birth weight, delivery mode, neonatal intensive-care unit admission
USA 2019		253; 2,398 211*; 1,755 42*; 643	< 10 y Yes Medical records			Exposure to AB in first 10 y of life associated with increased risk.  • <b>aOR 3.54 (95%CI 1.99-6.30), p&lt;0.01</b>  Results according to antibiotic class nr	
Metzler et al. <sup>93</sup>	Multicentre prospective cohort study (2b)	73; 1,019 35; 419 38; 600	< 1 y No Parent questionnaire	< 6 y	Questionnaire for asthma symptoms (based on ISAAC) plus parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.65 (95%CI 0.95-2.86), p&lt;0.05</b>	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, pet exposure during pregnancy, delivery mode, duration of breastfeeding, pet exposure
Switzerland 2019							

(continued on next page)

Table 1 (continued)

Norbäck et al. <sup>103</sup>	Multicentre retrospective cohort study	2,936; 39,782	< 1 y	3-6 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.	Living area, time spend outdoors, air pollution, temperature in each city
China	(2b)	2,586; 29,303	No			• <b>aOR 2.03 (95%CI 1.72-2.40), p&lt;0.01</b>	
2019		250; 10,479	Parent questionnaire			• 1 AB course: <b>aOR 1.26 (95%CI 1.11-1.44), p&lt;0.01</b> • > 1 AB courses: <b>aOR 2.08 (95%CI 1.87-2.33), p&lt;0.01</b>	
Soto-Martinez et al. <sup>132</sup>	Multicentre cross-sectional study (3b)	595; 2,689	< 1 y	6-13 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	Atopy, dry cough, medication use, traffic exposure
Costa Rica		380; 1,290	No			• <b>aOR 1.20 (95%CI 1.01-1.43), p=0.04</b>	
2019		215; 1,399	Parent questionnaire				
Chen et al. <sup>34</sup>	Multicentre case-control study (3b)	2,082; 4,164	< 5 y before diagnosis	2-18 y	ICD-9-CM codes plus prescription records (ATC codes)	Exposure to AB in 5 y before diagnosis associated with increased risk.	Age, sex, living area, comorbidities, medication use
Taiwan		1,849; 3,512	Yes			• <b>aOR 2.10 (95%CI 1.75-2.52), p&lt;0.01</b>	
2018		233; 652	Registry			• low-dose: <b>aOR 1.64 (95%CI 1.35-2.01), p&lt;0.01</b> • moderate-dose: <b>aOR 2.23 (95%CI 1.81-2.74), p&lt;0.01</b> • high-dose: <b>aOR 3.33 (95%CI 2.67-4.15), p&lt;0.01</b>  • penicillins: <b>aOR 1.77 (95%CI 1.43-2.20), p&lt;0.01</b> • cephalosporins: <b>aOR 1.67 (95%CI 1.32-2.11), p&lt;0.01</b> • macrolides: <b>aOR 2.02 (95%CI 1.48-2.76), p&lt;0.01</b>	
Mitre et al. <sup>96</sup>	Multicentre retrospective cohort study (2b)	111,792; 792,130	< 6 m	1-6 y	ICD-9-CM codes	Exposure to AB in first 6 m of life associated with increased risk.	Sex, prematurity, delivery mode, medication (incl. anti-reflux medication) use
USA		27,488; 131,708	No			• <b>aHR 2.09 (95%CI 2.05-2.13), p=nr</b>	
2018		84,304; 660,422	Registry				
Strömberg et al. <sup>134</sup>	Multicentre prospective cohort study (2b)	233; 3,637	< 1 w	12 y	Atopic asthma Questionnaire for asthma symptoms (ISAAC and BAMSE)	Exposure to AB in first w of life associated with increased risk.	Family history of atopy, prematurity, weight for gestational age, delivery mode
Sweden		19; 152	No			• <b>aOR 2.20 (95%CI 1.20-4.20), p&lt;0.05</b>	
2018		214; 3,485	Parent questionnaire		Non-atopic asthma Questionnaire for asthma symptoms (ISAAC and BAMSE)	Exposure to AB in first w of life not associated with increased risk.	
						• <b>aOR 1.40 (95%CI 0.50-3.40), p=nr</b>	

(continued on next page)

Table 1 (continued)

Yoshida et al. <sup>195</sup>	Multicentre retrospective cohort study (2b)	3,633; 83,470 2,517; 46,562 1,116; 36,908	< 1 y Yes Registry	1-3 y	ICD-10 codes plus prescription records	Exposure to AB in first y of life associated with increased risk.  • <b>aHR 2.43 (95%CI 2.20-2.69), p=nr</b>  • 1-2 AB courses: <b>aHR 1.89 (95%CI 1.69-2.11), p=nr</b> • 3-4 AB courses: <b>aHR 2.93 (95%CI 2.58-3.33), p=nr</b> • > 5 AB courses: <b>aHR 4.66 (95%CI 4.04-5.36), p=nr</b>  • penicillins: <b>aHR 1.39 (95%CI 1.26-1.53), p=nr</b> • cephalosporins: <b>aHR 1.55 (95%CI 1.41-1.70), p=nr</b> • macrolides: <b>aHR 2.00 (95%CI 1.83-2.20), p=nr</b>	Sex
Japan 2018				3-6 y		Exposure to AB in first y of life associated with increased risk.  • <b>aHR 1.23 (95%CI 1.11-1.36), p=nr</b>  • 1-2 AB courses: <b>aHR 1.15 (95%CI 1.03-1.29), p=nr</b> • 3-4 AB courses: <b>aHR 1.28 (95%CI 1.11-1.48), p=nr</b> • > 5 AB courses: <b>aHR 1.53 (95%CI 1.28-1.83), p=nr</b>  • penicillins: <b>aHR 0.87 (95%CI 0.76-0.98), p=nr</b> • cephalosporins: <b>aHR 1.20 (95%CI 1.08-1.33), p=nr</b> • macrolides: <b>aHR 1.17 (95%CI 1.05-1.31), p=nr</b>	
Ahmadizar et al. <sup>12</sup>	Multicentre prospective cohort study (2b)	74; 891 28*; 260 46*; 631	< 6 m No Parent questionnaire	9-10 y	Parent-reported physician's diagnosis	Exposure to AB in first 6 m of life not associated with increased risk.  • <b>aOR 1.50 (95%CI 0.91-2.46), p=nr</b>	Sex, family history of asthma
Netherlands Scotland 2017		448, 3,960 414*; 3,178 34*; 782	< 3 y No Parent questionnaire	10 y		Exposure to AB in first 3 y of life associated with increased risk.  • <b>aOR 2.84 (95%CI 1.70-4.75), p=nr</b>	Sex, family history of atopy

(continued on next page)

Table 1 (continued)

Han et al. <sup>59</sup>	Multicentre cross-sectional study (3b)	58; 1,517 44; 921 14; 596	< 1 y No Parent questionnaire	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk. • aOR 1.30 (95%CI 0.60-2.60), p=nr	Number of LRTIs, medication use
Argentina 2017							
Yamamoto-Hanada et al. <sup>157</sup>	Multicentre prospective cohort study (2b)	95; 902 58; 436 37; 466	< 2 y Yes Parent questionnaire	5 y	Questionnaire for asthma symptoms (ISAAC) plus medical records	Exposure to AB in first 2 y of life associated with increased risk. • aOR 1.72 (95%CI 1.10-2.70), p=0.02 • penicillins: aOR 1.21 (95%CI 0.58-2.56), p=0.61 • cephem: aOR 1.97 (95%CI 1.23-3.16), p<0.01 • macrolides: aOR 1.46 (95%CI 0.88-2.44), p=0.15	Sex, maternal age, BMI, education, maternal and history of atopy, parity, day care, smoking during pregnancy, gestational age, delivery mode, number of LRTIs,
Japan 2017							
Wu et al. <sup>166</sup>	Multicentric prospective cohort study (2b)	18,087; 136,098 13,740*; 99,054 4,347*; 37,044	< 1 y No Medical records	4.5-6 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk. • aOR 1.16 (95% CI, 1.15-1.18), p=nr	Sex, ethnicity, maternal age, education, and asthma; number of siblings, smoking during pregnancy, gestational age, neonatal intensive-care unit admission, birth weight, delivery mode, number of LRTIs, comorbidities, healthcare use
USA 2016							
Korpela et al. <sup>75</sup>	Multicentre case-control study (3b)	16*; 148 9*; 32 7*; 116	< 2 y Yes Registry	2-7 y	Parent-reported physician's diagnosis	Exposure to AB in first 2 y of life associated with increased risk. • macrolides: OR 6.11 (95%CI 1.53-26.58), p<0.01	
Finland 2016							
Pitter et al. <sup>111</sup>	Multicentre retrospective cohort study (2b)	34,957; 143,163 16,406; 54,685 18,551; 88,478	< 1 y Yes Registry	13 m-18 y	ICD-9 codes plus prescription records (ATC codes)	Exposure to AB in first y associated with increased risk. • aIRR 1.50 (95%CI 1.46-1.53), p<0.05	Age, sex, maternal age, and education; gestational age, birth weight, hospital admissions for infections
Italy 2016							

(continued on next page)



Table 1 (continued)

						<ul style="list-style-type: none"> <li>• penicillins: <b>aIRR 1.43 (95%CI 1.40-1.46), p&lt;0.05</b></li> <li>• cephalosporins: <b>aIRR 1.36 (95%CI 1.32-1.40), p&lt;0.05</b></li> <li>• macrolides: <b>aIRR 1.57 (95%CI 1.52-1.63), p&lt;0.05</b></li> </ul>	
						<ul style="list-style-type: none"> <li>• 1-2 AB courses: <b>aIRR 1.41 (95%CI 1.38-1.44), p&lt;0.01</b></li> <li>• 3-4 AB courses: <b>aIRR 1.84 (95%CI 1.77-1.92), p&lt;0.01</b></li> <li>• ≥ 5 AB courses: <b>aIRR 2.13 (95%CI 2.00-2.28), p&lt;0.01</b></li> </ul>	
Krenz-Niedbala et al. <sup>77</sup>	Multicentre cross-sectional study (3b)	130; 1,277 59*; 433 71*; 844	< 1 y No	8 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.	
Poland			Parent questionnaire			<ul style="list-style-type: none"> <li>• <b>OR 1.71 (95%CI 1.29-2.26) p=nr</b></li> </ul>	
2015							
Metsälä et al. <sup>92</sup>	Multicentre case-control study (3b)	1,419; 6,690 1,212; 5,352 207; 1,338	< 6 m before diagnosis Yes	3-10 y	ICD-10 codes plus prescription records (ATC codes)	Exposure to AB 6 m before diagnosis associated with increased risk.	Parity, maternal asthma, gestational age
Finland			Registry			<ul style="list-style-type: none"> <li>• <b>aOR 1.60 (95%CI 1.48-1.73), p&lt;0.05</b></li> </ul>	
2015						<ul style="list-style-type: none"> <li>• penicillin: <b>aOR 1.33 (95%CI 1.21-1.47), p=nr</b></li> <li>• amoxicillin: <b>aOR 2.35 (95%CI 2.10-2.63), p=nr</b></li> <li>• cephalosporins: <b>aOR 1.91 (95%CI 1.76-2.07), p=nr</b></li> <li>• macrolides: <b>aOR 2.74 (95%CI 2.50-2.99), p=nr</b></li> <li>• trimethoprim/sulfamethoxazole: <b>aOR 1.98 (95%CI 1.80-2.18), p=nr</b></li> </ul>	
Lee et al. <sup>169</sup>	Multicentre cross-sectional study (3b)	459; 6,161 189; 1,865 270; 4,296	< 1 y No	13.9 y (mean)	Questionnaire for asthma symptoms (based on ISAAC)	Exposure to AB in first y of life associated with increased risk.	Age, sex, family history of atopy, income, BMI, smoke exposure
Korea			Parent questionnaire			<ul style="list-style-type: none"> <li>• <b>aOR 1.94 (95%CI 1.49-2.53) p=nr</b></li> </ul>	
2015							
Eldeirawi et al. <sup>191</sup>	Multicentre cross-sectional study (3b)	133; 1,786 92; 799 41; 987	< 1 y No	1 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.	Age, sex, country of birth, family history of atopy, having a regular doctor or clinic, number of ear infections
USA			Parent questionnaire			<ul style="list-style-type: none"> <li>• <b>aOR 2.33 (95% CI, 1.53-3.55), p&lt;0.01</b></li> </ul>	
2015						<ul style="list-style-type: none"> <li>• 1-2 AB courses: <b>aOR 1.81 (95%CI 1.13-2.88), p=0.01</b></li> <li>• ≥ 3 AB courses: <b>aOR 3.43 (95%CI 2.06-5.73), p&lt;0.01</b></li> </ul>	

(continued on next page)

Table 1 (continued)

Khalkhali et al. <sup>168</sup>	Single-centre prospective case-control study (3b)	157; 361 120; 230 47; 131	< 1 y No Parent questionnaire	2-8 y	Global Initiative for Asthma (GINA) criteria	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.91 (95%CI 1.27-2.88), p=0.03</b>	Family history of atopy, prematurity, delivery mode, birth order
Iran							
2014							
Lapin et al. <sup>164</sup>	Multicentre prospective cohort study (2b)	44; 295 nr; 162 nr; 133	< 1 y No nr	3 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk in high-risk children.  • <b>aOR 1.58 (95%CI 1.27-1.96), p=nr</b>	Ethnicity, smoking during pregnancy, antibiotic and medication use during pregnancy, maternal asthma, birth weight, breastfeeding, household smoking
USA							
2014							
Ong et al. <sup>104</sup>	Multicentre retrospective cohort study (2b)	5,946; 62,576 3,162*; 26,693 2,784*; 35,883 6,418; 62,576 2,875*; 26,693 3,543*; 35,883	< 1 y No Registry	< 3 y Registry > 3 y	ICD-9 codes	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.60 (95%CI 1.50-1.70), p&lt;0.01</b>  Exposure to AB in first y of life not associated with increased risk.  • <b>OR 1.10 (95%CI 1.00-1.10), p=0.10</b>	
Australia							
2014							
Semic-Jusufagic et al. <sup>126</sup>	Multicentre prospective cohort study (2b)	529; 800 nr; 564 nr; 236	< 1 y No Parent questionnaire	1-11 y	Parent-reported plus medical records	Exposure to AB in first y of life associated with increased risk.  • <b>HR 2.26 (95%CI 1.03-4.94), p=0.04</b>	
UK							
2014							
Örtqvist et al. <sup>198</sup>	Multicentre prospective cohort study (2b)	29,753; 493,785 25,306; 305,938 4,447; 187,847	< 2 y Yes Registry	< 5 y > 2 y	ICD-10 codes or prescription records (ATC codes)	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aHR 2.03 (95%CI 1.93-2.12), p=nr</b>  Results according to antibiotic class nr	Sex, maternal country of birth and age; parity, parental marital status, parental education, antibiotic use during pregnancy, gestational age, birth weight,
Sweden							
2014							

(continued on next page)

Table 1 (continued)

Goksoer et al. <sup>55</sup>	Multicentre prospective cohort study (2b)	231; 4,051 19; 187 212; 3,864	< 1 w No Parent questionnaire	8 y	Questionnaire for asthma symptoms (ISAAC and BAMSE)	Exposure to AB in first w of life associated with increased risk.  • <b>aOR 2.30 (95%CI 1.20-4.20), p&lt;0.05</b>	delivery mode, respiratory diagnosis (respiratory distress, congenital pneumonia, neonatal aspiration syndromes, interstitial emphysema, pulmonary haemorrhage, chronic respiratory disease)  Family history of atopy, prematurity, weight for gestational age, delivery mode
Hoskin-Parr et al. <sup>176</sup>	Single-centre prospective cohort study (2b)	630; 5,780 367*; 2,659 263*; 3,121	< 2 y No Parent questionnaire	7.5 y (mean)	Parents-reported physician's diagnosis	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aOR 1.75 (95%CI 1.40-2.17), p=nr</b>  • 1 AB course: aOR 1.11 (95%CI 0.84-1.48), p=nr • 2 AB courses: aOR 1.50 (95%CI 1.14-1.98), p=nr • 3 AB courses: aOR 1.79 (95%CI 1.34-2.40), p=nr • ≥ 4 AB courses: aOR 2.82 (95%CI 2.19-3.63), p=nr	Age, sex, maternal age and education; parental marital status, home ownership status, degree of difficulty in paying for food, smoking during pregnancy, disinfectant use during pregnancy, gestational age, birth weight, delivery mode, age of child at outcome, breastfeeding, time spend outdoors, pet exposure
Muc et al. <sup>97</sup>	Multicentre cross-sectional study (3b)	106; 1,037 38*; 237 68*; 800	< 1 y No Parent questionnaire	6-9 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.96 (95%CI 1.25-3.08), p&lt;0.01</b>	Age, sex, prematurity, atopy
Wang et al. <sup>150</sup>	Multicentre prospective cohort study (2b)	57,328; 263,620 nr; 15,663 nr; 247,957	< 1 y Yes Medical records	2-6 y	ICD-9-CM codes	Exposure to AB in first y of life associated with increased risk.  • <b>aHR 1.38 (95%CI 1.32-1.46), p&lt;0.05</b>  Results according to antibiotic class nr	Sex, living area, socioeconomic status, healthcare use

(continued on next page)

Table 1 (continued)

Almqvist et al. <sup>197</sup> Sweden 2012	Multicentre prospective cohort study (2b)	nr; 9,400,000 95,628; 211,192 nr; 9,188,808	< 3 y Yes Registry	<1 y	Prescription records (ATC codes)	Exposure to AB in first 3 y of life associated with increased risk.
						<ul style="list-style-type: none"> <li>• <b>HR 2.20 (95%CI 2.12-2.28), p=nr</b></li> <li>• 1-2 AB courses: <b>HR 1.72 (95%CI 1.45-2.05), p=nr</b></li> <li>• 3-5 AB courses: <b>HR 1.25 (95%CI 1.86-2.72), p=nr</b></li> <li>• ≥ 6 AB courses: <b>HR 2.36 (95%CI 1.76-3.16), p=nr</b></li> <li>• narrow-spectrum: <b>HR 1.60 (95%CI 1.35-1.91), p=nr</b></li> <li>• broad-spectrum: <b>HR 2.04 (95%CI 1.71-2.42), p=nr</b></li> </ul>
						Results according to antibiotic class nr
						<ul style="list-style-type: none"> <li>• <b>HR 1.73 (95%CI 1.66-1.82), p=nr</b></li> <li>• 1-2 AB courses: <b>HR 1.37 (95%CI 1.16-1.61), p=nr</b></li> <li>• 3-5 AB courses: <b>HR 2.03 (95%CI 1.72-2.40), p=nr</b></li> <li>• ≥ 6 AB courses: <b>HR 2.50 (95%CI 2.09-3.01), p=nr</b></li> <li>• narrow-spectrum: <b>HR 1.28 (95%CI 1.09-1.50), p=nr</b></li> <li>• broad-spectrum: <b>HR 1.83 (95%CI 1.56-2.15), p=nr</b></li> </ul>
1 y	Results according to antibiotic class nr					
2 y	<ul style="list-style-type: none"> <li>• <b>HR 1.29 (95%CI 1.15-1.45), p=nr</b></li> <li>• 1-2 AB courses: HR 0.85 (95%CI 0.53-1.36), p=nr</li> <li>• 3-5 AB courses: HR 1.26 (95%CI 0.78-2.02), p=nr</li> <li>• ≥ 6 AB courses: <b>HR 1.77 (95%CI 1.10-2.86), p=nr</b></li> <li>• narrow-spectrum: HR 0.96 (95%CI 0.65-1.41), p=nr</li> <li>• broad-spectrum: HR 1.38 (95%CI 0.94-2.04), p=nr</li> </ul>					
≥ 3 y	Results according to antibiotic class nr					
	<ul style="list-style-type: none"> <li>• HR 1.15 (95%CI 0.73-1.83), p=nr</li> </ul>					
	Results according to antibiotic class nr					

(continued on next page)

Table 1 (continued)

Raciborski et al. <sup>115</sup>	Multicentre retrospective cohort study (2b)	63; 1,330 52; 820 11; 510	< 1 y No Parent questionnaire	6-8 y	Questionnaire for asthma symptoms (ISAAC and ECRHS II)	Exposure in first y of life associated with increased risk when $\geq 2$ AB courses.  • 1 AB course: OR 1.54 (95%CI nr), p=0.30 • 2 AB courses: <b>OR 2.55 (95%CI nr), p=0.02</b> • > 3 AB courses: <b>OR 5.59 (95%CI 2.6-12.01), p&lt;0.01</b>	
Poland		63; 1,321 60; 1,145 3; 176	1-3 y No Parent questionnaire			Exposure in second and third y of life associated with increased risk when > 4 AB courses.  • 1-2 AB courses: OR 1.42 (95%CI nr), p=0.59 • 3-4 AB courses: OR 2.87 (95%CI nr), p=0.09 • > 4 AB courses: <b>OR 4.73 (95%CI 1.41-15.90), p&lt;0.01</b>	
Jedrychowski et al. <sup>69</sup>	Multicentre prospective cohort study (2b)	29; 310 26*; 244 3*; 66	< 2 y Yes Parent questionnaire	5 y	Parent-reported physician's diagnosis	Exposure to AB in first 5 y of life associated with increased risk.  • <b>aOR 2.08 (95%CI 1.32-3.28), p=nr</b>  • penicillins: aOR 1.49 (95%CI 0.89-2.49), p=nr • cephalosporins: <b>aOR 2.45 (95%CI 1.49-4.02), p=nr</b> • macrolides: <b>aOR 2.14 (95%CI 1.16-3.95), p=nr</b>	Age, maternal atopy and education, parity, smoke exposure
USA							
2011							
Risnes et al. <sup>116</sup>	Multicentric prospective cohort study (2b)	164; 1,401 65; 464 99; 937	< 6 m No Parent questionnaire	6 y	ICD-9 codes	Exposure to AB in first 6 m of life associated with increased risk.  • <b>aOR 1.52 (95% CI, 1.07-2.16), p=nr</b>  • 1 AB course: aOR 1.40 (95%CI 0.90-2.15), p=nr • $\geq 2$ AB courses: aOR 1.72 (95%CI 1.11-2.65), p=0.01	Maternal age, family history of asthma, income, number of LRTIs
USA							
2011							
Sandini et al. <sup>177</sup>	Single-centre prospective cohort study (2b)	121; 891 nr; nr nr; nr	< 6 m No Parent questionnaire	5 y	Parent-reported physician's diagnosis	Exposure to AB in first 6 m of life not associated with increased risk.  • OR 0.90 (95%CI 0.41-1.98), p=0.79	
Finland							
2011							

(continued on next page)

Table 1 (continued)

Yeh et al. <sup>159</sup> Taiwan 2011	Multicentre cross-sectional study (3b)	566; 2,037 nr; nr nr; nr	< 1 y No Parent questionnaire	3-6 y	Questionnaire for asthma symptoms (ISAAC) plus parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.35 (95%CI 1.52-3.66), p&lt;0.01</b>	
Su et al. <sup>135</sup> USA 2010	Multicentre prospective cohort study (2b)	50; 424 22; 136 28; 288	< 9 m No Parent questionnaire	1-5 y	Parent-reported physician's diagnosis (questionnaire for respiratory symptoms)	Exposure to AB in first 9 m of life associated with increased risk.  • <b>aOR 1.50 (95%CI 1.10-2.10), p=0.02</b>  Exposure to AB in first 9 m of life not associated with increased risk after adjustment for number of illness visits.  • aOR 1.20 (95%CI 0.60-2.30), p=0.70	Number of illness visits
Mai et al. <sup>178</sup> Sweden 2010	Single-centre prospective cohort study (2b)	228; 3,306 125; 1,420 103; 1,886	< 1 y No Parent questionnaire	4 y	Questionnaire for asthma symptoms (BAMSE based on ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.50 (95%CI 1.10-2.00), p=nr</b>  • <b>≥ 2 AB courses: aOR 1.90 (95%CI 1.20-3.00), p&lt;0.01</b>	Sex, maternal age and smoking; family history of atopy, number of siblings, breastfeeding
		210; 3,306 104; 1,420 106; 1,886		8 y		Exposure to AB in first y of life not associated with increased risk.  • aOR 1.20 (95%CI 0.90-1.60), p=nr	
Foljaki et al. <sup>50</sup> Sweden 2009	Multicentre retrospective cross-sectional study (3b)	nr; 193,412 nr; 135,775 nr; 57,637	< 1 y No Parent questionnaire	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.94 (95%CI 1.83-2.06), p=nr</b>	Sex, language, living area, income
Karimi et al. <sup>162</sup> Iran 2009	Multicentre cross-sectional study (3b)	49; 1,476 39; 950* 10; 526*	< 1 y No nr	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.21 (95%CI 1.05-4.80), p=0.02</b>	

(continued on next page)

Table 1 (continued)

Martel et al. <sup>88</sup>	Multicentre prospective case-control study (3b)	5,226; 109,746 2,057; 29,509 3,169; 80,237	< 6 m No Registry	< 10 y	ICD-9 codes	Exposure to AB in first 6 m of life associated with increased risk.  • aOR 1.70 (95%CI 1.34-2.15), p=nr	Maternal asthma
Canada 2009							
Garcia et al. <sup>52</sup>	Multicentre cross-sectional study (3b)	175; 641 nr; 420 nr; 221	< 1 y No Parent questionnaire	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • aOR 1.90 (95%CI 1.40-2.50), p<0.01	Maternal and medication use; time spent watching television per day, pet exposure
Colombia 2008							
Wickens et al. <sup>153</sup>	Multicentre prospective cohort study (2b)	119; 1,064 29*; 148 90*; 916	< 3 m No Parent questionnaire	15 m	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first 3 m of life not associated with increased risk after adjustment for chest infections.  • aOR 1.58 (95% CI, 0.96-2.60), p=0.07	Number of LRTIs
New Zealand 2008							
		168; 1,011	< 15 m	4 y		Exposure to AB in first 15 m of life not associated with increased risk.  • aOR 0.98 (95%CI 0.60-1.59), p=0.92	
		128*; 722 40*; 289	No Parent questionnaire				
Kusel et al. <sup>80</sup>	Multicentre prospective cohort study (2b)	37; 198 24*; 107 13*; 91	< 1 y Yes Parent questionnaire	0-5 y	Parent-reported current asthma	Exposure to AB in first y of life not associated with increased risk.  • aOR 0.90 (95%CI 0.40-2.30), p=nr  Results according to antibiotic class nr	Sex, day care, number of GP visits, pet exposure
Australia 2008							
		57; 198 39*; 107 18*; 91			Parent-reported physician's diagnosis	Exposure to AB in first y of life not associated with increased risk.  • aOR 1.50 (95%CI 0.70-3.20), p=nr  Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Kozyrskyj et al. <sup>76</sup>	Multicentre prospective cohort study (2b)	787; 13,116 nr; 8,525 nr; 4,591	< 1 y Yes Registry	7 y	≥ 1 physician visits or hospitalizations for asthma or 2 prescriptions for asthma	Exposure to AB in first y of life associated with increased risk. • <b>aOR 1.86 (95%CI 1.02-3.37), p=nr</b> • 1-2 AB courses: <b>aOR 1.21 (95%CI 1.011-1.46), p=nr</b> • 3-4 AB courses: <b>aOR 1.30 (95%CI 1.04-1.63), p=nr</b> • > 4 AB courses: <b>aOR 1.46 (95%CI 1.14-1.88), p=nr</b>	Sex, maternal history of asthma, living area, number of siblings, number of LRTIs, healthcare use
Canada 2007						Results according to antibiotic class nr	
Mullooly et al. <sup>98</sup>	Single-centre case-control study (3b)	383; 844 nr; nr nr; nr	< 2 y No Medical records	10.3 y (mean)	Parent-reported physician's diagnosis	Exposure to AB in first 2 y of life not associated with increased risk. • <b>aOR 1.02 (95%CI 0.98-1.06), p=nr</b>	Sex, ethnicity, maternal age, birth weight, age of child at outcome, breastfeeding, household smoking
USA 2007							
Del-Rio-Navarro et al. <sup>39</sup>	Multicentre cross-sectional study (3b)	794; 4,106 601*; 2,583 193*; 1,523 Boys: 451; 2,098 342*; 1,364 109*; 734 Girls: 343; 2,008 259*; 1,219 84*; 789	< 1 y No Parent questionnaire	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk. • <b>OR 2.09 (95%CI 1.75-2.49), p&lt;0.01</b> Exposure to AB in first y of life associated with increased risk boys. • <b>OR 1.92 (95%CI 1.41-2.62), p&lt;0.01</b> Exposure to AB in first y of life associated with increased risk in girls. • <b>OR 2.27 (95%CI 1.49-3.44), p&lt;0.01</b>	
Mexico 2006							

(continued on next page)



Table 1 (continued)

Flojstrup et al. <sup>49</sup>	Multicentre cross-sectional study (3b)	419; 4,606 161*; 788 258*; 3,818	< 1 y No Parent questionnaire	7-11 y	Parent-reported physician's diagnosis	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 2.79 (95%CI 2.03-3.83), p=nr</b>	Age, sex, family history of atopy, number of siblings, country, parental education, measles infection, vaccination status, medication use, smoking during pregnancy, diet, household smoking, pet exposure
Netherlands, Austria, Germany, Sweden, Switzerland							
2006							
Ahn et al. <sup>13</sup>	Multicentre cross-sectional study (3b)	2,354; 25,787 976*; 6,273 1,378*; 19,514	< 1 y No Parent questionnaire	7-12 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.86 (95%CI 1.67-2.08), p&lt;0.01</b>  • 1-2 AB courses: <b>aOR 1.54 (95%CI 1.35-1.76), p&lt;0.01</b> • 3-4 AB courses: <b>aOR 1.79 (95%CI 1.47-2.18), p&lt;0.01</b> • ≥ 5 AB courses: <b>aOR 2.53 (95%CI 2.10-3.06), p&lt;0.01</b>	Episodes of fever or acute gastroenteritis
Korea							
2005							
Celedon et al. <sup>196</sup>	Multicentre prospective cohort study (2b)	323; 4,408 280; 3,292 43; 1,116	< 1 y Yes Prescription records	1-2 y	ICD-9 codes	Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.32 (95%CI 1.67-3.22), p&lt;0.01*</b>  • 1-2 AB courses: <b>aOR 1.90 (95%CI 1.30-2.70), p&lt;0.01</b> • 3-4 AB courses: <b>aOR 1.60 (95%CI 1.10-2.40), p=0.03</b> • > 4 AB courses: <b>aOR 2.10 (95%CI 1.50-3.20), p&lt;0.01</b>	Number of respiratory tract infections
USA							
2004							
		314; 4,178		2-5 y		Exposure to AB in first y of life not associated with increased risk.  • <b>OR 1.17 (95%CI 0.89-1.54), p=0.25</b>  • 1-2 AB courses: <b>aOR 1.10 (95%CI 0.80-1.40), p=0.72</b> • 3-4 AB courses: <b>aOR 1.30 (95%CI 0.90-1.80), p=0.14</b> • > 4 AB courses: <b>aOR 1.00 (95%CI 0.70-1.40), p=0.87</b>	
		241; 3,092 73; 1,086				Results according to antibiotic class nr	
						Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.10 (95%CI 1.79-2.48), p=nr</b>	
Cohet et al. <sup>37</sup>	Single-centre case-control study (3b)	1,277; 3,927 1,020; 2,684 257; 1,243	< 1 y No Parent questionnaire	6-7 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk.  • <b>OR 2.10 (95%CI 1.79-2.48), p=nr</b>	
New Zealand							
2004							

(continued on next page)

Table 1 (continued)

Celedon et al. <sup>32</sup>	Multicentre prospective cohort study (2b)	38; 448 24; 314 14; 134	< 1 y No Parent questionnaire	5 y	Parent-reported physician's diagnosis (telephone questionnaire)	Exposure to AB in first y of life not associated with increased risk.  • OR 0.71 (95%CI 0.35-1.42), p=0.33  • 1 AB course: aOR 0.50 (95%CI 0.20-1.40), p=nr • ≥ 2 AB courses: aOR 0.90 (0.40-1.80), p=nr	Sex, family history of atopy, income
McKeever et al. <sup>182</sup>	Single-centre prospective cohort study (2b)	915; 21,129 nr; 13,497 nr; 7,632	< 1 y Yes Medical records	2.2 y (mean)	Oxford Medical Information System (OXMIS), ICD-8 or Read codes	Exposure to AB in first y of life associated with increased risk.  • 1 AB course: <b>aHR 1.26 (95%CI 1.13-1.40), p=nr</b> • 2 AB courses: <b>aHR 1.46 (95%CI 1.30-1.65), p=nr</b> • 3 AB courses: <b>aHR 1.76 (95%CI 1.56-2.13), p=nr</b> • 4 AB courses: <b>aHR 1.82 (95%CI 1.56-2.13), p=nr</b> • > 4 AB courses: <b>aHR 1.99 (95%CI 1.72-2.31), p=nr</b>  • penicillin: aHR 0.99 (95%CI 0.89-1.10), p=nr • amoxicillin: <b>aHR 1.25 (95%CI 1.16-1.36), p=nr</b> • amoxicillin/clavulanic acid: <b>aHR 1.43 (95%CI 1.19-1.72), p=nr</b> • cephalosporins: <b>aHR 1.44 (95%CI 1.28-1.63), p=nr</b> • macrolides: <b>aHR 1.41 (95%CI 1.30-1.53), p=nr</b>	Number of GP visits
Illi et al. <sup>167</sup>	Multicentre prospective cohort study (2b)	57; 937 22; 338 35; 599	< 3 y No Parent questionnaire	0-7 y	Parent-reported physician's diagnosis	Exposure to AB in first 3 y of life not associated with increased risk.  • aOR 1.08 (95%CI 0.59-1.99), p=nr	High risk of atopy at birth (elevated cord blood IgE or family history of atopy), parental education and smoking
Wjst et al. <sup>155</sup>	Multicentre cross-sectional study (3b)	37; 2,512 nr; 2,025 nr; 487	< 5-14 y No Medical records	5-14 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life not associated with increased risk.  • aOR 0.90 (95%CI 0.60-1.40), p=0.71	Age, sex, family history of atopy, season, parental education

(continued on next page)

Table 1 (continued)

Droste et al. <sup>43</sup>	Multicentre cross-sectional study (3b)	55; 1,206 27; 384 28; 822	< 1 y No Parent questionnaire	7-8 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first y of life associated with increased risk in high-risk children.  • <b>aOR 1.70 (95%CI 1.00-3.10), p&lt;0.01</b>	Sex, family history of atopy, number of siblings, living area, smoking during pregnancy, smoke exposure
Ponsonby et al. <sup>112</sup>	Multicentre prospective cohort study (2b)	276; 856 40; 114 236; 742	< 1 m No Parent questionnaire	2.1 y (mean)	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first m of life not associated with increased risk.  • aRR 1.04 (95%CI 0.78-1.37), p=nr	Age, family history of asthma, household size, prematurity, birth weight, age of child at time of outcome, breastfeeding, maternal smoking, household smoking, gas heater in living room
Von Mutius et al. <sup>181</sup>	Single-centre cross-sectional study (3b)	374; 5,006 340; 3,904 34; 1,102 461; 5,267 397; 4,006 64; 1,261	< 3 y No Medical records	5-7 y 9-11 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first 3 y of life associated with increased risk.  • <b>aOR 1.64 (95%CI 1.26-2.13), p=nr</b>  • ≥ 6 AB courses: aOR 7.95 (95%CI 6.02-10.50), p=nr  Exposure to AB in first 3 y of life associated with increased risk.  • <b>OR 2.06 (95%CI 1.57-2.70), p&lt;0.01*</b>	Family history of atopy, number of siblings, parental education, study area, school grade
Wickens et al. <sup>154</sup>	Multicentre retrospective cross-sectional study (3b)	71; 447 65; 334 6; 113	< 10 y No Parent questionnaire	5-10 y	Questionnaire for asthma symptoms (ISAAC)	Exposure to AB in first 10 y of life associated with increased risk.  • <b>aOR 2.74 (95%CI 1.10-6.85), p=nr</b>  • 1-2 AB courses: aOR 2.27 (95%CI 1.14-4.51), p=nr • ≥ 3 AB courses: aOR 4.02 (95%CI 1.57-10.31), p=nr	Age, sex, ethnicity, family history of atopy, household size, parental smoking
Farooqi et al. <sup>48</sup>	Single-centre retrospective cohort study (2b)	484; 1,855 402*; 1,237 82*; 618	< 2 y Yes Medical records	6-12 y	Recurrent episodes of wheeze > 2 y of life	Exposure to AB in first 2 y of life associated with increased risk.  • <b>OR 3.19 (95%CI 2.43-4.18), p&lt;0.01</b>  Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Allergic symptoms						
Levin et al. <sup>82</sup>	Multicentre prospective cohort study (2b)	528; 1,185	< 1 y	12-36 m	Questionnaire for allergic symptoms (based on ISAAC)	Exposure to AB in first y of life associated with increased risk in urban cohort. • <b>OR 1.62 (95%CI 1.28-2.04), p&lt;0.01*</b>
South-Africa		326; 654	No			
2020		202; 531	Parent questionnaire			Exposure to AB in first y of life not associated with increased risk in rural cohort. • <b>OR 1.58 (95%CI 0.36-6.94), p=0.55*</b>
		23; 398				
		21; 347				
		2; 51				
Hirsch et al. <sup>51</sup>	Multicentre case-control study (3b)	3,652; 21,912	1-2 m before diagnosis	< 7 y	ICD-9 codes plus medical or prescription records for milk allergy, non-milk food allergies and other unspecified allergies incl. allergic rhinitis	Exposure to AB in 2 m before diagnosis associated with increased risk. • <b>aOR 2.32 (95%CI 2.07-2.59), p=nr</b> • 1-2 AB courses: <b>aOR 1.69 (95%CI 1.50-1.92), p=nr</b> • ≥ 3 AB courses: <b>aOR 3.07 (95%CI 2.72-3.46), p=nr</b> • penicillins: <b>aOR 2.28 (95%CI 2.06-2.53), p=nr</b> • cephalosporins: <b>aOR 1.70 (95%CI 1.57-1.83), p=nr</b> • macrolides: <b>aOR 1.98 (95%CI 1.83-2.15), p=nr</b>
USA		3,145; 16,967	Yes			
2017		507; 4,945	Medical records			
Batool et al. <sup>183</sup>	Multicentre prospective cohort study (2b)	360; 818	< 1 y	1 y	Parent-reported allergic symptoms (atopic dermatitis, allergic rhinitis, wheezing or asthma)	Exposure to AB in first y of life associated with increased risk. • <b>OR 2.28 (95%CI 1.70-3.6), p&lt;0.01*</b>
Canada		163; 285	No			
2016		197; 533	Parent questionnaire			
Sandini et al. <sup>177</sup>	Single-centre prospective cohort study (2b)	308; 925	< 6 m	2 y	Parent-reported allergic symptoms (atopic dermatitis, food allergy, allergic rhinitis, asthma)	Exposure to AB in first 6 m of life not associated with increased risk. • <b>OR 1.25 (95%CI 0.82-1.90), p=0.30</b>
Finland		nr; nr	No			
2011		nr; nr	Parent questionnaire	5 y		Exposure to AB in first 6 m of life not associated with increased risk. • <b>OR 1.26 (95%CI 0.83-1.92), p=0.27</b>
		479; 891				
		nr; nr				
		nr; nr				

(continued on next page)

Table 1 (continued)

Infantile colic							
Oosterloo et al. <sup>105</sup>	Multicentre prospective cohort study (2b)	74; 436 33; 151 41; 285	< 1 w No Parent questionnaire	0-1 y	Parent-reported	Exposure to AB in first w of life not associated with increased risk.  • aOR 1.66 (95%CI 1.00-2.77), p=0.05	Family history of atopy, parental education, day care, number of siblings, smoking during pregnancy, delivery mode, duration of breastfeeding, household smoking
Netherlands							
2018							
Abdominal pain							
Uusijarvi et al. <sup>144</sup>	Multicentre prospective cohort study (2b)	231; 2,654 87; 861 144; 1,793	< 2 y Yes Parent questionnaire	11-14 y	Questionnaire for abdominal pain and GI disorders (QPGS-RIII)	Exposure to AB in first 2 y of life not associated with increased risk abdominal pain.  • aOR 1.37 (95%CI 0.94-1.99), p=nr	Sex, asthma at 12 years of age
Sweden							
2014							
		245; 2,732	9-12 y			Results according to antibiotic class nr	
		94; 1,045 151; 1,687	Yes Parent questionnaire			Exposure to AB between 9 and 12 y of life not associated with increased risk.  • 1 AB course: aOR 0.88 (95%CI 0.61-1.25), p=nr • 2 AB courses: aOR 0.76 (95%CI 0.44-1.31), p=nr • ≥ 3 AB courses: aOR 1.18 (95%CI 0.71-1.98), p=nr  • penicillin: aOR 1.04 (95%CI 0.76-1.43), p=nr • amoxicillin: aOR 1.27 (95%CI 0.76-2.11), p=nr • flucloxacillin: aOR 0.80 (95%CI 0.46-1.41), p=nr • erythromycin: aOR 1.01 (95%CI 0.53-1.94), p=nr • cefadroxil: aOR 0.65 (95%CI 0.28-1.53), p=nr • tetracycline: aOR 1.75 (95%CI 0.71-4.31), p=nr	
Inflammatory bowel disease							
Canova et al. <sup>30</sup>	Multicentre retrospective case-control study (3b)	70; 770 33; 353 37; 417	< 1 y No Registry	< 18 y	ICD-9-CM codes	Exposure to AB in first 12 m of life not associated with increased risk.  • aOR 1.07 (95%CI 0.64-1.80), p=nr	Age, sex, maternal age and education; parity, number of siblings, gestational age, birth weight, Apgar scores, season of birth, gastrointestinal infections
Italy							
2020						Exposure to AB for ≥ 4 AB courses associated with increased risk.  • first 6 m: aOR 6.34 (95%CI 1.68-24.02), p=0.01 • first 12 m: aOR 2.91 (95%CI 1.31-6.45), p=0.01	

(continued on next page)

Table 1 (continued)

Örtqvist et al. <sup>106</sup>	Multicentre prospective cohort study (2b)	51; 827,239 43; 539,809 8; 287,430	< 1 y before diagnosis Yes	< 6 y	ICD-10 codes	Exposure to AB in 12 m before diagnosis associated with increased risk.  • <b>OR 2.86 (95%CI 1.35-6.09), p&lt;0.01*</b> • aHR 1.11 (95%CI 0.57-2.15), p=nr  • 1 AB course: aHR 0.73 (95%CI 0.28-1.89), p=nr • 2 AB courses: aHR 1.85 (95%CI 0.80-4.30), p=nr • ≥ 3 AB courses: aHR 1.12 (95%CI 0.47-2.65), p=nr  • penicillin: aHR 1.25 (95%CI 0.70-2.26), p=nr	Parental country of birth, education and history of IBD; mode of delivery, gastroenteritis
Sweden			Registry				
2019							
Kronman et al. <sup>78</sup>	Multicentre retrospective cohort study (2b)	748; 1,072,426 436; 618,663 312; 453,763	< 1 y Yes	< 17 y	Read codes	Exposure to AB in first y of life associated with increased risk.  • <b>aHR 5.51 (95%CI 1.66-18.28), p&lt;0.01</b>  • 1-2 AB courses: <b>aHR 3.13 (95%CI 1.54-6.36), p&lt;0.01</b> • > 2 AB courses: <b>aHR 5.15 (95%CI 2.36-11.25), p&lt;0.01</b>  • penicillins: <b>aHR 5.26 (95%CI 1.60-17.25), p&lt;0.01</b> • cephalosporins: <b>aHR 1.58 (95%CI 1.21-2.05), p&lt;0.01</b> • macrolides: aHR 1.21 (95%CI 0.96-1.51), p=0.10 • sulfonamides: aHR 1.31 (95%CI 0.98-1.74), p=0.07 • metronidazole: <b>aHR 337.78 (95%CI 37.42-3,048.96), p&lt;0.01</b> • fluoroquinolones: <b>aHR 3.70 (95%CI 2.25-6.08), p&lt;0.01</b> • tetracyclines: aHR 1.05 (95%CI 0.65-1.69), p=0.85	Sex, chronic granulomatous disease, primary sclerosing cholangitis, socioeconomic deprivation, family history of IBD
UK			Registry				
2012							
Virta et al. <sup>148</sup>	Multicentric case-control study (3b)	595; 2,975 359; 1,576 236; 1,399	< 1 y Yes	1-16 y	ICD-10 plus endoscopy and histologic verification	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.45 (95%CI, 1.21-1.75), p&lt;0.01</b>  Results according to antibiotic class nr	Additional chronic diseases
Finland			Registry				
2012							

(continued on next page)

Table 1 (continued)

		Crohn's disease: 233; 1,165  152; 613 81; 552				Exposure to AB in first y of life associated with increased risk of Crohn's disease.  • <b>aOR 1.87 (95%CI 1.37-2.56), p=nr</b>  • 1 AB course: aOR 1.32 (95%CI 0.92-1.88), p=nr • 2 AB courses: <b>aOR 1.98 (95%CI 1.22-3.20), p=nr</b> • ≥ 3 AB courses: aOR 1.42 (95%CI 0.87-2.33), p=nr  • 3 cephalosporin courses: <b>aOR 2.82 (95%CI 1.65-4.81), p=nr</b>  Results according to antibiotic class nr	
		Ulcerative colitis: 362; 1,810  207; 963 155; 847				Exposure to AB in first y of life not associated with increased risk of ulcerative colitis.  • aOR 1.18 (95%CI, 0.92-1.52), p=nr  • 1 AB course: aOR 0.98 (95%CI 0.72-1.34), p=nr • 2 AB courses: aOR 1.45 (95%CI 0.98-2.16), p=nr • ≥ 3 AB courses: aOR 1.26 (95%CI 0.87-1.82), p=nr  Results according to antibiotic class nr	
Hviid et al. <sup>68</sup> Denmark 2011	Multicentre prospective cohort study (2b)	117; 577,627 84; 489,946 33; 87,681	< 10 y Yes Registry	< 10 y	ICD-10 codes	Exposure to AB in first y of life associated with increased risk.  • <b>aRR 1.84 (95% CI 1.08-3.15), p=nr</b>  Results according to antibiotic class nr  Strongest association for AB < 3 m before diagnosis and risk of Crohn's disease.  • <b>aRR 4.43 (95% CI 1.88-10.44), p=nr</b>  • narrow-spectrum penicillins: <b>aRR 2.92 (95%CI 1.22-6.97), p=nr</b> • broad-spectrum penicillins: <b>aRR 3.13 (95%CI 1.33-7.40), p=nr</b> • macrolides: aRR 0.97 (95%CI 0.13-7.14), p=nr	Age, season risk.

(continued on next page)

Table 1 (continued)

Shaw et al. <sup>127</sup>	Multicentre case-control study (3b)	36; 396 21; 160 15; 236	< 1 y No Registry	< 12 y	ICD-9-CM and ICD-10-CA codes	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 2.91 (95%CI 1.21-6.97), p=0.02</b>	Age, sex, living area
<b>Celiac disease</b>							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study (2b)	45; 14,572 40; 10,220 5; 4,352	< 2 y Yes Medical records	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aHR 2.89 (95%CI 1.14-7.35), p=0.03</b>  Girls • penicillins: <b>HR 6.74 (95%CI 1.56-29.23), p=0.01</b> • cephalosporins: HR 0.49 (95%CI 0.16-1.50), p=0.21 • macrolides: HR 1.26 (95%CI 0.53-3.03), p=0.60 • sulfonamides: HR 0.57 (95%CI 0.07-4.28), p=0.58  Boys • penicillins: HR 1.61 (95%CI 0.51-5.12), p=0.42 • cephalosporins: HR 1.53 (95%CI 0.59-3.95), p=0.38 • macrolides: HR 1.08 (95%CI 0.42-2.79), p=0.87 • sulfonamides: HR 1.42 (95%CI 0.32-6.34), p=0.65	Sex, ethnicity, maternal age and education; antibiotic use during pregnancy, birth weight, delivery mode, maternal smoking
Dydensborg et al. <sup>44</sup>	Multicentre prospective cohort study (2b)	3,346; 1,706,113 1,012; 550,746 2,334; 1,155,367	< 1 y No Registry	11.6 y (mean Denmark) 5.4 y (mean Norway)	ICD-10 codes	Exposure to AB in first y of life associated with increased risk.  • <b>aOR 1.26 (95%CI 1.16-1.36), p=nr</b>	Maternal age, BMI, country of birth, autoimmune diseases and education; parity, smoking during pregnancy, gestational age, weight for gestational age, birth weight, season of birth

(continued on next page)



Table 1 (continued)

Kemppainen et al. <sup>33</sup>	Multicentre prospective cohort study (2b)	783; 6,558 nr; nr nr; nr	3 m-4 y Yes Medical records	2-4 y	Islet or tissue transglutaminase autoantibodies	Exposure to AB in first 4 y of life not associated with increased risk.  • aHR 1.00 (95%CI 0.98-1.02), p=nr  • penicillin: aHR 1.03 (95%CI 0.92-1.09), p=nr • amoxicillin: aHR 0.99 (95%CI 0.96-1.02), p=nr • cephalosporins: aHR 1.01 (95%CI 0.94-1.09), p=nr • macrolides: aHR 0.99 (95%CI 0.91-1.08), p=nr	Sex, HLA genotype, family history of type 1 diabetes or celiac disease, country, antibiotic use during pregnancy, season of birth, delivery mode, probiotic use, breastfeeding
Myleus et al. <sup>199</sup>	Multicentric case-control study (3b)	373; 954 97; 231 276; 723	< 6 m No Parent questionnaire	< 2 y	Small intestinal biopsy or diagnostic criteria of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition	Exposure to AB in first 6 m of life not associated with increased risk.  • OR 1.20 (95%CI 0.87-1.60), p=0.27	
<b>Increased weight gain and overweight</b>							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study (2b)	4,856; 14,572 3,637; 10,220 1,219; 4,352	< 2 y Yes Medical records	6-11 y	BMI ≥ 85 <sup>th</sup> percentile	Exposure to AB in first 2 y of life associated with increased risk of overweight.  • <b>aHR 1.22 (95%CI 1.14-1.30), p&lt;0.01</b>  Girls • penicillins: <b>HR 1.11 (95%CI 1.02-1.22), p=0.02</b> • cephalosporins: HR 1.10 (95%CI 1.00-1.22), p=0.06 • macrolides: <b>HR 1.16 (95%CI 1.05-1.28), p&lt;0.01</b> • sulfonamides: HR 1.11 (95%CI 0.94-1.31), p=0.23  Boys • penicillins: <b>HR 1.13 (95%CI 1.03-1.24), p&lt;0.01</b> • cephalosporins: <b>HR 1.11 (95%CI 1.01-1.22), p=0.03</b> • macrolides: <b>HR 1.11 (95%CI 1.01-1.21), p=0.03</b> • sulfonamides: <b>HR 1.20 (95%CI 1.01-1.41), p=0.03</b>	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode
Chelimo et al. <sup>33</sup>	Multicentre prospective cohort study (2b)	1,051; 5,128 1,010; 4,886 41; 242	< 2 y Yes Registry	4.5 y	BMI	Exposure to AB in first 2 y of life not associated with increased risk of d overweight.  • OR 1.22 (95%CI 0.87-1.71), p=0.25* • < 1 y of age: aOR: 1.21 (95%CI 0.81-1.81), p=0.36 • > 1 y of age: aOR: 1.18 (95%CI 0.79-1.78), p=0.42	Sex, ethnicity, maternal age, parity, pre-pregnancy weight, socioeconomic status, school grade, alcohol and antibiotic use during pregnancy, birth weight,

(continued on next page)

Table 1 (continued)

						<ul style="list-style-type: none"> <li>• 1-3 AB courses: aOR 0.95 (95%CI 0.63-1.46), p=0.83</li> <li>• 4-6 AB courses: aOR 1.36 (95%CI 0.90-2.07), p=0.15</li> <li>• 7-9 AB courses: aOR 1.38 (95%CI 0.90-2.13), p=0.14</li> <li>• &gt; 9 AB courses: aOR 1.23 (95%CI 0.81-1.86), p=0.34</li> </ul> <ul style="list-style-type: none"> <li>• penicillins: aOR 0.95 (95%CI 0.67-1.34), p=0.77</li> <li>• macrolides: aOR 1.16 (95%CI 0.94-1.43), p=0.17</li> <li>• cephalosporins: aOR 1.19 (95%CI 0.97-1.47), p=0.10</li> <li>• trimethoprim/sulfamethoxazole: aOR 1.05 (95%CI 0.85-1.30), p=0.64</li> </ul>	season of birth, delivery mode, birth order, anti-reflux medication use, breastfeeding, diet, sleep duration, time spent watching television, DVDs, or videos
Dawson-Hahn et al. <sup>200</sup>	Multicentre retrospective cohort study (2b)	65; 586 39*; 355 25*; 231	< 1 y No	6 y	BMI z-score	Exposure to AB in first y of life associated with increased risk of overweight.	
USA			Parent questionnaire			<ul style="list-style-type: none"> <li>• <b>OR 1.03 (95%CI 1.01-1.05), p=nr</b> (from<sup>240</sup>)</li> <li>• BMI z-score: +0.17 (95%CI 0.09-0.25), p=nr</li> </ul>	
2019							
Kamphorst et al. <sup>71</sup>	Multicentre prospective cohort study (2b)	nr, 436 nr; 151 nr 285	< 1 y Yes	1 y	Weight	Exposure to AB in first y of life associated with increased risk of increased weight gain.	
Netherlands			Parent questionnaire			<ul style="list-style-type: none"> <li>• <b>weight gain of 76 g after every AB course, p=0.03</b></li> </ul>	Results according to antibiotic class nr
2019							
Sejersen et al. <sup>170</sup>	Multicentre prospective cohort study (2b)	nr; 661 nr; 306 nr; 355	< 1 y Yes	6 y	BMI z-score	Exposure to AB in first y of life not associated with increased risk of overweight.	
Denmark			Parent questionnaire			<ul style="list-style-type: none"> <li>• BMI z-score: -0.06 (95%CI -0.17-0.06), p=0.33</li> </ul>	
2019		nr; 467 nr; 216 nr; 251		3.5 y	Fat percentage with dual-energy X-ray absorptiometry	Exposure to AB in first y of life not associated with increased risk of increased fat percentage.	<ul style="list-style-type: none"> <li>• difference in fat percentage: 0.85% (95%CI -1.84-3.55), p=0.53</li> </ul>
						Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

		nr; 500		6 y		Exposure to AB in first y of life not associated with increased risk of increased fat percentage.	
		nr; 221					
		nr; 279				• difference in fat percentage: 0.60% (95%CI -0.21-1.41), p=0.15	
						Results according to antibiotic class nr	
Smith-Brown et al. <sup>131</sup>	Single-centre cross-sectional study (3b)	11; 50	< 1 m	6-24 m	BMI z-score plus bioelectrical impedance analysis	Exposure to AB in first m of life associated with increased risk of increased BMI z-score and body fat.	
Australia		nr, 11	No				
2019		nr; 39	Parent questionnaire			• BMI z-score: <b>+1.17 (p&lt;0.01) (mean increase 1.1 vs mean of 0.025)</b>	
						• bioelectrical impedance analysis: <b>+3.5% (p&lt;0.01)</b>	
Block et al. <sup>27</sup>	Multicentre retrospective cohort study (2b)	45,295; 310,947	< 2 y	5 y	BMI z-score (≥ 85 <sup>th</sup> percentile)	Exposure to AB in first 2 y of life associated with increased risk of overweight.	Age, sex, prematurity, ethnicity, asthma, corticosteroid use, number of infections
USA		27,225; 180,739	Yes			• <b>aOR 1.05 (95%CI 1.03-1.07), p=nr</b>	
2018		18,070; 130,208	Registry			Results according to antibiotic class nr	
Poulsen et al. <sup>201</sup>	Multicentre retrospective cohort study (2b)	nr; 8,793	< 3 y	3 y	BMI z-score	Exposure to AB in first 3 y of life associated with increased risk of increased BMI.	
USA		nr; 7,224	Yes			• <b>OR 1.17 (95%CI 1.06-1.29), p=nr</b> (from <sup>240</sup> )	
2017		nr; 1,569	Medical records			• 1 AB course: BMI z-score + 0.04 (95%CI -0.04-0.11), p=0.39	
						• 2-3 AB courses: BMI z-score +0.02 (95%CI -0.05-0.09), p=0.58	
						• 4-5 AB courses: BMI z-score +0.09 (95%CI 0.01-0.17), p=0.03	
						• 6-8 AB courses: BMI z-score +0.11 (95%CI 0.03-0.20), p<0.01	
						• ≥ 9 AB courses: BMI z-score +0.175 (95%CI 0.09-0.26), p<0.01	
						• ≥ 4 courses of penicillins: BMI z-score +0.08 (95%CI 0.01-0.15), p=0.08	
						• ≥ 3 courses of cephalosporins: BMI z-score +0.11 (95%CI 0.03-0.29), p=0.02	
						• ≥ 2 courses of macrolides: BMI z-score +0.10 (95%CI 0.01-0.19), p=0.04	

(continued on next page)

Table 1 (continued)

Rogawski et al. <sup>202</sup>	Multicentre prospective cohort study (2b)	nr; 1,954 nr; 1,284 nr; 670	< 6 m Yes Parent questionnaire	2 y	Weight-for-age (WAZ) z-score	Exposure to AB in first 6 m of life associated with increased risk of increased weight gain.  <ul style="list-style-type: none"> <li>• <b>OR 1.23 (95%CI 1.04-1.45), p=nr</b> (from<sup>240</sup>)</li> <li>• WAZ difference: +0.03 (95%CI 0.00-0.05), p=ns</li> <li>• penicillins, WAZ difference: +0.09 (95%CI -0.02-0.19), p=ns</li> <li>• cephalosporins, WAZ difference: +0.03 (95%CI -0.09-0.16), p=ns</li> <li>• metronidazole, WAZ difference: +0.14 (95%CI -0.01-0.29), p=ns</li> <li>• macrolides, WAZ difference: +0.09 (95%CI -0.03-0.21), p=ns</li> <li>• sulfonamides, WAZ difference: +0.03 (95%CI -0.09-0.15), p=ns</li> <li>• fluoroquinolones, WAZ difference: +0.08 (95%CI -0.14-0.30), p=ns</li> </ul>	
8 countries 2017							
Korpela et al. <sup>75</sup>	Multicentre prospective case-control study (3b)	28; 148 nr; 32 nr; 116	< 2 y Yes Registry	2-7 y	BMI z-score	Exposure to AB in first 2 y of life not associated with increased risk of overweight.  Results according to antibiotic class nr	
Finland 2016							
Mbakwa et al. <sup>69</sup>	Multicentre prospective cohort study (2b)	135; 979 90*; 613 45*; 366	< 1 y Yes Parent questionnaire	1 y	BMI z-score	Exposure to AB in first y of life not associated with increased risk of overweight.  <ul style="list-style-type: none"> <li>• OR 1.23 (95%CI 0.84-1.80), p=0.30*</li> <li>• 1 AB course: aOR 1.09 (95%CI 0.76-1.57), p=0.64</li> <li>• 2-3 AB courses: aOR 1.13 (95%CI 0.79-1.63), p=0.51</li> <li>• ≥ 4 AB courses: aOR 1.03 (95%CI 0.66-1.60), p=0.89</li> <li>• narrow-spectrum penicillins: aOR 0.95 (95%CI 0.68-1.34), p=0.79</li> <li>• broad-spectrum penicillins: aOR 1.00 (95%CI 0.57-1.76), p=0.99</li> <li>• macrolides: aOR 1.29 (95%CI 0.89-1.86), p=0.18</li> </ul>	Age, sex, maternal education, weight and pregnancy weight gain, household size, gestational diabetes, gestational hypertension, smoking during pregnancy, gestational age, birth weight, delivery mode, breastfeeding duration, diet, child's physical activity
Netherlands 2016							

(continued on next page)

Table 1 (continued)

Schwartz et al. <sup>124</sup>	Multicentre prospective cohort study (2b)	79,752; 142,824 54,802*; 97,120 24,950*; 45,704	< 1 y before each BMI Yes Registry	3-18 y	BMI	Exposure to AB 1 y before BMI measure associated with increased risk of weight gain.  • <b>OR 1.08 (95%CI 1.06-1.10), p=nr</b> (from <sup>240</sup> )  Strongest association with macrolides: BMI +0.43  Results according to antibiotic class nr
USA 2016						
Gerber et al. <sup>54</sup>	Multicentre retrospective cohort study (2b)	nr; 38,522 nr; 5,287 nr; 33,235	< 6 m Yes Registry	< 8 y	Weight	Exposure to AB in first 6 m of life not associated with increased weight gain.  • OR* 1.02 (95%CI 0.86-1.20), p=nr (from <sup>240</sup> ) • weight gain difference: +0.07% (95%CI -0.10-1.50), p=0.07  • narrow-spectrum: +0.40% (95%CI -0.60-1.30), p=0.45 • broad-spectrum: -0.30% (95%CI -2.10-1.50), p=0.72 • macrolides: +2.20% (95%CI -1.20-5.70), p=0.20
USA 2016						
			< 2 y Yes Registry			Exposure to AB in first 2 y of life associated with increased risk of weight gain.  • <b>weight gain difference: +2.10% (95%CI 0.80-3.30), p&lt;0.01</b>  • narrow-spectrum: +1.90% (95%CI 0.50-3.20), p<0.01 • broad-spectrum: +2.20% (95%CI 0.70-3.80), p<0.01 • macrolides: +2.40% (95%CI 0.60-4.20), p<0.01
Saari et al. <sup>121</sup>	Multicentre prospective cohort study (2b)	2,094; 12,062 1,673; 9,236 421; 2826	< 2 y Yes Registry	2-3 y	BMI z-score	Exposure to AB in first 2 y of life associated with increased risk of overweight.  • <b>OR 1.26 (95%CI 1.12-1.42), p&lt;0.01*</b>
Finland 2015		Boys: 1,376; 6,114				Exposure to AB in first 2 y of life associated with increased risk of overweight.  Birth weight, birth length, delivery mode,

(continued on next page)

Table 1 (continued)

		1,121; 4,828 255; 1,286				<ul style="list-style-type: none"> <li>• <b>OR 1.26 (95%CI 1.04-1.49), p&lt;0.01</b></li> <li>• 1 AB course: aOR 1.16 (95% CI, 0.92-1.48), p=nr</li> <li>• 2-3 AB courses: <b>aOR 1.28 (95%CI 1.04-1.59), p&lt;0.05</b></li> <li>• ≥ 4 AB courses: <b>aOR 1.27 (95%CI 1.04-1.55), p&lt;0.05</b></li> </ul> Strongest effects in boys, exposures before < 6 m of life <ul style="list-style-type: none"> <li>• &lt; 6 m: <b>aOR 1.34 (95%CI 1.06-1.66), p&lt;0.05</b></li> </ul> <ul style="list-style-type: none"> <li>• 1 penicillin course: aOR 1.13 (95%CI 0.90-1.41), p=ns</li> <li>• 1 cephalosporin course: <b>aOR 1.39 (95%CI 1.10-1.76), p&lt;0.05</b></li> <li>• 1 macrolide course: aOR 1.20 (95%CI 0.96-1.49), p=ns</li> <li>• ≥ 2 macrolide courses: <b>aOR 1.47 (95%CI 1.16-1.86), p&lt;0.05</b></li> </ul>	smoking during pregnancy, parental relationship
		Girls: 718; 5,948  552; 4,408 166; 1,540				Exposure to AB in first 2 y of life not associated with increased risk of overweight. <ul style="list-style-type: none"> <li>• 1 AB course: aOR 1.03 (95% CI, 0.81-1.32), p=nr</li> <li>• 2-3 AB courses: aOR 1.14 (95%CI 0.91-1.42), p=nr</li> <li>• ≥ 4 AB courses: aOR 1.19 (95%CI 0.96-1.48), p=nr</li> </ul> <ul style="list-style-type: none"> <li>• 1 penicillin course: aOR 1.11 (95%CI 0.89-1.40), p=ns</li> <li>• 1 cephalosporin course: aOR 1.05 (95%CI 0.80-1.38), p=ns</li> <li>• 1 macrolide course: aOR 0.94 (95%CI 0.94-1.50), p=ns</li> </ul>	Birth weight, delivery mode, smoking during pregnancy
Azad et al. <sup>23</sup>	Single-centre, retrospective nested case-control study (3b)	181; 616  144; 438 37; 178	< 1 y  Yes  Medical records	9 y	BMI (> 85 <sup>th</sup> percentile)	Exposure to AB in first y of life associated with increased risk of overweight. <ul style="list-style-type: none"> <li>• <b>aOR 1.74 (95%CI 1.04-2.94), p=nr</b></li> <li>• girls: aOR 1.20 (95%CI 0.53-2.70), p=nr</li> <li>• <b>boys: aOR 2.19 (95%CI 1.06-4.54), p=nr</b></li> </ul> Results according to antibiotic class nr	Maternal asthma and overweight; number of siblings, income, birth weight, asthma, breastfeeding, diet, child's physical activity, smoke exposure
Canada  2014		121; 431  97; 299 24; 132		12 y		Exposure to AB in first y of life associated with increased risk of overweight. <ul style="list-style-type: none"> <li>• <b>aOR 2.56 (95%CI 1.36-4.79), p=nr</b></li> <li>• girls: aOR 1.13 (95%CI 0.46-2.81), p=nr</li> <li>• <b>boys: aOR 5.35 (95%CI 1.94-14.72), p=nr</b></li> </ul> Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Trasande et al. <sup>143</sup> USA 2013	Single-centre prospective cohort study (2b)	1,700; 8,881	< 6 m	38 m	BMI z-score	Exposure to AB in first 6 m of life associated with increased risk of overweight.	Ethnicity, parity, parental education, BMI and socioeconomic status; smoking during pregnancy, birth weight, breastfeeding, diet, timing of solid food introduction, sleep duration, time watching television and in car
		1,322*; 6,598 378*; 2,283	No			• aOR 1.22 (95%CI nr), p<0.05	
		1,700; 8,881	< 6-14 m			Exposure to AB in at 6 to 14 m of life not associated with increased risk of overweight.	
		1,274*; 6,598 426*; 2,283	No			• aOR 1.04 (95%CI nr), p=0.63	
		1,700; 8,881	< 15-23 m			Exposure to AB at 15 to 23 m of life not associated with increased risk of overweight.	
		1,317*; 6,598 383*; 2,283	No			• aOR 1.24 (95%CI nr), p=0.09	
		1,962; 8,881	< 6 m	7 y		Exposure to AB in first 6 m of life not associated with increased risk of overweight.	
		1,467*; 6,598 495*; 2,283	No			• aOR 1.03 (95%CI nr), p=0.78	
		1,962; 8,881	< 6-14 m			Exposure to AB in at 6 to 14 m of life not associated with increased risk of overweight.	
		1,442*; 6,598 520*; 2,283	No			• aOR 0.95 (95%CI nr), p=0.58	
1,962; 8,881	< 15-23 m			Exposure to AB at 15 to 23 m of life not associated with increased risk of overweight.			
1,464*; 6,598 498*; 2,283	No			• aOR 1.02 (95%CI nr), p=0.87			

(continued on next page)

Table 1 (continued)

Ajslev et al. <sup>14</sup> Denmark 2011	Multicentre prospective cohort study (2b)	2,333; 22,368 197*; 1,628 2,136*; 20,740	< 6 m No Parent questionnaire	7 y	BMI	Exposure to AB in first 6 m of life not associated with increased risk of overweight. • aOR 1.04 (95%CI 0.79-1.37), p<0.78	Sex, maternal age, BMI, and smoking; weight gain during pregnancy, parity, paternal BMI, socioeconomic status, birth weight, delivery mode, breastfeeding,
<b>Obesity</b>							
Aversa et al. <sup>172</sup> USA 2021	Multicentre prospective cohort study (2b)	2,567; 14,572 1,932; 10,220 635; 4,352	< 2 y Yes Medical records	6-11 y	BMI ≥ 95 <sup>th</sup> percentile	Exposure to AB in first 2 y of life associated with increased risk. • aHR 1.20 (95%CI 1.10-1.32), p<0.01  Girls • penicillins: HR 1.05 (95%CI 0.92-1.19), p=0.50 • cephalosporins: <b>HR 1.17 (95%CI 1.02-1.35), p=0.03</b> • macrolides: HR 1.08 (95%CI 0.94-1.24), p=0.26 • sulfonamides: HR 1.15 (95%CI 0.92-1.45), p=0.22  Boys • penicillins: <b>HR 1.15 (95%CI 1.02-1.31), p=0.02</b> • cephalosporins: HR 1.08 (95%CI 0.96-1.22), p=0.22 • macrolides: <b>HR 1.15 (95%CI 1.02-1.29), p=0.02</b> • sulfonamides: HR 1.11 (95%CI 0.89-1.39), p=0.34	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode
Chelimo et al. <sup>33</sup> New Zealand 2020	Multicentre prospective cohort study (2b)	437; 5,128 428; 4,886 9; 242	< 2 y Yes Registry   Registry	4.5 y	BMI	Exposure to AB in first 2 y of life not associated with increased risk, except trimethoprim/sulfamethoxazole • penicillins: aOR 0.95 (95%CI 0.51-1.78), p=0.87 • cephalosporins: aOR 1.11 (95%CI 0.97-1.47), p=0.52 • macrolides: aOR 1.24 (95%CI 0.94-1.43), p=0.19 • trimethoprim/sulfamethoxazole: <b>aOR 1.60 (95%CI 1.18-2.17), p&lt;0.01</b>  Exposure to AB in first y of life not associated with increased risk. • aOR 1.90 (95%CI 0.86-4.23), p=0.11	Sex, ethnicity, maternal age, parity, pre-pregnancy weight, socioeconomic status, school grade, alcohol and antibiotic use during pregnancy, birth weight, season of birth, delivery mode, birth order, anti-reflux medication use, breastfeeding, diet, sleep duration, time spent watching television, DVDs, or videos

(continued on next page)



Table 1 (continued)

			1-2 y			Exposure to AB in second y of life not associated with increased risk.	
			Yes			• aOR 1.69 (95%CI 0.75-3.82), p=0.20	
			Registry			More than 9 AB courses in first 2 y of life associated with increased risk.	
						• <b>aOR 2.41 (95%CI 1.07-5.41), p=0.03</b>	
Leong et al. <sup>81</sup>	Single-centre retrospective cross-sectional study (4)	23,921; 151,359 nr; 124,506 nr; 26,853	< 2 y	4 y	BMI	Exposure to AB in first 2 y of life associated with increased risk.	Sex, ethnicity, maternal age, parity and diabetes, living area, socioeconomic status, hyperemesis gravidarum, prolonged hospitalisation during pregnancy, gestational age, birth weight, season of birth, delivery mode, prolonged hospitalisation during the first 2 y of life, number of days overseas during first 2 y of life
New Zealand 2020			No			• <b>aOR 1.04 (95%CI 1.04-1.05), p=nr</b>	
			Medical records				
Stark et al. <sup>133</sup>	Multicentre retrospective cohort study (2b)	46,993; 333,353 36,899; 241,502 10,094; 91,851	< 2 y	3 y	BMI ≥ 95 <sup>th</sup> percentile	Exposure to AB in first 2 y of life associated with increased risk.	Sex, delivery mode, medication use
USA 2019			Yes			• <b>HR 1.26 (95%CI 1.23-1.28), p=nr</b>	
			Medical records			• 1 AB course: aHR 1.12 (95%CI 1.09-1.15), p=nr • 2 AB courses: aHR 1.23 (95%CI 1.20-1.26), p=nr • 3 AB courses: aHR 1.33 (95%CI 1.29-1.37), p=nr • ≥ 4 AB courses: aHR 1.42 (95%CI 1.37-1.46), p=nr  • penicillins: aHR 1.11 (95%CI 1.09-1.13), p=nr • cephalosporins: aHR 1.03 (95%CI 1.01-1.06), p=nr • macrolides: aHR 1.12 (95%CI 1.10-1.15), p=nr • sulfonamides boys: aHR 1.05 (95%CI 1.01-1.10), p=nr • sulfonamides girls: aHR 1.19 (95%CI 1.14-1.15), p=nr	

(continued on next page)

Table 1 (continued)

Kelly et al. <sup>72</sup>	Multicentre cross-sectional study (3b)	1,034; 8,186	2-3 y	3 y	BMI	Exposure to AB between second and third y of life not associated with increased risk.	
Ireland		682*; 5,285	No				
2019		352*; 2,901	Parent questionnaire			<ul style="list-style-type: none"> <li>• OR 1.07 (95%CI 0.75-1.52), p=0.26</li> <li>• 1 AB course: OR 0.88 (95%CI 0.61-.127), p=nr</li> <li>• 2 AB courses: OR 0.95 (95%CI 0.66-1.38), p=nr</li> <li>• 3 AB courses: OR 1.16 (95%CI 0.80-1.69), p=nr</li> <li>• ≥ 4 AB courses: <b>OR 1.60 (95%CI 1.11-2.31), p=0.04</b></li> </ul>	
		470; 8,186	4-5 y	5 y		Exposure to AB between fourth and fifth y of life not associated with increased risk.	
		279*; 4,594	No				
		191*; 3,592	Parent questionnaire			<ul style="list-style-type: none"> <li>• 1 AB course: OR 1.15 (95%CI 0.80-1.64), p=0.09</li> <li>• 2 AB courses: OR 1.04 (95%CI 0.65-1.67), p=0.20</li> <li>• 3 AB courses: OR 1.16 (95%CI 0.63-2.16), p=0.59</li> <li>• ≥ 4 AB courses: OR 1.37 (95%CI 0.74-2.53), p=0.37</li> </ul>	
Block et al. <sup>27</sup>	Multicentre retrospective cohort study (2b)	40,797; 310,947	< 2 y	5 y	BMI z-score	Exposure to AB in first 2 y of life associated with increased risk.	Age, sex, prematurity, ethnicity, asthma, corticosteroid use, number of infections
USA		24,162; 180,739	Yes			<ul style="list-style-type: none"> <li>• <b>aOR 1.05 (95%CI 1.03-1.07), p=nr</b></li> </ul>	
2018		16,635; 130,208	Registry			Results according to antibiotic class nr	
Edmonson et al. <sup>45</sup>	Multicentre randomised controlled trial (1b)	74; 607	2 m-6 y	2 m-6 y	BMI z-score	Exposure to AB in first 6 y of life not associated with increased risk.	Age, sex, ethnicity, parental education, health insurance, vesicoureteral reflux, hydronephrosis, scarring or pyelonephritis on baseline scan, breastfeeding
USA		29; 302	Yes			<ul style="list-style-type: none"> <li>• aOR 0.65 (95%CI 0.33-1.28), p=0.22</li> </ul>	
2017		45; 305	Randomly assigned			Results according to antibiotic class nr	
Li et al. <sup>83</sup>	Multicentre prospective cohort study (2b)	nr; 216,306	< 1 y	1-18 y	BMI z-score	Exposure to AB in first y of life not associated with increased risk.	Ethnicity, maternal age, pre-pregnancy BMI, antibiotic use and infection during pregnancy, prematurity, birth weight, infection type and severity
USA		nr; 138,417	No			<ul style="list-style-type: none"> <li>• aOR 1.01 (95% CI, 0.98-1.04), p=nr</li> </ul>	
2017		nr; 77,889	Registry				

(continued on next page)

Table 1 (continued)

Ville et al. <sup>147</sup>	Single-centre prospective cohort study (2b)	10; 97 5; 16 5; 81	< 6 m No Parent questionnaire	2 y	BMI	Exposure to AB in first 6 m of life associated with increased risk.  • <b>aOR 6.15 (95%CI 1.03-36.70), p&lt;0.05</b>	Sex, maternal BMI, weight for length z-score at birth, breastfeeding
USA 2017							
Scott et al. <sup>125</sup>	Multicentre retrospective cohort study (2b)	1,306; 21,714 951; 14,870 355; 6,844	< 2 y Yes Medical records	4 y	BMI z-score	Exposure to AB in first 2 y of life associated with increased risk.  • <b>aOR 1.24 (95%CI 1.09-1.41), p=nr</b>  Results according to antibiotic class nr	Age, country, maternal and sibling obesity, maternal diabetes, urban environment, Townsend score, delivery mode
USA 2016							
Bailey et al. <sup>25</sup>	Single-centre prospective cohort study (2b)	9,822; 65,480 6,967*; 45,181 2,855*; 20,299	< 2 y No Medical records	2-5 y	BMI	Exposure to AB in first 2 y of life associated with increased risk.  • <b>OR 1.11 (95%CI 1.03-1.19), p=nr (from<sup>240</sup>)</b> • 1 AB course: RR 1.03 (95% CI, 0.97-1.09), p=0.31 • 2 AB courses: RR 1.04 (95%CI 0.96-1.13), p=0.36 • 3 AB courses: RR 1.04 (95%CI 0.95-1.14), p=0.37 • ≥ 4 AB courses: <b>RR 1.11 (95%CI 1.02-1.21), p=0.02</b>  • < 6 m of life: <b>RR 1.11 (95%CI 1.03-1.19), p=nr</b>	
USA 2014							
Murphy et al. <sup>99</sup>	Multicentre cross-sectional study (3b)	nr; 74,946 nr; nr nr; nr	< 1 y No Parent questionnaire	5-8 y	BMI z-score	Exposure to AB in first y of life associated with increased risk.  • <b>OR 1.02 (95%CI 1.00-1.04), p=nr (from<sup>240</sup>)</b>  • boys: +0.107 SD units, p<0.01 • girls: +0.008 SD units, p=0.75	
18 countries 2014							
Trasande et al. <sup>143</sup>	Single-centre prospective cohort study (2b)	793; 8,881 622*; 6,598 171*; 2,283	< 6 m No Parent questionnaire	38 m	BMI z-score	Exposure to AB in first 6 m of life not associated with increased risk.  • aOR 1.23 (95%CI nr), p=0.10	Ethnicity, parity, parental education, BMI, and socioeconomic status; smoking during pregnancy, birth weight,
USA							

(continued on next page)

Table 1 (continued)

2013		793; 8,881	6-14 m			Exposure to AB in first 6 to 14 m of life not associated with increased risk.	breastfeeding, diet, timing of solid food introduction, sleep duration, time spent watching television and in car					
		603*; 6,598	No									
		190*; 2,283	Parent questionnaire									
		793; 8,881	15-23 m									
		613*; 6,598	No									
		180*; 2,283	Parent questionnaire									
706; 8,881	< 6 m	7 y			Exposure to AB in first 6 m of life not associated with increased risk.							
537*; 6,598	No											
169*; 2,283	Parent questionnaire											
706; 8,881	6-14 m											
531*; 6,598	No											
175*; 2,283	Parent questionnaire											
706; 8,881	15-23 m				Exposure to AB in first 15 to 23 m of life not associated with increased risk.							
534*; 6,598	No											
172*; 2,283	Parent questionnaire											
Ajslev et al. <sup>14</sup>	Multicentre prospective cohort study (2b)						378; 22,368	< 6 m	7 y	BMI (> 85 <sup>th</sup> percentile)	Exposure to AB in first 6 m of life associated with increased risk among children of normal-weight mothers.	Sex, maternal age and smoking; parity, pre-pregnancy BMI, gestational weight gain, paternal BMI, socioeconomic status, birth weight, delivery mode, breastfeeding
Denmark							nr; 1,628	No			• aOR 1.54 (95%CI 1.09-2.17), p=nr	
2011							nr; 20,740	Parent questionnaire			Exposure to AB in first 6 m of life associated with decreased risk among children of obese mothers. • aOR 0.54 (95%CI 0.30-0.98), p=nr	

(continued on next page)

Table 1 (continued)

Growth failure							
Uzan-Yulzari et al. <sup>145</sup>	Multicentre prospective cohort study (2b)	Boys: nr; 6,316 nr; 673 nr; 5,643	< 2 w No	6 y	Weight z-score BMI z-score	Exposure to AB in first w of life not associated with decreased weight gain in boys.	
Israel			Medical records			<ul style="list-style-type: none"> <li>weight z-score: -0.43 (95%CI -0.96- -0.00), p=0.05</li> <li>BMI z-score: -0.11 (95%CI -0.68-0.47), p=0.71</li> </ul>	
2021		Girls: nr; 6,115 nr; 478 nr; 5,637				Exposure to AB in first w of life not associated decreased weight gain in girls.	
						<ul style="list-style-type: none"> <li>weight z-score: 0.28 (95%CI -0.21-0.77), p=0.26</li> <li>BMI z-score: 0.62 (95%CI -0.19-1.44), p=0.13</li> </ul>	
Kamphorst et al. <sup>71</sup>	Multicentre prospective cohort study (2b)	nr, 436 nr; 151 nr 285	< 1 w Yes	1 y	Weight	Exposure to AB in first w of life associated with decreased weight gain.	
Netherlands			Parent questionnaire			<ul style="list-style-type: none"> <li>weight gain: <b>6.26 kg (SE 0.07 kg) vs 6.47 (SE 0.06 kg), p&lt;0.05</b></li> </ul>	
2019						Results according to antibiotic class nr	
Rogawski et al. <sup>205</sup>	Single-centre prospective cohort study (2b)	140; 497 nr; 276 nr; 221	< 6 m No	6 m-3 y	Weight-for-age (WAZ)	Exposure to AB in first 6 m of life not associated with decreased weight gain.	
India			Parent questionnaire			<ul style="list-style-type: none"> <li>RR 0.98 (95%CI 0.86-1.13), p=nr</li> </ul>	
2015		68; 497 nr; 276 nr; 221			Weight-for-height (WHZ) z-scores	Exposure to AB in first 6 m of life not associated with decreased weight gain.	
						<ul style="list-style-type: none"> <li>RR 0.96 (95%CI 0.78-1.18), p=nr</li> </ul>	
Juvenile idiopathic arthritis							
Horton et al. <sup>64</sup>	Multicentre nested case-control study (3b)	152; 1,672 133; 1,280 19; 392	Before diagnosis Yes	1-15 y	ICD-9 and ICD-10 codes	Exposure to AB associated with increased risk.	Age, sex, autoimmune disease, number of infections
USA			Medical records			<ul style="list-style-type: none"> <li><b>aOR 2.10 (95%CI 1.20-3.50), p&lt;0.01</b></li> <li>AB within 1 y before diagnosis: <b>aOR 2.90 (95% 1.60-5.30), p&lt;0.01</b></li> <li>1-2 AB courses: aOR 1.50 (95%CI 0.80-2.70), p=0.16</li> <li>3-5 AB courses: <b>aOR 2.50 (95%CI 1.40-4.40), p&lt;0.01</b></li> <li>&gt; 5 AB courses: <b>aOR 3.00 (95%CI 1.60-5.60), p&lt;0.01</b></li> </ul>	
2015						Results according to antibiotic class nr	

(continued on next page)

Table 1 (continued)

Arvonen et al. <sup>18</sup> Finland 2015	Multicentre case-control study (3b)	1,298; 6,477	< 1 y	< 13 y	ICD 10 codes	Exposure to AB in first y associated with increased risk.	
		644; 2,986	Yes				• <b>OR 1.20 (95%CI 1.10-1.40), p=nr</b>
		654; 3,491	Registry				• penicillins: <b>OR 1.20 (95%CI 1.10-1.40), p=nr</b> • cephalosporins: <b>OR 1.30 (95%CI 1.10-1.70), p=nr</b> • macrolides: OR 1.20 (95%CI 1.02-1.40), p=nr • sulfonamides: OR 1.20 (95%CI 0.90-1.50), p=nr • lincosamides: OR 1.00 (95%CI 0.10-8.90), p=nr
		1,298; 6,477	< 2 y			Exposure to AB in first 2 y associated with increased risk.	• <b>OR 1.40 (95%CI 1.20-1.60), p&lt;0.01</b>
		1,015; 4,737 283; 1,740	Yes			• penicillins: OR 1.50 (95%CI 1.30-1.70), p=nr • cephalosporins: OR 1.30 (95%CI 0.99-1.60), p=nr • macrolides: OR 1.30 (95%CI 1.10-1.50), p=nr • sulfonamides: OR 1.30 (95%CI 0.90-1.70), p=nr • lincosamides: <b>OR 3.50 (95%CI 1.30-9.70), p=0.01</b>	
		1,298; 6,477	Before diagnosis			Exposure to AB from birth to diagnosis associated with increased risk.	• <b>OR 1.60 (95%CI 1.30-1.90), p&lt;0.01</b>
		1,158; 5,529 140; 948	Yes			• penicillins: OR 1.80 (95%CI 1.50-2.20), p=nr • cephalosporins: <b>OR 1.60 (95%CI 1.40-1.80), p=nr</b> • macrolides: OR 1.50 (95%CI 1.20-1.90), p=nr • sulfonamides: OR 1.60 (95%CI 1.20-2.20), p=nr • lincosamides: <b>OR 6.60 (95%CI 3.70-11.70), p=nr</b>	
			Registry				
<b>Psoriasis</b>							
Horton et al. <sup>65</sup> USA 2016	Multicentre nested case-control study (3b)	845; 9,295 710; 7,053 135; 2,242	< 2 y before diagnosis Yes	1-15 y	ICD-9 codes	Exposure to AB within 2 y before diagnosis associated with increased risk.	Age, sex, country, socioeconomic status, infections, number of GP visits
			Medical records			• <b>aOR 1.20 (95%CI 1.00-1.50), p=0.05</b>	Results according to antibiotic class nr

(continued on next page)

Table 1 (continued)

Type 1 diabetes							
Antvorskov et al. <sup>171</sup>	Multicentre prospective cohort study (2b)	322; 91,998 235; 64,793 87; 27,205	< 2 y Yes Registry	14.3 y (mean)	ICD-10 codes	Exposure to AB in first 2 y of life not associated with increased risk.  • aHR 1.26 (95%CI 0.89-1.79), p=nr  • penicillins: aHR 1.30 (95%CI 0.92-1.85), p=nr • macrolides/lincosamides/ streptogramins: aHR 1.29 (95%CI 0.75-2.22), p=nr	Breastfeeding
Denmark							
2020							
Wernroth et al. <sup>152</sup>	Multicentre prospective cohort study (2b)	1,297; 797,318 347; 189,682 950; 607,636	< 1 y Yes Registry	< 10 y	ICD-10 codes	Exposure to AB in first y of life associated with increased risk.  • aHR 1.19 (95%CI 1.05-1.36), p=nr  • narrow-spectrum: HR 1.26 (95%CI 1.09-1.47), p=nr • broad-spectrum: 1.06 (95%CI 0.80-1.40), p=nr  Results according to antibiotic class nr	Age, sex, maternal age, parental country of birth, education, income and type 1 diabetes; living area, population density, smoking during pregnancy, gestational age, season of birth, delivery mode
Sweden							
2020							
Tapia et al. <sup>140</sup>	Multicentre prospective cohort study (2b)	403, 101,842 nr; 32,386 nr; 69,456	< 18 m Yes Parent questionnaire	7.4 y (mean)	ICD-10 codes	Exposure to AB in first 6 m of life not associated with increased risk.  • aHR 1.05 (95%CI 0.68-1.63), p=0.82  • 1 AB course: aHR 1.10 (95%CI 0.83-1.41), p=0.51 • ≥ 2 AB courses: aHR 1.03 (95%CI 0.65-1.65), p=0.88  Results according to antibiotic class nr	Sex, maternal age, education and type 1 diabetes; parity, pre-pregnancy BMI, smoking during pregnancy, birth weight, number of infections, medication use
Norway							
2018							
Mikkelsen et al. <sup>94</sup>	Multicentre prospective case-control study (3b)	1,578; 14,188 1,366; 12,239 212; 1,949	< 2 y No Registry	< 16 y	ICD-10 codes	Exposure to AB in first 2 y of life not associated with increased risk.  • 1-4 AB courses: OR 1.02 (95%CI 0.85-1.22), p=nr • > 5 AB courses: OR 1.01 (95%CI 0.85-1.22), p=nr	
Denmark							
2016							

(continued on next page)

Table 1 (continued)

						<ul style="list-style-type: none"> <li>• narrow-spectrum 1-4 AB courses: OR 0.90 (95%CI 0.78-1.03), p=nr</li> <li>• narrow-spectrum <math>\geq</math> 5 AB courses: OR 0.98 (95%CI 0.80-1.21), p=nr</li> <li>• broad-spectrum 1-4 AB courses: OR 1.11 (95%CI 0.98-1.24), p=nr</li> <li>• broad-spectrum <math>\geq</math> 5 AB courses: OR 1.15 (95%CI 0.95-1.39), p=nr</li> </ul>	
Clausen et al. <sup>36</sup>	Multicentre prospective cohort study (2b)	1,503; 858,201	< 2 y	2-14 y	Hospital discharge or prescription records	Overall exposure to AB in first 2 y of life not associated with increased risk.	Age, sex, parental education, age and type 1 diabetes, parity, delivery mode
Denmark		1,107; 615,782	Yes			<ul style="list-style-type: none"> <li>• aHR 1.06 (95%CI 0.94-1.19), p=nr</li> </ul>	
2016		396; 242,419	Registry			<ul style="list-style-type: none"> <li>• narrow-spectrum: aHR 1.02 (95%CI 0.92-1.13), p=nr</li> <li>• broad-spectrum: <b>aHR 1.13 (95%CI 1.02-1.25), p=nr</b></li> </ul> <p>Exposure to broad-spectrum AB in first 2 y of life associated with increased risk in children delivered by delivery mode.</p> <ul style="list-style-type: none"> <li>• <b>aHR 1.70 (95%CI 1.15-2.51), p=nr</b></li> </ul> <p>Results according to antibiotic class nr</p>	
Hviid et al. <sup>204</sup>	Multicentre prospective cohort study (2b)	454; 606,420	< 9 y	< 9 y	ICD-10 codes	Exposure to AB in first w of life not associated with increased risk.	Age, ethnicity, season
Denmark		373; 538,298	Yes			<ul style="list-style-type: none"> <li>• aRR 1.16 (95%CI 0.91-1.50), p=nr</li> </ul>	
2009		81; 68,122	Registry			<ul style="list-style-type: none"> <li>• penicillins: aRR 1.10 (95%CI 0.90-1.34), p=nr</li> <li>• macrolides: aRR 1.15 (95%CI 0.92-1.43), p=nr</li> </ul>	

(continued on next page)



Table 1 (continued)

Fluorosis						
Hong <i>et al.</i> <sup>63</sup>	Single-centre prospective	68; 192	< 32 m	13 y	Fluorosis risk index	Overall exposure to AB in first 32 m of life not associated with increased risk.
USA 2011	case-control study (3b)	62; 174 6; 18	Yes	Parent questionnaire		<ul style="list-style-type: none"> <li>• amoxicillin: RR 1.07 (95%CI 0.54-2.12), p=0.85</li> </ul>
Autism spectrum disorders						
Aversa <i>et al.</i> <sup>172</sup>	Multicentre prospective cohort study (2b)	142; 14,572	< 2 y	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life not associated with increased risk.
USA 2021		108; 10,220 34; 4,352	Yes	Medical records		<ul style="list-style-type: none"> <li>• aHR 1.19 (95%CI 0.81-1.75), p=0.39</li> </ul> <p>Girls</p> <ul style="list-style-type: none"> <li>• penicillins: <b>HR 0.39 (95%CI 0.16-0.95), p=0.04</b></li> <li>• cephalosporins: <b>HR 2.77 (95%CI 1.09-7.02), p=0.03</b></li> <li>• macrolides: HR 1.21 (95%CI 0.47-3.14), p=0.70</li> <li>• sulfonamides: HR 1.08 (95%CI 0.24-4.81), p=0.92</li> </ul> <p>Boys</p> <ul style="list-style-type: none"> <li>• penicillins: HR 0.96 (95%CI 0.62-1.47), p=0.84</li> <li>• cephalosporins: <b>HR 1.89 (95%CI 1.25-2.84), p&lt;0.01</b></li> <li>• macrolides: HR 0.83 (95%CI 0.55-1.28), p=0.41</li> <li>• sulfonamides: HR 1.13 (95%CI 0.54-2.35), p=0.75</li> </ul> <p>Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode</p>
Axelsson <i>et al.</i> <sup>21</sup>	Multicentre prospective cohort study (2b)	8,267; 671,606	< 2 y	< 15 y	ICD-10 codes	Exposure to AB in first y of life associated with increased risk.
Denmark 2019		Penicillins: 6,316; 483,423 1,951; 188,183	Yes	Registry		<ul style="list-style-type: none"> <li>• <b>OR 1.26 (95%CI 1.20-1.33), p&lt;0.01*</b></li> </ul> <hr/> <ul style="list-style-type: none"> <li>• penicillins: aHR 1.09 (95%CI 0.91-1.29), p=nr</li> <li>• <b>OR 1.16 (95%CI 1.11-1.21), p&lt;0.01*</b></li> </ul> <hr/> <ul style="list-style-type: none"> <li>• broad-spectrum AB: <b>aHR 1.16 (95%CI 1.01-1.36), p=nr</b></li> </ul> <p>Sex, maternal age and smoking; parental education, age difference, marital status epilepsy and psychiatric history; parity, preeclampsia or hypertension, gestational diabetes, antibiotic use and infections during pregnancy, Apgar score, delivery mode, use of CPAP or ventilator, asphyxia</p>
		Broad-spectrum: 4,943; 377,254 3,324; 294,352				

(continued on next page)

Table 1 (continued)

Hamad et al. <sup>57</sup>	Multicentre prospective cohort study	2,965; 214,834	< 1 y	18 m-18 y	ICD-9 and ICD-10 codes	Exposure to AB in first y of life not associated with increased risk.	Age, sex, maternal age, and mental disorders (mood and anxiety disorders, schizophrenia, diabetes, prenatal infections), parity, living area, socioeconomic status, healthcare access, antidepressants use during pregnancy, size for gestational age, season of birth, delivery mode, birth complications, multiple birth, childhood medical disorders (epilepsy, infections, neonatal jaundice, asthma and diagnosis with other developmental disability disorder), breastfeeding
Canada	(2b)	1,355; 94,024	Yes			<ul style="list-style-type: none"> <li>• aHR 0.91 (95%CI 0.84-0.99), p=0.05</li> </ul>	
2018		1,610; 120,810	Registry			<ul style="list-style-type: none"> <li>• 1 AB course: aHR 0.92 (95%CI 0.83-1.01), p=nr</li> <li>• 2 AB courses: aHR 0.89 (95%CI 0.78-1.01), p=nr</li> <li>• 3 AB courses: aHR 0.93 (95%CI 0.79-1.09), p=nr</li> <li>• ≥ 4 AB courses: aHR 0.90 (95%CI 0.76-1.06), p=nr</li> <li>• penicillins: <b>aHR 0.92 (95%CI 0.84-1.00), p&lt;0.05</b></li> <li>• macrolides: <b>aHR 0.87 (95%CI 0.77-0.99), p&lt;0.05</b></li> </ul>	
<b>Attention deficit hyperactivity disorder</b>							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study	1,085; 14,572	< 2 y	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk.	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode
USA	(2b)	841; 10,220	Yes			<ul style="list-style-type: none"> <li>• <b>aHR 1.32 (95%CI 1.15-1.53), p&lt;0.01</b></li> </ul>	
2021		244; 4,352	Medical records			<p>Girls</p> <ul style="list-style-type: none"> <li>• penicillins: <b>HR 1.50 (95%CI 1.14-1.96), p&lt;0.01</b></li> <li>• cephalosporins: HR 1.21 (95%CI 0.92-1.59), p=0.18</li> <li>• macrolides: HR 1.03 (95%CI 0.79-1.34), p=0.85</li> <li>• sulfonamides: HR 0.65 (95%CI 0.38-1.10), p=0.11</li> </ul> <p>Boys</p> <ul style="list-style-type: none"> <li>• penicillins: HR 1.08 (95%CI 0.91-1.27), p=0.38</li> <li>• cephalosporins: HR 1.18 (95%CI 1.00-1.39), p=0.05</li> <li>• macrolides: HR 1.09 (95%CI 0.93-1.28), p=0.28</li> <li>• sulfonamides: HR 1.19 (95%CI 0.89-1.58), p=0.23</li> </ul>	

(continued on next page)

Table 1 (continued)

Axelsson et al. <sup>22</sup>	Multicentre prospective cohort study (2b)	17,971; 671,592	< 2 y	2-17 y	ICD-10 codes	Exposure to AB in first 2 y of life not associated with increased risk.	Sex, maternal age, parental education, age difference, marital status, epilepsy, and ADHD history, parity, preeclampsia or hypertension, gestational diabetes, antibiotic use and infections during pregnancy, Apgar score, delivery mode, instrument use at delivery, induction of labour or contraction, use of CPAP or ventilator, asphyxia, maternal smoking
Denmark		Penicillins: 2,822; 106,170 15;149; 565,422	Yes			<ul style="list-style-type: none"> <li>• <b>OR 1.47 (95%CI 1.42-1.53), p&lt;0.01*</b></li> <li>• penicillins: aHR 0.98 (95%CI 0.90-1.07), p=nr</li> </ul>	
2019		Broad-spectrum: 11,365; 377,238 6,606; 294,354	Registry			<ul style="list-style-type: none"> <li>• <b>OR 1.35 (95%CI 1.31-1.40), p&lt;0.01*</b></li> <li>• broad-spectrum AB: aHR 0.99 (95%CI 0.92-1.06), p=nr</li> </ul>	
Hamad et al. <sup>58</sup>	Multicentre prospective cohort study (2b)	6,087; 69,738	< 1 y	> 4 y	ICD-9 and ICD-10 codes	Exposure to AB in first y of life not associated with increased risk.	Age, sex, maternal age, antidepressants use and infections during pregnancy, size for gestational age, season of birth, delivery mode, birth order, birth complications, childhood medical disorders (asthma, epilepsy, infections, neonatal jaundice, diagnosis with other developmental disorder), breastfeeding
Canada		3,045; 34,869 3,042; 34,869	Yes			<ul style="list-style-type: none"> <li>• aHR 1.02 (95%CI 0.97-1.08), p=nr</li> </ul>	
2019			Registry			<ul style="list-style-type: none"> <li>• 1 AB course: aHR 0.94 (95%CI 0.87-1.02), p=nr</li> <li>• 2 AB courses: aHR 1.09 (95%CI 0.94-1.27), p=nr</li> <li>• 3 AB courses: aHR 1.09 (95%CI 0.83-1.43), p=nr</li> <li>• ≥ 4 AB courses: <b>aHR 1.57 (95%CI 1.23-2.00), p=nr</b></li> <li>• penicillins: <b>aHR 1.11 (95%CI 1.03-1.19), p=nr</b></li> <li>• macrolides: <b>aHR 1.11 (95%CI 1.04-1.34), p=nr</b></li> </ul>	
Slykerman et al. <sup>130</sup>	Multicentre prospective cohort study (2b)	nr; 446	< 2 y	11 y	Psychologist-administered, parent-reported and self-reported measures <sup>1</sup>	Exposure to AB in first 2 y of life associated with increased risk.	Income, delivery mode, probiotic use, breastfeeding
New Zealand		nr; 376 nr; 70	No			<ul style="list-style-type: none"> <li>• <b>aOR 2.40 (95%CI 1.00-5.90), p=0.02</b></li> </ul>	
2019			Parent questionnaire				

(continued on next page)

Table 1 (continued)

Neurodevelopmental disorders							
Aversa et al. <sup>172</sup>	Multicentre prospective cohort study	751; 14,572	< 2 y	6-11 y	ICD-9 and ICD-10 codes	Exposure to AB in first 2 y of life associated with increased risk of learning disorders.	Sex, ethnicity, maternal age, education and smoking; antibiotic use during pregnancy, birth weight, delivery mode
USA	(2b)	563; 10,220	Yes			<ul style="list-style-type: none"> <li>• <b>aHR 1.21 (95%CI 1.03-1.43), p=0.02</b></li> </ul>	
2021		188; 4,352	Medical records			<p>Girls</p> <ul style="list-style-type: none"> <li>• penicillins: HR 1.18 (95%CI 0.88-1.58), p=0.28</li> <li>• cephalosporins: HR 1.36 (95%CI 0.99-1.85), p=0.06</li> <li>• macrolides: HR 0.93 (95%CI 0.68-1.28), p=0.67</li> <li>• sulfonamides: HR 0.96 (95%CI 0.56-1.64), p=0.87</li> </ul> <p>Boys</p> <ul style="list-style-type: none"> <li>• penicillins: HR 1.06 (95%CI 0.87-1.29), p=0.56</li> <li>• cephalosporins: <b>HR 1.48 (95%CI 1.21-1.80), p&lt;0.01</b></li> <li>• macrolides: <b>HR 0.79 (95%CI 0.65-0.98), p=0.03</b></li> <li>• sulfonamides: HR 1.03 (95%CI 0.71-1.51), p=0.87</li> </ul>	
Slykerman et al. <sup>130</sup>	Multicentre prospective cohort study	nr; 446	< 2 y	11 y	Psychologist-administered, parent-reported and self-reported measures <sup>1</sup>	Exposure to AB in first 6 m of life associated with lower overall cognitive and verbal comprehension abilities, increased risk of problems with metacognition, executive function, impulsivity, hyperactivity, ADHD, anxiety and emotional problems.	Income, delivery mode, probiotic use, breastfeeding
New Zealand	(2b)	nr; 376	No			<ul style="list-style-type: none"> <li>• <b>full scale IQ: mean difference -5.70 (95%CI -10.30, -1.20), p=0.04</b></li> <li>• <b>verbal comprehension index: mean difference -8.40 (95%CI -14.00, -2.80), p=0.02</b></li> <li>• metacognition index: aOR 2.20 (95%CI 0.90, 5.50), p=0.05</li> <li>• <b>impulsivity/hyperactivity: aOR 2.10 (95%CI 0.90-5.00), p=0.02</b></li> <li>• <b>executive function: aOR 3.80 (95%CI 1.20-11.70), p=0.04</b></li> <li>• <b>emotional problems: aOR 9.20 (95%CI 2.00-43.00), p&lt;0.01</b></li> <li>• <b>hyperactivity: aOR 8.20 (95%CI 0.90-73.10), p&lt;0.01</b></li> <li>• <b>total anxiety score: aOR 5.40 (95%CI 1.40-20.70), p&lt;0.01</b></li> </ul>	
2019		nr; 70	Parent questionnaire				

(continued on next page)

**Table 1** (continued)

\* calculated from reported data

<sup>1</sup>WISC-IV (Wechsler Intelligence Scale for Children-fourth edition), CPT 3 (Conners Continuous Performance Test-third edition), CANTAB (Cambridge Automated Neuropsychological Test Battery), BRIEF (Behavior Rating Inventory of Executive Function), Conners 3, SDQ (Strengths and Difficulties Questionnaire), MASC 2 (Multidimensional Anxiety Scale for Children), CES-DC (Center for Epidemiological Studies for Children)

AB – antibiotic

ADHD – attention deficit hyperactivity disorder

a – adjusted

ASD – autism spectrum disorders

ATC – anatomical-therapeutic-chemical

BASME – Barn, Allergi, Miljö, Stockhol, Epidemiologi

BMI – body mass index

CI – confidence interval

ECRHS II – European Community Respiratory Health Survey second version

GP – general practitioner

HLA – human leucocyte antigen

HR – hazard ratio

IBD – inflammatory bowel disease

ICD-10-CA – international classification of disease, tenth revision, Canadian Edition

ICD-9-CM – international classification of disease, ninth revision, clinical modification

ICD-9/10 – international classification of disease, ninth/tenth revision

IgE – immunoglobulin E

IRR – incidence rate ratio

ISAAC – International Study of Allergy and Asthma in Childhood

JIA – juvenile idiopathic arthritis

LRTI – lower respiratory tract infections

m – month

nr – not reported

OR – odds ratio

RP – ratio of proportion

RR – risk ratio

RRR – prevalence ratio

SPT – skin prick test

w – week

y – year

diagnosed by ISAAC questionnaire, ICD codes, skin prick test or serum IgE levels in 1,859,024 children (45,479 cases) (Table 1).<sup>42,46,51,61,82,91,93,96,115,161,163,172,178,183,185</sup> Of the 15 studies, 13 (87%) investigated the effect of antibiotic exposure in the first two years of life.<sup>42,46,51,82,93,96,115,161,163,172,178,183,185</sup> Nine (60%) reported a significantly increased incidence of food allergies in children who were exposed to antibiotics.<sup>61,91,96,115,161,163,172,178,183,185</sup> Two studies reported a positive correlation between the risk of developing food allergies and the number of antibiotic courses.<sup>61,115</sup> One study reported that the risk of developing food allergies was higher when children were exposed in the first year of life compared to the second or third year of life.<sup>115</sup> Four studies investigated the effect of different antibiotic classes.<sup>61,91,163,172</sup> One reported an increased risk of food allergies only after the exposure to cephalosporins, but not penicillins, macrolides and sulfonamides.<sup>172</sup> Three studies reported an increased risk of all investigated antibiotic classes: penicillins, cephalosporins and macrolides<sup>61</sup>; penicillins, cephalosporins, macrolides and sulfonamides<sup>163</sup>; and penicillin, amoxicillin, cephalosporins, macrolides and trimethoprim/sulfamethoxazole,<sup>91</sup> respectively.

All studies provided sufficient data to be included in the meta-analysis (supplementary Fig. 3).<sup>42,46,51,61,82,91,93,96,115,161,163,172,178,183,185</sup> Of the 659,863 children exposed to antibiotics 16,703 (2.5%) developed food allergies compared to 28,776 (2.4%) of the 1,199,161 children not exposed to antibiotics. Overall, antibiotic exposure was associated with an increased risk of developing food allergies (OR 1.35, 95%CI 1.20–1.52,  $p < 0.01$ ) (Fig. 2).

### Allergic rhinoconjunctivitis

Forty studies investigated the association between antibiotic exposure and the risk of developing allergic rhinoconjunctivitis diagnosed by ISAAC questionnaire, ICD codes or parent's-reported diagnosis in 1,554,337 children (359,568 cases with one study not reporting number of cases) (Table 1).<sup>16,29,32,35,37,43,48–50,59,60,74,82,93,96–98,102,103,110,112,129,150,154,155,157,158,161,162,172,176–178,181,182,186–190</sup> Of the 40 studies, 38 (95%) investigated the effect of antibiotic exposure in the first five years of life (35 (88%) in the first two years of life).<sup>16,29,32,35,37,43,48–50,59,60,74,82,93,96–98,102,103,110,112,129,150,157,158,161,162,172,176–178,172,181,186–190</sup> Twenty-nine (73%) reported a significantly increased incidence of allergic rhinoconjunctivitis in children who were exposed to antibiotics.<sup>16,29,35,37,43,48–50,59,60,74,82,96,97,102,103,110,129,150,157,158,161,172,176,181,186–189</sup> One study reported that the risk of developing allergic rhinitis was higher when children were exposed to antibiotics in the third year of life compared to the second or first year of life.<sup>29</sup> Three studies reported that the risk increased after more than one antibiotic course,<sup>29,103,176</sup> while another could not confirm this finding.<sup>182</sup> Four studies investigated the effect of antibiotic class.<sup>29,157,172,182</sup> One study reported that the risk of developing allergic rhinoconjunctivitis was higher after exposure to cephalosporins and macrolides compared to penicillins and sulfonamides,<sup>172</sup> and one study after exposure to cephem compared to penicillins or macrolides.<sup>157</sup> Two studies did not find a difference between antibiotic classes and the risk of allergic rhinoconjunctivitis.<sup>29,182</sup>

Twenty-seven (68%) studies provided sufficient data to be included in the meta-analysis (supplementary Fig. 4).<sup>16,32,35,37,43,48,49,59,74,82,93,96,97,102,103,112,154,157,158,161,162,172,176,178,181,188,190</sup> Of the 200,029 children exposed to antibiotics 61,899 (30%) developed allergic rhinoconjunctivitis compared to 204,006 (28%) of the 718,124 children not exposed to antibiotics. Overall, antibiotic exposure was associated with an increased risk of

allergic rhinoconjunctivitis (OR 1.66, 95%CI 1.51–1.83,  $p < 0.01$ ) (Fig. 2).

### Wheezing

Thirty-two studies investigated the association between antibiotic exposure and the risk of developing wheezing in 220,415 children (29,229 cases) diagnosed by ISAAC questionnaire, ICD codes or parent-reported diagnosis (Table 1).<sup>13,15,37,40,49,56,59,60,79,80,95,97,103–105,115,119,126,137,154,155,157,161,162,164–166,178,191–194</sup> Of the 32 studies, 29 (91%) investigated the effect of antibiotic exposure in the first five years of life (26 (81%) in the first two years of life).<sup>13,15,37,40,49,56,59,60,69,79,80,95,97,103–105,115,119,126,137,157,161,162,164,165,178,191–194</sup>

Twenty-seven (84%) reported a significantly increased incidence of wheezing in children who were exposed to antibiotics.<sup>13,15,37,49,56,59,60,79,95,97,103,104,115,119,126,137,154,155,161,164–166,178,191–194</sup> Five studies reported that the risk of developing wheezing increased with the number of antibiotics courses.<sup>13,103,115,178,191</sup> One study reported that the risk of wheezing was higher after exposure to cephem compared to penicillins or macrolides<sup>157</sup> and one study after exposure to macrolides compared to other antibiotic classes.<sup>137</sup>

Twenty-seven (84%) studies provided sufficient data to be included in the meta-analysis (supplementary Fig. 5).<sup>13,15,37,40,49,56,59,79,80,95,97,103–105,115,119,154,155,157,161,162,166,178,191–194</sup> Of the 94,076 children exposed to antibiotics 16,172 (17%) developed wheezing compared to 11,169 (9%) of the 120,466 children not exposed to antibiotics. Overall, antibiotic exposure was associated with an increased risk of developing wheezing (OR 1.81, 95%CI 1.65–1.97,  $p < 0.01$ ) (Fig. 2).

### Asthma

Sixty-three studies investigated the association between antibiotic exposure and the risk of developing asthma mainly diagnosed by ISAAC questionnaire, ICD codes or parent-reported diagnosis in 12,366,759 children (312,230 cases with two studies not reporting number of cases) (Table 1).<sup>12,13,32,34,37,39,41,43,48–50,52,55,59,69,75–77,80,82,88,92,93,96–98,101–104,109,111,112,115,116,126,132,134,135,150,153–157,159,161,162,164,167–169,172,176–178,181,182,191,195–197,175</sup> Of the 63 studies, 59 (94%) investigated the effect of antibiotic exposure in the first five years of life (56 (89%) in the first two years of life).<sup>12,13,31,32,37,39,41,43,48–50,52,55,59,69,75–77,80,82,88,93,96–98,101–104,109,111,112,115,116,126,132,134,135,150,153,156,157,159,161,162,164,167–169,172,176–178,172,181,191,195–197</sup>

Fifty-four (86%) reported a significantly increased incidence of asthma in children who were exposed to antibiotics.<sup>12,13,31,34,37,39,41,43,48–50,52,55,69,75–77,82,88,92,93,96,97,101–104,109,111,115,116,126,132,134,135,150,154,156,157,159,161,162,164,168,169,172,176,178,172,181,191,195–197</sup> However, one study only after two courses of antibiotics.<sup>115</sup> One study reported that the risk of developing asthma was higher when higher doses of antibiotics were used.<sup>34</sup> Another study reported that the risk of asthma was not increased after antibiotic exposure in the first six months of life, but it was increased when exposed during the first three years of life<sup>12</sup>; and one study that the effect of antibiotics on the incidence of asthma was stronger in children with younger age at onset.<sup>197</sup> Six studies reported that the risk of asthma was highest after exposure to macrolides,<sup>34,69,92,111,195</sup> three studies that it was higher after exposure to cephalosporins compared to penicillins and macrolides,<sup>69,157,182</sup> and one study after exposure to penicillins, cephalosporins and macrolides compared to sulfonamides.<sup>172</sup> One study reported that the risk of asthma was higher after exposure to broad-spectrum compared to narrow-spectrum antibiotics.<sup>197</sup> Many studies reported that the risk of

developing asthma increased with the number of antibiotics courses<sup>13,32,48,76,103,109,111,115,116,154,176,178,181,182,191,195,197,175</sup> and one study that the risk was higher after higher doses of antibiotics.<sup>34</sup> Two studies did not find an association between antibiotic exposure and the development of asthma after adjusting for number of illnesses or chest infections.<sup>135,153</sup> One study found a higher risk in girls to develop asthma after exposure to antibiotics.<sup>39</sup>

Fifty-one (81%) studies provided sufficient data to be included in the meta-analysis (supplementary Fig. 6).<sup>12,13,31,32,34,37,39,41,43,48,49,55,59,69,75,77,80,82,88,92,93,96,97,101–104,109,111,115,116,132,134,135,153,154,156,157,161,162,167–169,172,176,178,181,191,195,196</sup> Of the 909,797 children exposed to antibiotics 122,450 (13%) developed asthma compared to 128,778 (10%) of the 1,245,440 children not exposed to antibiotics. Overall, antibiotic exposure was associated with an increased risk of developing asthma (OR 1.96, 95%CI 1.76–2.17,  $p < 0.01$ ) (Fig. 2).

### Allergic symptoms

Four studies including 24,840 children (5019 cases) investigated the association between antibiotic exposure and the development of allergic symptoms without specifying the symptoms or reporting results separately for atopic dermatitis, allergic rhinitis, food allergies, wheezing or asthma (Table 1).<sup>61,82,177,183</sup> All four studies investigated the effect of antibiotic exposure in the first year of life.<sup>61,82,177,183</sup> Three (75%) of the studies reported a significantly increased risk of developing allergic symptoms in children who were exposed to antibiotics.<sup>61,82,183</sup> One study reported that the risk of allergic sensitisation increased with the number of antibiotic courses and that it was higher after exposure to penicillin compared to cephalosporins and macrolides.<sup>61</sup>

Three (75%) studies could be included in the meta-analysis (supplementary Fig. 7).<sup>61,82,183</sup> Of the 17,906 children exposed to antibiotics 3634 (20%) developed allergic symptoms compared to 906 (15%) of 6009 children not exposed to antibiotics. The overall OR for developing allergic symptoms after antibiotic exposure was 1.93, 95%CI 1.66–2.26,  $p < 0.01$  (Fig. 2).

### Infantile colic

One study investigated the association between antibiotic exposure and the development of infantile colic in 436 neonates (74 cases) (Table 1 and supplementary Fig. 8).<sup>105</sup> Of the 151 neonates exposed to antibiotics in the first week of life, 33 (22%) developed infantile colic compared to 41 (14%) of the 285 neonates not exposed. The OR was 1.66 (95%CI 1.00–2.77,  $p = 0.05$ ) (Fig. 2 and supplementary Fig. 8).

### Abdominal pain

One study investigated the association between antibiotic exposure and the development of abdominal pain in 2732 children (245 cases) diagnosed by a validated questionnaire (Table 1 and supplementary Fig. 9).<sup>144</sup> Of the 861 children exposed to antibiotics in the first two years of life, 87 (10%) developed abdominal pain compared to 144 (8%) of the 1793 children not exposed to antibiotics. Of the children exposed to antibiotics between the age of nine to twelve years these numbers were 94 (9%) of 1045 and 151 (9%) of 1687, respectively. The risk of abdominal pain increased with the number of antibiotic courses and was highest after exposure to tetracycline compared to other antibiotics. Overall, the evidence did not support an association between exposure to antibiotics and the incidence of abdominal pain later in life (Fig. 2 and supplementary Fig. 9). OR 1.01 (95%CI 0.77–1.32,  $p = 0.37$ ).

### Inflammatory bowel disease

Six studies investigated the association between exposure to antibiotics and the development of inflammatory bowel disease (IBD) in 2481,433 children (1617 cases) (Table 1).<sup>30,68,78,106,127,148</sup> Four (67%) studies investigated the effect of antibiotic exposure in the first year of life.<sup>30,78,127,148</sup> Five (83%) of the studies reported a significant association between antibiotic exposure and developing IBD.<sup>68,78,106,127,148</sup> One study reported a higher association between Crohn's disease than ulcerative colitis<sup>68</sup> and another study an association between antibiotic exposure and developing Crohn's disease but not ulcerative colitis.<sup>148</sup> Two studies found an association between the number of antibiotic courses and the risk of IBD.<sup>30,78</sup> However two other studies could not confirm this association.<sup>106,148</sup> One study reported that the risk was highest after exposure to metronidazole, penicillins, cephalosporins and fluoroquinolones compared to other antibiotic classes,<sup>78</sup> one after cephalosporins,<sup>148</sup> and one that it was after exposure to penicillins compared to macrolides.<sup>68</sup>

All six studies were included in the meta-analysis (supplementary Fig. 10).<sup>30,68,78,106,127,148</sup> Of the 1,650,507 children exposed to antibiotics 976 (0.06%) developed IBD compared to 641 (0.08%) of the 830,926 children not exposed to antibiotics. Overall, the evidence did not support an association between antibiotic exposure and developing IBD (OR 1.19, 95%CI 0.83–1.71,  $p = 0.35$ ) (Fig. 2).

### Celiac disease

Four studies investigated the association between antibiotic exposure and developing celiac disease by ICD codes, antibody measurement or the criteria by the European Society for pediatric Gastroenterology, Hepatology and Nutrition in 1728,197 children (4,547 cases) (Table 1).<sup>44,73,172,199</sup> All of the studies were done in children less than 4 years of age (three (75%) in children less than 2 years of age).<sup>44,73,172,199</sup> Two (50%) of the studies found a positive association between antibiotic exposure and developing celiac disease.<sup>44,172</sup> One study reported that the risk was highest in girls after exposure to penicillins<sup>172</sup> and one study did not find a difference in the risk of celiac disease after exposure to different antibiotic classes.<sup>73</sup>

Three (75%) studies were included in the meta-analysis (supplementary Fig. 11).<sup>44,172,199</sup> Of the 531,197 children exposed to antibiotics 1149 (0.22%) developed celiac disease compared to 2615 (0.23%) of the 1160,442 children not exposed to antibiotics. Overall, the evidence did not support an association between antibiotic exposure and developing celiac disease (OR 1.21, 95%CI 0.80–1.83,  $p = 0.37$ ) (Fig. 2).

### Increased weight gain or overweight

Seventeen studies investigated the association between antibiotic exposure and the risk of developing increased weight gain or overweight evaluated by weight, weight-for-age z-scores, body mass index (BMI), BMI z-scores, or fat percentage in 569,527 children (137,744 cases with five studies not reporting number of cases) (Table 1).<sup>14,23,27,33,54,71,75,89,121,124,131,143,170,172,176,200–202</sup> Of the 17 studies, 16 (94%) investigated the effect of antibiotic exposure in the first five years of life (15 (88%) in the first two years of life).<sup>162–171</sup> Overall, 12 (71%) studies reported a significant increased weight gain in children who were exposed to antibiotics.<sup>23,27,38,54,71,121,124,131,143,172,201,202</sup> Three studies reported that the strongest association with antibiotic exposure and developing increased weight gain was observed after exposure to macrolides.<sup>121,124,201</sup> Two studies reported that the association between antibiotic exposure and increased weight gain was stronger in boys.<sup>23,121</sup> In two studies the risk of increased weight gain



increased the number of antibiotic courses given<sup>33,121</sup> and in one study an association could only be found when antibiotics were given in the first six months of life.<sup>143</sup> In contrast, another study did not find increased weight gain after antibiotic exposure in the first six months of life but in first two years of life.<sup>54</sup> Four studies found a higher risk of overweight after exposure to macrolides,<sup>54,89,121,124</sup> while no clear influence of different antibiotic classes and the risk of increased weight gain could be found in other studies.<sup>33,172,201,202</sup>

Of the 17 studies, 10 (59%) provided sufficient data to be included in the meta-analysis (supplementary Fig. 12).<sup>14,23,27,33,38,89,121,124,143,172</sup> Of the 311,694 children exposed to antibiotics 90,234 (29%) developed increased weight gain or overweight compared to 47,429 (23%) of the 207,084 children not exposed to antibiotics. Overall, the OR for developing increased weight gain or overweight after antibiotic exposure was 1.18, 95% CI 1.11 to 1.26,  $p < 0.01$  (Fig. 2).

### Obesity

Fourteen studies investigated the association between antibiotic exposure and the risk of developing obesity evaluated by BMI or BMI z-scores in 1,233,944 children (128,132 cases with two studies not reporting number of cases) (Table 1).<sup>14,25,27,33,45,72,81,83,99,125,133,143,147,172</sup> Of the 14 studies, 13 (93%) investigated the effect of antibiotic exposure in the first five years of life (12 (86%) in the first two years of life).<sup>14,25,27,33,72,81,83,99,125,133,143,147,172</sup> Overall, nine (64%) studies reported a significant increased incidence of obesity in children who were exposed to antibiotics.<sup>14,25,27,81,99,125,133,147,172</sup> Three studies reported that the risk of obesity increased with the number of antibiotic courses.<sup>33,72,133</sup> One study reported that the risk of developing obesity was highest with antibiotic exposure in the first six months of life.<sup>25</sup> One study found an increased risk of obesity only after exposure to trimethoprim/sulfamethoxazole but not penicillins, cephalosporins and macrolides.<sup>33</sup> No influence of different antibiotic classes and the risk of increased weight gain was found in two other studies.<sup>133,172</sup>

Of the 14 studies, 10 (71%) provided sufficient data to be included in the meta-analysis (supplementary Fig. 13).<sup>25,27,33,45,72,125,133,143,147,172</sup> Of the 508,908 children exposed to antibiotics 72,186 (14%) developed obesity compared to 30,996 (12%) of the 260,057 children not exposed to antibiotics 47,429 (23%). The overall OR for developing obesity after antibiotic exposure was 1.21, 95% CI 1.05 to 1.40,  $p < 0.01$  (Fig. 2).

### Growth failure

Three studies investigated the association between antibiotic exposure and growth failure evaluated by weight, weight z-scores or weight-for-height z-scores in 13,364 children.<sup>71,145,203</sup> Only one study found that antibiotics were associated with decreased weight gain, this was a small study investigating antibiotic exposure in the first week of life and weight at one year of age.<sup>71</sup>

### Juvenile idiopathic arthritis

Two studies investigated the association between antibiotic exposure and the risk of developing juvenile idiopathic arthritis (JIA) by evaluating ICD codes in 8149 children (1450 cases).<sup>18,64</sup> One study investigated antibiotic exposure in the first and second year of life and any antibiotic exposure before diagnosis<sup>18</sup> and the other study any antibiotic exposure before diagnosis.<sup>64</sup> The risk of developing JIA was increased after antibiotic exposure at all these time points. In the first year of life the strongest association was found after exposure to penicillins and cephalosporins and at the later

time points after exposure to lincosamides and cephalosporins.<sup>18</sup> One study reported that the risk of JIA increased with the number of antibiotic courses.<sup>64</sup>

Both studies were included in the meta-analysis the OR was 1.74 (95%CI 1.21–2.52),  $p < 0.01$  (Fig. 2 and supplementary data Fig. 14).<sup>18,64</sup> Of the 6809 children exposed to antibiotics 1291 (19%) developed JIA compared to 159 (12%) of the 1340 children not exposed to antibiotics.

### Psoriasis

One study investigated the association between antibiotic exposure and the risk of developing psoriasis by evaluating ICD codes in 9295 children (845 cases).<sup>65</sup> They investigated antibiotic exposure in the two years before diagnosis. The OR was 1.75 (95%CI 1.44–2.11),  $p < 0.01$  (adjusted OR 1.20 ((95%CI 1.00–1.50),  $p = 0.05$ )) (Fig. 2 and supplementary data Fig. 15). Of the 7053 children exposed to antibiotics 710 (10%) developed psoriasis compared to 135 (6%) of the 2242 children not exposed to antibiotics.

### Type 1 diabetes

Six studies investigated the association between antibiotic exposure and the risk of developing type 1 diabetes in 2,469,967 children (5557 cases).<sup>36,94,140,152,171,204</sup> The diagnosis was mainly made by ICD codes; in one study by hospital discharge or prescription records. Of the six studies, five (83%) evaluated antibiotic exposure before the age of two years.<sup>36,94,140,152,171</sup> Only one of the studies reported an increased risk of developing type 1 diabetes in children who were exposed to antibiotics, this was in children who had an exposure in the first year of life.<sup>152</sup> No association between the number of antibiotic courses and the risk of type 1 diabetes could be found.<sup>94,140</sup> Two studies found a slightly higher risk of type 1 diabetes after exposure to broad-spectrum antibiotics<sup>36,94</sup> and one after exposure to macrolides compared to penicillins.<sup>204</sup>

Five (83%) studies were included in the meta-analysis the overall OR was 0.99 (95%CI 0.82–1.19),  $p = 0.93$  (Fig. 2 and supplementary data Fig. 16).<sup>36,67,94,152,171</sup> Of the 1,420,794 children exposed to antibiotics 3428 (0.24%) developed type 1 diabetes compared to 1726 (0.18%) of the 947,331 children not exposed to antibiotics.

### Fluorosis

One study investigated the association between antibiotic exposure and the development of fluorosis.<sup>63</sup> The study did not find an increased risk of developing fluorosis in children who were exposed to antibiotics. The OR was 1.11 (95%CI 0.40–3.09),  $p = 0.85$  (Fig. 2 and supplementary data Fig. 17). Of the 174 children exposed to antibiotics 62 (36%) developed fluorosis compared to 6 (33%) of the 18 children not exposed to antibiotics.

### Autism spectrum disorders

Three studies investigated the association between antibiotic exposure and the risk of developing autism spectrum disorders evaluated by ICD codes in 901,012 children (11,374 cases).<sup>21,57,172</sup> All three studies investigated antibiotic exposure in the first two years of life.<sup>21,57,172</sup> Two studies found an association between antibiotic exposure and the development of autism spectrum disorders.<sup>21,172</sup> However, one study only after exposure to cephalosporins and not penicillins, macrolides or sulfonamides.<sup>172</sup> The other study reported that the risk of autism was higher for broad-spectrum antibiotics compared to penicillins.<sup>21</sup> Two studies reported a decreased risk of autism spectrum disorders after exposure to penicillins and one after exposure to macrolides.<sup>57,172</sup> The one study which investigated the effect of the number of antibiotic



courses on the risk of autism spectrum disorders could not find an association.<sup>57</sup>

All three studies were included in the meta-analysis the overall OR was 1.19 (95%CI 1.04–1.36),  $p=0.01$  (Fig. 2 and supplementary data Fig. 18).<sup>21,57,172</sup> Of the 587,667 children exposed to antibiotics 7779 (1.3%) developed autism spectrum disorders compared to 3595 (1.1%) of the 313,345 children not exposed to antibiotics.

### Attention deficit hyperactivity disorder

Four studies investigated the association between antibiotic exposure and the development of attention deficit hyperactivity disorders (ADHD) in 756,348 children (25,143 cases with one study not reporting number of cases).<sup>22,58,130,172</sup> They evaluated children by ICD codes. All four studies evaluated antibiotic exposure before two years of age.<sup>22,58,130,172</sup> Two studies reported a significant increased risk of developing ADHD in children who were exposed to antibiotics.<sup>130,172</sup> One study could not find a difference in the risk of developing ADHD after exposure to penicillins or broad-spectrum antibiotics,<sup>22</sup> while another study found an increased risk after exposure to penicillin in girls compared to other antibiotic classes.<sup>172</sup>

Three (75%) studies were included in the meta-analysis and the overall OR was 1.30 (95%CI 0.97–1.75),  $p=0.08$  (Fig. 2 and supplementary data Fig. 19).<sup>22,58,172</sup> Of the 528,497 children exposed to antibiotics 18,073 (3%) developed ADHD compared to 7070 (3%) of the 227,405 children not exposed to antibiotics.

### Neurodevelopmental disorders

Two studies investigated the association between antibiotic exposure and the development of neurodevelopmental disorders.<sup>130,172</sup> Both studies evaluated antibiotic exposure before two years of age. The first study found an increased risk of developing learning disorders in children who were exposed to antibiotics in the first two years of life (Fig. 2 and supplementary data Fig. 20).<sup>172</sup> The second study found that exposure to antibiotics in first 6 months of life was associated with lower overall cognitive and verbal comprehension abilities, an increased risk of developing problems with metacognition, executive function, impulsivity, hyperactivity, ADHD, anxiety and emotional problems.<sup>130</sup>

### Discussion

Our rigorous systematic review and meta-analysis suggest an association between antibiotic exposure and the development of several immunological, metabolic, and neurobehavioural adverse long-term health outcomes in children. For developing wheezing and asthma the risk is nearly double in children who are exposed to antibiotics, for JIA and allergic rhinoconjunctivitis up to 75% higher, for food allergies and atopic dermatitis up to 38% higher and for increased weight gain, overweight and obesity 20% higher. No association was found between antibiotic exposure and the risk of developing allergic sensitisation, abdominal pain, inflammatory bowel diseases, celiac disease, type 1 diabetes, psoriasis, fluorosis. There is limited data in relation to the association between antibiotic exposure and developing neuropsychological diseases, however three studies suggest an association between antibiotic exposure and the development of ADHD or learning disorders.<sup>22,130,172</sup>

Our findings are in line with these from smaller systematic reviews which indicated that antibiotic exposure is associated with the development of allergic symptoms such as allergic rhinoconjunctivitis, atopic dermatitis, food allergies, as well as asthma and obesity, but not celiac disease or autism spectrum disorder.<sup>205–218</sup> In contrast, previous reviews have reported an association between antibiotic exposure and the development of inflammatory bowel

diseases, especially Crohn's disease.<sup>219–222</sup> However, these reviews either included less studies, did not pool the results from different studies or included children who were born preterm.

There is an association between the timing, number and type of antibiotic exposure and the risk of adverse health outcomes. Most of the studies included in this review investigated early-life exposure to antibiotics (in the first two years of age). This coincides with the time when antibiotic consumption is at its highest.<sup>4,5</sup> Up to 70% of children receive antibiotics during the second year of life.<sup>4,5</sup> One of the main reasons for antibiotic exposure in this age group are respiratory tract infections, including otitis media, for which antibiotics could be deferred or even avoided.<sup>223–225</sup> Additionally, many studies show that the risk of adverse long-term health outcomes increases with the number of antibiotic courses, particularly for asthma.<sup>13,25,29,32,61,64,76,78,93,103,109,111,115,116,121,123,148,154,176,181,182,191,195,197,198,201</sup> Moreover, the risk of adverse long-term health outcomes is often higher for antibiotics with a broad-spectrum including cephalosporins and macrolides.<sup>18,21,34,36,57,58,61,69,78,91,92,111,121,123,137,157,163,172,182,195,197</sup> These findings underline the importance of antibiotic stewardship, specifically to avoid antibiotics for infections that are likely viral and to use the most narrow-spectrum antibiotic possible.<sup>226</sup> A recent large population-based prospective study showed that a reduction in the incidence of asthma in children correlated with the decrease in antibiotic exposure during infancy.<sup>227</sup>

One of the most probable mechanism underlying the association between antibiotic exposure and adverse long-term health outcomes is changes in the microbiota. It is well known that antibiotics cause profound changes in the microbiota.<sup>228,229</sup> The disruption of intestinal microbiota in the early-life period, during which the microbiota and the immune response develop currently, is likely associated with the development of immune- and non-immune-mediated diseases.<sup>230,231</sup> Even transient perturbations of the microbiota during this 'critical window' may compromise immune tolerance and inflammatory responses.<sup>232</sup>

The disruption of intestinal microbiota in the early-life period has been associated with an increased risk of development of the same diseases as antibiotic exposure, including allergies, eczema, asthma, chronic inflammatory bowel disease, obesity and type 1 diabetes.<sup>125,230,233,234</sup> In adolescents with ADHD, perturbations of the intestinal microbiota has also been described.<sup>235</sup>

The strengths of this review are the comprehensive literature search and depth of the review. Most of the included studies defined outcomes using validated tools, adjusted their estimates appropriately, and investigated antibiotic exposure in the first two years of life, which decreases heterogeneity. However, any antibiotic exposure beyond this period could impact the outcome and ignoring them could dilute the effect observed. The same is true for any antibiotic exposure not measured due to the multiple potential sources (e.g. emergency department, general practice, hospital, relative, other country, self-administration), and the availability of antibiotics over the counter in some settings.

The studies included are also limited by their observational nature and potential bias, mainly recall. There are also other potential confounding factors, for example the possibility that early or frequent respiratory infections for which antibiotics are prescribed increase the risk of subsequent asthma. In addition, it can be difficult to differentiate the effect of antibiotic exposure from that of the infection being treated.

Protopathic bias, a false conclusion on a causal relationship between exposure and outcome, is also important to consider. For example, it is possible that children who are predisposed to immune-mediated diseases are more likely to have infections that need antibiotics or seek antibiotics. For example, early symptoms of undiagnosed asthma could be mis-

taken for a respiratory tract infection and be treated with antibiotics. Furthermore, the risk of infection in children with a predisposition to immune-mediated diseases is increased in the years preceding the diagnosis,<sup>236</sup> and therefore causation could be in the opposite direction. Likewise for autism spectrum disorders, in which symptoms can be present from birth but is rarely diagnosed before three years of age, difference in antibiotic exposure could reflect difference in practice. Finally, many unmeasured socio-economics factors could also influence both the exposure to antibiotics and the outcomes.

However, the fact that, in many studies, an association between antibiotic exposure and adverse health-outcomes was only found after broad-spectrum antibiotics and the influence of number of doses of antibiotics supports the notion that antibiotics are the cause.

In summary, the studies in our review suggest that antibiotic exposure plays an important role in the development of childhood immune disorders, likely through disruption of the microbiota during early-life.<sup>227</sup> Although a definite causal association cannot be determined from these studies, the results support the meticulous application of sound antibiotic stewardship to avoid potential adverse long-term health outcomes. It also questions the use of antibiotic prophylaxis outside well-recognised indications. Further assessment of long-term outcomes should be included within RCTs comparing antibiotic treatment or prophylaxis to placebo. Future studies are needed to provide evidence-based interventions to prevent adverse long-term outcomes when antibiotics cannot be avoided, such as modifying the intestinal microbiota with directed pre- and probiotics, bacteriophages, or microbial DNA.<sup>237–239</sup>

#### Declaration of Competing Interest

The authors declare no conflict of interest.

#### CRedit authorship contribution statement

**Quynh A Duong:** Investigation, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. **Laure F Pittet:** Writing – review & editing. **Nigel Curtis:** Writing – review & editing. **Petra Zimmermann:** Investigation, Formal analysis, Writing – review & editing.

#### Acknowledgment

We thank Poh Chua for her assistance with the literature search.

#### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.jinf.2022.01.005](https://doi.org/10.1016/j.jinf.2022.01.005).

#### References

- Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010–2011. *JAMA* 2016;**315**:1864–73.
- Machowska A, Stålsby Lundborg C. Drivers of Irrational Use of Antibiotics in Europe. *Int J Environ Res Public Health* 2018;**16**.
- Mueller T, Östergren PO. The correlation between regulatory conditions and antibiotic consumption within the WHO European Region. *Health Policy* 2016;**120**:882–9.
- Hellman J, Grape M, Ternhag A. Antibiotic consumption among a Swedish cohort of children born in 2006. *Acta Paediatr* 2015;**104**:1035–8.
- Resi D, Milandri M, Moro ML. Antibiotic prescriptions in children. *J Antimicrob Chemother* 2003;**52**:282–6.
- Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;**368**:733–43.
- Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *N Engl J Med* 2017;**376**:1419–29.
- Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 2002;**347**:911–20.
- Strachan DP. Hay fever, hygiene, and household size. *Bmj* 1989;**299**:1259–60.
- Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene hypothesis. *Nat Immunol* 2017;**18**:1076–83.
- Hyerne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *Bmj* 2016;**355**:i4919.
- Ahmadizar F, Vijverberg SJH, Arets HGM, et al. Early life antibiotic use and the risk of asthma and asthma exacerbations in children. *Pediatric Allergy & Immunology* 2017;**28**:430–7.
- Ahn KM, Lee MS, Hong SJ, et al. Fever, use of antibiotics, and acute gastroenteritis during infancy as risk factors for the development of asthma in Korean school-age children. *Journal of Asthma* 2005;**42**:745–50.
- Ajslev TA, Andersen CS, Gamborg M, Sorensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. *International Journal of Obesity* 2011;**35**:522–9.
- Alm B, Erdes L, Mollborg P, et al. Neonatal antibiotic treatment is a risk factor for early wheezing. *Pediatrics* 2008;**121**:697–702.
- Alm B, Goksor E, Pettersson R, et al. Antibiotics in the first week of life is a risk factor for allergic rhinitis at school age. *Pediatric Allergy & Immunology* 2014;**25**:468–72.
- Almqvist C, Wettermark B, Hedlin G, Ye W, Lundholm C. Antibiotics and asthma medication in a large register-based cohort study - confounding, cause and effect. *Clinical & Experimental Allergy* 2012;**42**:104–11.
- Arvonen M, Virta LJ, Pokka T, Kroger L, Vahasalo P. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group's greater susceptibility to infections? *Journal of Rheumatology* 2015;**42**:521–6.
- Aversa Z, Atkinson EJ, Schafer MJ, et al. Association of Infant Antibiotic Exposure With Childhood Health Outcomes. *Mayo Clinic Proceedings* 2021;**96**:66–77.
- Awasthi S, Kalra E, Roy S, Awasthi S. Prevalence and risk factors of asthma and wheeze in school-going children in Lucknow. *North India. Indian Pediatrics* 2004;**41**:1205–10.
- Axelsson PB, Clausen TD, Petersen AH, et al. Relation Between Infant Microbiota and Autism?: Results from a National Cohort Sibling Design Study. *Epidemiology* 2019;**30**:52–60.
- Axelsson PB, Clausen TD, Petersen AH, et al. Investigating the effects of cesarean delivery and antibiotic use in early childhood on risk of later attention deficit hyperactivity disorder. *Journal of Child Psychology & Psychiatry & Allied Disciplines* 2019;**60**:151–9.
- Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. *International Journal of Obesity* 2014;**38**:1290–8.
- Azad MB, Konya T, Guttman DS, et al. Infant gut microbiota and food sensitization: associations in the first year of life. *Clinical & Experimental Allergy* 2015;**45**:632–43.
- Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. *JAMA Pediatrics* 2014;**168**:1063–9.
- Batool T, Reece PL, Schulze KM, et al. Prenatal and early-life predictors of atopy and allergic disease in Canadian children: results of the Family Atherosclerosis Monitoring In early life (FAMILY) Study. *Journal of Developmental Origins of Health and Disease* 2016;**7**:665–71.
- Block JP, Bailey LC, Gillman MW, et al. Early Antibiotic Exposure and Weight Outcomes in Young Children. *Pediatrics* 2018;**142**:12.
- Bohme M, Lannero E, Wickman M, Nordvall SL, Wahlgren CF. Atopic dermatitis and concomitant disease patterns in children up to two years of age. *Acta Dermato-Venereologica* 2002;**82**:98–103.
- Bremner SA, Carey IM, DeWilde S, et al. Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network. *Clinical & Experimental Allergy* 2003;**33**:1518–25.
- Canova C, Ludvigsson JF, Di Domenicantonio R, Zanier L, Barbiellini Amidei C, Zingone F. Perinatal and Antibiotic Exposures and the Risk of Developing Childhood-Onset Inflammatory Bowel Disease: A Nested Case-Control Study Based on a Population-Based Birth Cohort. *International Journal of Environmental Research & Public Health* 2020;**17**(02) [Electronic Resource].
- Celedon JC, Fuhlbrigge A, Rifas-Shiman S, Weiss ST, Finkelstein JA. Antibiotic use in the first year of life and asthma in early childhood. *Clinical & Experimental Allergy* 2004;**34**:1011–16.
- Celedon JC, Litonjua AA, Ryan L, Weiss ST, Gold DR. Lack of association between antibiotic use in the first year of life and asthma, allergic rhinitis, or eczema at age 5 years. *American Journal of Respiratory & Critical Care Medicine* 2002;**166**:72–5.
- Chelimo C, Camargo CA Jr, Morton SMB, Grant CC. Association of Repeated Antibiotic Exposure Up to Age 4 Years With Body Mass at Age 4.5 Years. *JAMA Network Open* 2020;**3**:e1917577.
- Chen IL, Huang HC, Chang YH, et al. Effect of antibiotic use for acute bronchitis on new-onset asthma in children. *Scientific Reports* 2018;**8**:6090.
- Chinratapanisit S, Suratannon N, Pacharn P, Sritipsukho P, Vichyanond P. Prevalence and risk factors of allergic rhinitis in children in Bangkok area. *Asian Pacific Journal of Allergy & Immunology* 2019;**37**:232–9.

36. Clausen TD, Bergholt T, Bouaziz O, et al. Broad-Spectrum Antibiotic Treatment and Subsequent Childhood Type 1 Diabetes: A Nationwide Danish Cohort Study. *PLoS ONE* 2016;**11**:e0161654 [Electronic Resource].
37. Cohet C, Cheng S, MacDonald C, et al. Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood. *Journal of Epidemiology & Community Health* 2004;**58**:852–7.
38. Dawson-Hahn EE, Rhee KE. The association between antibiotics in the first year of life and child growth trajectory. *BMC Pediatrics* 2019;**19**:23.
39. Del-Rio-Navarro B, Berber A, Blandon-Vijil V, et al. Identification of asthma risk factors in Mexico City in an International Study of Asthma and Allergy in Childhood survey. *Allergy & Asthma Proceedings* 2006;**27**:325–33.
40. Dom S, Droste JH, Sariachvili MA, et al. Pre- and post-natal exposure to antibiotics and the development of eczema, recurrent wheezing and atopic sensitization in children up to the age of 4 years. *Clinical & Experimental Allergy* 2010;**40**:1378–87.
41. Donovan BM, Abreo A, Ding T, et al. Dose, Timing, and Type of Infant Antibiotic Use and the Risk of Childhood Asthma. *Clinical Infectious Diseases* 2020;**70**:1658–65.
42. Dowhower Karpa K, Paul IM, Leckie JA, et al. A retrospective chart review to identify perinatal factors associated with food allergies. *Nutrition Journal* 2012;**11**:87.
43. Droste JH, Wieringa MH, Weyler JJ, Nelen VJ, Vermeire PA, Van Bever HP. Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease? *Clinical & Experimental Allergy* 2000;**30**:1547–53.
44. Dydensborg Sander S, Nybo Andersen AM, Murray JA, Karlstad O, Husby S, Stordal K. Association Between Antibiotics in the First Year of Life and Celiac Disease. *Gastroenterology* 2019;**156**:2217–29.
45. Edmonson MB, Eickhoff JC. Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis. *JAMA Pediatrics* 2017;**171**:150–6.
46. Eggesbo M, Botten G, Stigum H, Nafstad P, Magnus P. Is delivery by cesarean section a risk factor for food allergy? *Journal of Allergy & Clinical Immunology* 2003;**112**:420–6.
47. Eldeirawi KM, Kunzweiler C, Atek A, Persky VW. Antibiotic use in infancy and the risk of asthma in Mexican American children. *Journal of Asthma* 2015;**52**:707–14.
48. Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. *Thorax* 1998;**53**:927–32.
49. Floitstrup H, Swartz J, Bergstrom A, et al. Allergic disease and sensitization in Steiner school children. *Journal of Allergy & Clinical Immunology* 2006;**117**:59–66.
50. Foliaki S, Pearce N, Bjorksten B, et al. Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies in Childhood Phase III. *Journal of Allergy & Clinical Immunology* 2009;**124**:982–9.
51. Gao X, Yan Y, Zeng G, et al. Influence of prenatal and early-life exposures on food allergy and eczema in infancy: a birth cohort study. *BMC Pediatrics* 2019;**19**:239.
52. Garcia E, Aristizabal G, Vasquez C, Rodriguez-Martinez CE, Sarmiento OL, Sotizabal CL. Prevalence of and factors associated with current asthma symptoms in school children aged 6–7 and 13–14 yr old in Bogota. *Colombia. Pediatric Allergy & Immunology* 2008;**19**:307–14.
53. Garcia-Marcos L, Gonzalez-Diaz C, Garvajal-Uruena I, et al. Early exposure to paracetamol or to antibiotics and eczema at school age: modification by asthma and rhinoconjunctivitis. *Pediatric Allergy & Immunology* 2010;**21**:1036–42.
54. Gerber JS, Bryan M, Ross RK, et al. Antibiotic Exposure During the First 6 Months of Life and Weight Gain During Childhood. *Jama* 2016;**315**:1258–65.
55. Goksor E, Alm B, Pettersson R, et al. Early fish introduction and neonatal antibiotics affect the risk of asthma into school age. *Pediatric Allergy & Immunology* 2013;**24**:339–44.
56. Goksor E, Alm B, Thengilsdottir H, Pettersson R, Aberg N, Wennergren G. Preschool wheeze - impact of early fish introduction and neonatal antibiotics. *Acta Paediatrica* 2011;**100**:1561–6.
57. Hamad AF, Alessi-Severini S, Mahmud SM, Brownell M, Kuo IF. Early childhood antibiotics use and autism spectrum disorders: a population-based cohort study. *International Journal of Epidemiology* 2018;**47**:1497–506.
58. Hamad AF, Alessi-Severini S, Mahmud SM, Brownell M, Kuo IF. Antibiotic Exposure in the First Year of Life and the Risk of Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study. *American Journal of Epidemiology* 2019;**188**:1923–31.
59. Han YY, Forno E, Badellino HA, Celedon JC. Antibiotic Use in Early Life, Rural Residence, and Allergic Diseases in Argentinean Children. *The Journal of Allergy & Clinical Immunology in Practice* 2017;**5**:1112–18 e2.
60. Harris JM, Mills P, White C, Moffat S, Newman Taylor AJ, Cullinan P. Recorded infections and antibiotics in early life: associations with allergy in UK children and their parents. *Thorax* 2007;**62**:631–7.
61. Hirsch AG, Pollak J, Glass TA, et al. Early-life antibiotic use and subsequent diagnosis of food allergy and allergic diseases. *Clinical & Experimental Allergy* 2017;**47**:236–44.
62. Ho CL, Chang LI, Wu WF. The prevalence and risk factors of atopic dermatitis in 6–8 year-old first graders in Taipei. *Pediatrics & Neonatology* 2019;**60**:166–71.
63. Hong L, Levy SM, Warren JJ, Broffitt B. Amoxicillin use during early childhood and fluorosis of later developing tooth zones. *Journal of Public Health Dentistry* 2011;**71**:229–35.
64. Horton DB, Scott FI, Haynes K, et al. Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case-Control Study. *Pediatrics* 2015;**136**:e333–43.
65. Horton DB, Scott FI, Haynes K, et al. Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis: A Nested Case-Control Study. *JAMA Dermatology* 2016;**152**:191–9.
66. Hoskin-Parr L, Teyhan A, Blocker A, Henderson AJ. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. *Pediatric Allergy & Immunology* 2013;**24**:762–71.
67. Hviid A, Svanstrom H. Antibiotic use and type 1 diabetes in childhood. *American Journal of Epidemiology* 2009;**169**:1079–84.
68. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. *Gut* 2011;**60**:49–54.
69. Jedrychowski W, Perera F, Maugeri U, et al. Wheezing and asthma may be enhanced by broad spectrum antibiotics used in early childhood. Concept and results of a pharmacoepidemiology study. *Journal of Physiology & Pharmacology* 2011;**62**:189–95.
70. Johnson CC, Ownby DR, Alford SH, et al. Antibiotic exposure in early infancy and risk for childhood atopy. *Journal of Allergy & Clinical Immunology* 2005;**115**:1218–24.
71. Kamphorst K, Oosterloo BC, Vlieger AM, et al. Antibiotic Treatment in the First Week of Life Impacts the Growth Trajectory in the First Year of Life in Term Infants. *Journal of Pediatric Gastroenterology & Nutrition* 2019;**69**:131–6.
72. Kelly D, Kelly A, O'Dowd T, Hayes CB. Antibiotic use in early childhood and risk of obesity: longitudinal analysis of a national cohort. *World Journal of Pediatrics* 2019;**15**:390–7.
73. Kemppainen KM, Vehik K, Lynch KF, et al. Association Between Early-Life Antibiotic Use and the Risk of Islet or Celiac Disease Autoimmunity. *JAMA Pediatrics* 2017;**171**:1217–25.
74. Kim WK, Kwon JW, Seo JH, et al. Interaction between IL13 genotype and environmental factors in the risk for allergic rhinitis in Korean children. *Journal of Allergy & Clinical Immunology* 2012;**130**:421–6 e5.
75. Korpela K, Salonen A, Virta LJ, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. *Nature communications* 2016;**7**:10410.
76. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. *Chest* 2007;**131**:1753–9.
77. Krenz-Niedbala M, Koscinski K, Puch EA, Zelent A, Breborowicz A. Is the Relationship Between Breastfeeding and Childhood Risk of Asthma and Obesity Mediated by Infant Antibiotic Treatment? *Breastfeeding Medicine: The Official Journal of the Academy of Breastfeeding Medicine* 2015;**10**:326–33.
78. Kronman MP, Zautout TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. *Pediatrics* 2012;**130**:e794–803.
79. Kummeling I, Stelma FF, Dagnelie PC, et al. Early life exposure to antibiotics and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOALA Birth Cohort Study. *Pediatrics* 2007;**119**:e225–31.
80. Kusel MM, de Klerk N, Holt PG, Sly PD. Antibiotic use in the first year of life and risk of atopic disease in early childhood. *Clinical & Experimental Allergy* 2008;**38**:1921–8.
81. Leong KSW, McClay J, Derraik JGB, et al. Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years. *JAMA Network Open* 2020;**3**:e1919681.
82. Levin ME, Botha M, Basera W, et al. Environmental factors associated with allergy in urban and rural children from the South African Food Allergy (SAFFA) cohort. *Journal of Allergy & Clinical Immunology* 2020;**145**:415–26.
83. Li DK, Chen H, Ferber J, Odouli R. Infection and antibiotic use in infancy and risk of childhood obesity: a longitudinal birth cohort study. *The Lancet Diabetes & Endocrinology* 2017;**5**:18–25.
84. Li M, Lu ZK, Amrol DJ, et al. Antibiotic Exposure and the Risk of Food Allergy: Evidence in the US Medicaid Pediatric Population. *The Journal of Allergy & Clinical Immunology in Practice* 2019;**7**:492–9.
85. Loo EX, Shek LP, Goh A, et al. Atopic Dermatitis in Early Life: Evidence for at Least Three Phenotypes? Results from the GUSTO Study. *International Archives of Allergy & Immunology* 2015;**166**:273–9.
86. Mai XM, Kull I, Wickman M, Bergstrom A. Antibiotic use in early life and development of allergic diseases: respiratory infection as the explanation. *Clinical & Experimental Allergy* 2010;**40**:1230–7.
87. Majkowska-Wojciechowska B, Pelka J, Korzon L, et al. Prevalence of allergy, patterns of allergic sensitization and allergy risk factors in rural and urban children. *Allergy* 2007;**62**:1044–50.
88. Martel MJ, Rey E, Malo JL, et al. Determinants of the incidence of childhood asthma: a two-stage case-control study. *American Journal of Epidemiology* 2009;**169**:195–205.
89. Mbakwa CA, Scheres L, Penders J, Mommers M, Thijs C, Arts IC. Early Life Antibiotic Exposure and Weight Development in Children. *Journal of Pediatrics* 2016;**176**:105–13.e2.
90. McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. *Journal of Allergy & Clinical Immunology* 2002;**109**:43–50.
91. Metsala J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Mother's and offspring's use of antibiotics and infant allergy to cow's milk. *Epidemiology* 2013;**24**:303–9.



92. Metsala J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. *Clinical & Experimental Allergy* 2015;**45**:137–45.
93. Metzler S, Frei R, Schmauser-Hechfellner E, et al. Association between antibiotic treatment during pregnancy and infancy and the development of allergic diseases. *Pediatric Allergy & Immunology* 2019;**30**:423–33.
94. Mikkelsen KH, Knop FK, Vilsbøll T, Frost M, Hallas J, Pottegard A. Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study. *Diabetic Medicine* 2017;**34**:272–7.
95. Mitchell EA, Stewart AW, Clayton T, et al. Cross-sectional survey of risk factors for asthma in 6–7-year-old children in New Zealand: International Study of Asthma and Allergy in Childhood Phase Three. *Journal of Paediatrics & Child Health* 2009;**45**:375–83.
96. Mitre E, Susi A, Kropp LE, Schwartz DJ, Gorman GH, Nylund CM. Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood. *JAMA Pediatrics* 2018;**172**:e180315.
97. Muc M, Padez C, Pinto AM. Exposure to paracetamol and antibiotics in early life and elevated risk of asthma in childhood. *Advances in Experimental Medicine & Biology* 2013;**788**:393–400.
98. Mullooly JP, Schuler R, Barrett M, Maher JE. Vaccines, antibiotics, and atopy. *Pharmacoepidemiology & Drug Safety* 2007;**16**:275–88.
99. Murphy R, Stewart AW, Braithwaite I, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. *International Journal of Obesity* 2014;**38**:1115–19.
100. Myleus A, Hernell O, Gøthefors L, et al. Early infections are associated with increased risk for celiac disease: an incident case-referent study. *BMC Pediatrics* 2012;**12**:194.
101. Neto ACP, Sole D, Hirakata V, Schmid LS, Klock C, Barreto SSM. Risk factors for asthma in schoolchildren in Southern Brazil. *Allergologia et Immunopathologia* 2020;**48**:237–43.
102. Ni J, Friedman H, Boyd BC, et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. *BMC Pediatrics* 2019;**19**:225.
103. Norback D, Lu C, Zhang Y, et al. Sources of indoor particulate matter (PM) and outdoor air pollution in China in relation to asthma, wheeze, rhinitis and eczema among pre-school children: Synergistic effects between antibiotics use and PM<sub>10</sub> and second hand smoke. *Environment International* 2019;**125**:252–60.
104. Ong MS, Umetsu DT, Mandl KD. Consequences of antibiotics and infections in infancy: bugs, drugs, and wheezing. *Annals of Allergy, Asthma, & Immunology* 2014;**112**:441–5 e1.
105. Oosterloo BC, van Elburg RM, Rutten NB, et al. Wheezing and infantile colic are associated with neonatal antibiotic treatment. *Pediatric Allergy & Immunology* 2018;**29**:151–8.
106. Ortvist AK, Lundholm C, Halfvarson J, Ludvigsson JF, Almqvist C. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. *Gut* 2019;**68**:218–25.
107. Ortvist AK, Lundholm C, Kieler H, et al. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. *BMJ* 2014;**349**:g6979.
108. Park YM, Lee SY, Kim WK, et al. Risk factors of atopic dermatitis in Korean schoolchildren: 2010 international study of asthma and allergies in childhood. *Asian Pacific Journal of Allergy & Immunology* 2016;**34**:65–72.
109. Patrick DM, Sbihi H, Dai DLY, et al. Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies. *The Lancet Respiratory Medicine* 2020;**8**:1094–105.
110. Penaranda A, Aristizabal G, Garcia E, Vasquez C, Rodriguez-Martinez CE, Sotizabal CL. Allergic rhinitis and associated factors in schoolchildren from Bogota, Colombia. *Rhinology* 2012;**50**:122–8.
111. Pitter G, Ludvigsson JF, Romor P, et al. Antibiotic exposure in the first year of life and later treated asthma, a population based birth cohort study of 143,000 children. *European Journal of Epidemiology* 2016;**31**:85–94.
112. Ponsosby AL, Couper D, Dwyer T, Carmichael A, Kemp A. Relationship between early life respiratory illness, family size over time, and the development of asthma and hay fever: a seven year follow up study. *Thorax* 1999;**54**:664–669.
113. Poulsen MN, Pollak J, Bailey-Davis L, Hirsch AG, Glass TA, Schwartz BS. Associations of prenatal and childhood antibiotic use with child body mass index at age 3 years. *Obesity* 2017;**25**:438–44.
114. Purvis DJ, Thompson JM, Clark PM, et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. *British Journal of Dermatology* 2005;**152**:742–9.
115. Raciborski F, Tomaszewska A, Komorowski J, et al. The relationship between antibiotic therapy in early childhood and the symptoms of allergy in children aged 6–8 years - the questionnaire study results. *International Journal of Occupational Medicine & Environmental Health* 2012;**25**:470–80.
116. Risnes KR, Belanger K, Murk W, Bracken MB. Antibiotic exposure by 6 months and asthma and allergy at 6 years: Findings in a cohort of 1,401 US children. *American Journal of Epidemiology* 2011;**173**:310–18.
117. Rogawski ET, Platts-Mills JA, Seidman JC, et al. Early Antibiotic Exposure in Low-resource Settings Is Associated With Increased Weight in the First Two Years of Life. *Journal of Pediatric Gastroenterology & Nutrition* 2017;**65**:350–6.
118. Rogawski ET, Westreich DJ, Adair LS, et al. Early Life Antibiotic Exposure Is Not Associated with Growth in Young Children of Vellore. *India. Journal of Pediatrics* 2015;**167**:1096–102 e3.
119. Rusconi F, Gagliardi L, Galassi C, et al. Paracetamol and antibiotics in childhood and subsequent development of wheezing/asthma: association or causation? *International Journal of Epidemiology* 2011;**40**:662–7.
120. Rutter CE, Silverwood RJ, Williams HC, et al. Are Environmental Factors for Atopic Eczema in ISAAC Phase Three due to Reverse Causation? *Journal of Investigative Dermatology* 2019;**139**:1023–36.
121. Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. *Pediatrics* 2015;**135**:617–26.
122. Sandini U, Kukkonen AK, Poussa T, Sandini L, Savilahti E, Kuitunen M. Protective and risk factors for allergic diseases in high-risk children at the ages of two and five years. *International Archives of Allergy & Immunology* 2011;**156**:339–48.
123. Schmitt J, Schmitt NM, Kirch W, Meurer M. Early exposure to antibiotics and infections and the incidence of atopic eczema: a population-based cohort study. *Pediatric Allergy & Immunology* 2010;**21**:292–300.
124. Schwartz BS, Pollak J, Bailey-Davis L, et al. Antibiotic use and childhood body mass index trajectory. *International Journal of Obesity* 2016;**40**:615–21.
125. Scott FI, Horton DB, Mamtani R, et al. Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. *Gastroenterology* 2016;**151**:120–9 e5.
126. Semic-Jusufagic A, Belgrave D, Pickles A, et al. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-based birth cohort study. *The Lancet Respiratory Medicine* 2014;**2**:621–30.
127. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. *American Journal of Gastroenterology* 2010;**105**:2687–92.
128. Simon MR, Havstad SL, Wegienka GR, Ownby DR, Johnson CC. Risk factors associated with transient wheezing in young children. *Allergy & Asthma Proceedings* 2008;**29**:161–5.
129. Singh S, Sharma BB, Salvi S, et al. Allergic rhinitis, rhinoconjunctivitis, and eczema: prevalence and associated factors in children. *The clinical respiratory journal* 2018;**12**:547–56.
130. Slykerman RF, Coomarasamy C, Wickens K, et al. Exposure to antibiotics in the first 24 months of life and neurocognitive outcomes at 11 years of age. *Psychopharmacology* 2019;**236**:1573–82.
131. Smith-Brown P, Morrison M, Krause L, Davies PSW. Microbiota and Body Composition During the Period of Complementary Feeding. *Journal of Pediatric Gastroenterology & Nutrition* 2019;**69**:726–32.
132. Soto-Martinez ME, Yock-Corrales A, Camacho-Badilla K, et al. The current prevalence of asthma, allergic rhinitis, and eczema related symptoms in school-aged children in Costa Rica. *Journal of Asthma* 2019;**56**:360–8.
133. Stark CM, Susi A, Emerick J, Nylund CM. Antibiotic and acid-suppression medications during early childhood are associated with obesity. *Gut* 2019;**68**:62–9.
134. Stromberg Celind F, Wennergren G, Vasileiadou S, Alm B, Goksor E. Antibiotics in the first week of life were associated with atopic asthma at 12 years of age. *Acta Paediatrica* 2018;**107**:1798–804.
135. Su Y, Rothers J, Stern DA, Halonen M, Wright AL. Relation of early antibiotic use to childhood asthma: confounding by indication? *Clinical & Experimental Allergy* 2010;**40**:1222–9.
136. Sultesz M, Katona G, Hirschberg A, Galfy G. Prevalence and risk factors for allergic rhinitis in primary schoolchildren in Budapest. *International Journal of Pediatric Otorhinolaryngology* 2010;**74**:503–9.
137. Sun W, Svendsen ER, Karmaus WJ, Kuehr J, Forster J. Early-life antibiotic use is associated with wheezing among children with high atopic risk: a prospective European study. *Journal of Asthma* 2015;**52**:647–52.
138. Tamay Z, Akcay A, Ergin A, Guler N. Prevalence of allergic rhinitis and risk factors in 6- to 7-year-old children in Istanbul, Turkey. *Turkish Journal of Pediatrics* 2014;**56**:31–40.
139. Tamay Z, Akcay A, Ones U, Guler N, Kilic G, Zencir M. Prevalence and risk factors for allergic rhinitis in primary school children. *International Journal of Pediatric Otorhinolaryngology* 2007;**71**:463–71.
140. Tapia G, Stordal K, Marild K, et al. Antibiotics, acetaminophen and infections during prenatal and early life in relation to type 1 diabetes. *International Journal of Epidemiology* 2018;**47**:1538–48.
141. Taylor-Robinson DC, Williams H, Pearce A, Law C, Hope S. Do early-life exposures explain why more advantaged children get eczema? Findings from the U.K. Millennium Cohort Study. *British Journal of Dermatology* 2016;**174**:569–78.
142. Thomsen SF, Ulrik CS, Porsbjerg C, Backer V. Early life exposures and risk of atopy among Danish children. *Allergy & Asthma Proceedings* 2006;**27**:110–14.
143. Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. *International Journal of Obesity* 2013;**37**:16–23.
144. Uusijarvi A, Bergstrom A, Simren M, et al. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain—a Swedish birth cohort study. *Neurogastroenterology & Motility* 2014;**26**:841–50.
145. Uzan-Yulzari A, Turta O, Belogolovski A, et al. Neonatal antibiotic exposure impairs child growth during the first six years of life by perturbing intestinal microbial colonization. *Nature communications* 2021;**12**:443.
146. Verhulst SL, Vael C, Beunckens C, Nelen V, Goossens H, Desager K. A longitudinal analysis on the association between antibiotic use, intestinal microflora, and wheezing during the first year of life. *Journal of Asthma* 2008;**45**:828–32.
147. Ville AP, Heyman MB, Medrano R, Wojcicki JM. Early Antibiotic Exposure and Risk of Childhood Obesity in Latinos. *Childhood Obesity* 2017;**13**:231–5.
148. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease—a nationwide, register-based Finnish case-control study. *American Journal of Epidemiology* 2012;**175**:775–84.

149. von Mutius E, Illi S, Hirsch T, Epton Z, Leupold W, Keil U, Weiland SK. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. *European Respiratory Journal* 1999;14:4–11.
150. Wang JY, Liu LF, Chen CY, Huang YW, Hsiung CA, Tsai HJ. Acetaminophen and/or antibiotic use in early life and the development of childhood allergic diseases. *International Journal of Epidemiology* 2013;42:1087–99.
151. Wang X, Liu W, Hu Y, Zou Z, Shen L, Huang C. Home environment, lifestyles behaviors, and rhinitis in childhood. *International Journal of Hygiene & Environmental Health* 2016;219:220–31.
152. Wernroth ML, Fall K, Svennblad B, et al. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis. *Diabetes Care* 2020;43:991–9.
153. Wickens K, Ingham T, Epton M, et al. The association of early life exposure to antibiotics and the development of asthma, eczema and atopy in a birth cohort: confounding or causality? *Clinical & Experimental Allergy* 2008;38:1318–24.
154. Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. *Clinical & Experimental Allergy* 1999;29:766–71.
155. Wjst M, Hoelscher B, Frye C, Wichmann HE, Dold S, Heinrich J. Early antibiotic treatment and later asthma. *European Journal of Medical Research* 2001;6:263–71.
156. Wu P, Feldman AS, Rosas-Salazar C, et al. Relative Importance and Additive Effects of Maternal and Infant Risk Factors on Childhood Asthma. *PLoS ONE* 2016;11:e0151705 [Electronic Resource].
157. Yamamoto-Hanada K, Yang L, Narita M, Saito H, Ohya Y. Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5. *Annals of Allergy, Asthma, & Immunology* 2017;119:54–8.
158. Yang SI, Lee E, Jung YH, et al. Effect of antibiotic use and mold exposure in infancy on allergic rhinitis in susceptible adolescents. *Annals of Allergy, Asthma, & Immunology* 2014;113:160–5 e1.
159. Yeh KW, Ou LS, Yao TC, et al. Prevalence and risk factors for early presentation of asthma among preschool children in Taiwan. *Asian Pacific Journal of Allergy & Immunology* 2011;29:120–6.
160. Yoshida S, Ide K, Takeuchi M, Kawakami K. Prenatal and early-life antibiotic use and risk of childhood asthma: A retrospective cohort study. *Pediatric Allergy & Immunology* 2018;29:490–5.
161. Zou Z, Liu W, Huang C, Sun C, Zhang J. First-Year Antibiotics Exposure in Relation to Childhood Asthma, Allergies, and Airway Illnesses. *International Journal of Environmental Research & Public Health* 2020;17(07) [Electronic Resource].
162. Karimi M, Mirzaei M. Antibiotic use and symptoms of asthma, allergic rhinitis and eczema in children. *Iranian Journal of Pediatrics* 2009;19:141–6.
163. Love BL, Mann JR, Hardin JW, Lu ZK, Cox C, Amrol DJ. Antibiotic prescription and food allergy in young children. *Allergy Asthma Clin Immunol* 2016;12:41.
164. Lapin B, Piorkowski J, Ownby D, et al. The relationship of early-life antibiotic use with asthma in at-risk children. *J Allergy Clin Immunol* 2014;134:728–9.
165. Kwon JW, Kim BJ, Song Y, et al. Changes in the prevalence of childhood asthma in Seoul from 1995 to 2008 and its risk factors. *Allergy Asthma Immunol Res* 2011;3:27–33.
166. Sharma SK, Banga A. Prevalence and risk factors for wheezing in children from rural areas of north India. *Allergy Asthma Proc* 2007;28:647–53.
167. Illi S, von Mutius E, Lau S, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. *Bmj* 2001;322:390–5.
168. Khalkhali HR, Oshnouei S, Salarilak S, Rahimi Rad M, Karamyar M, Khashabi J. Effects of antibiotic consumption on children 2–8 years of age developing asthma. *Epidemiol Health* 2014;36:e2014006.
169. Lee E, Kwon JW, Kim HB, et al. Association Between Antibiotic Exposure, Bronchiolitis, and TLR4 (rs1927911) Polymorphisms in Childhood Asthma. *Allergy Asthma Immunol Res* 2015;7:167–74.
170. Sejersten TS, Vinding RK, Stokholm J, et al. Antibiotic exposure in infancy and development of BMI and body composition in childhood. *EClinicalMedicine* 2019;17:100209.
171. Antvorskov JC, Morgen CS, Buschard K, Jess T, Allin KH, Josefsen K. Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study. *Pediatr Diabetes* 2020;21:1457–64.
172. Aversa Z, Atkinson EJ, Schafer MJ, et al. Association of Infant Antibiotic Exposure With Childhood Health Outcomes. *Mayo Clin Proc* 2021;96:66–77.
173. Taylor-Robinson DC, Williams H, Pearce A, Law C, Hope S. Do early-life exposures explain why more advantaged children get eczema? Findings from the U.K. Millennium Cohort Study. *Br J Dermatol* 2016;174:569–78.
174. Park YM, Lee SY, Kim WK, et al. Risk factors of atopic dermatitis in Korean schoolchildren: 2010 international study of asthma and allergies in childhood. *Asian Pac J Allergy Immunol* 2016;34:65–72.
175. Loo EX, Shek LP, Goh A, et al. Atopic Dermatitis in Early Life: Evidence for at Least Three Phenotypes? Results from the GUSTO Study. *Int Arch Allergy Immunol* 2015;166:273–9.
176. Hoskin-Parr L, Teyhan A, Blocker A, Henderson AJ. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. *Pediatr Allergy Immunol* 2013;24:762–71.
177. Sandini U, Kukkonen AK, Poussa T, Sandini L, Savilahti E, Kuitunen M. Protective and risk factors for allergic diseases in high-risk children at the ages of two and five years. *Int Arch Allergy Immunol* 2011;156:339–48.
178. Mai XM, Kull I, Wickman M, Bergström A. Antibiotic use in early life and development of allergic diseases: respiratory infection as the explanation. *Clin Exp Allergy* 2010;40:1230–7.
179. McKeever TM, Lewis SA, Smith C, Hubbard R. The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database. *American Journal of Respiratory & Critical Care Medicine* 2002;166:827–32.
180. Böhme M, Lannerö E, Wickman M, Nordvall SL, Wahlgren CF. Atopic dermatitis and concomitant disease patterns in children up to two years of age. *Acta Derm Venereol* 2002;82:98–103.
181. von Mutius E, Illi S, Hirsch T, Leupold W, Keil U, Weiland SK. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. *Eur Respir J* 1999;14:4–11.
182. McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. *J Allergy Clin Immunol* 2002;109:43–50.
183. Batool T, Reece PL, Schulze KM, et al. Prenatal and early-life predictors of atopy and allergic disease in Canadian children: results of the Family Atherosclerosis Monitoring In early Life (FAMILY) Study. *J Dev Orig Health Dis* 2016;7:665–71.
184. Dubakienė R, Rudzėvičienė O, Butienė I, et al. Studies on early allergic sensitization in the Lithuanian birth cohort. *TheScientificWorldJournal* 2012;2012:909524.
185. Marisen J, Hais A, Meyer C, et al. Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0–32+6 weeks of gestation: a randomised, placebo-controlled, double-blind, multicentre trial: the PRIMAL Clinical Study protocol. *BMJ Open* 2019;9:e032617.
186. Wang X, Liu W, Hu Y, Zou Z, Shen L, Huang C. Home environment, lifestyles behaviors, and rhinitis in childhood. *Int J Hyg Environ Health* 2016;219:220–31.
187. Tamay Z, Akçay A, Ergin A, Güler N. Prevalence of allergic rhinitis and risk factors in 6- to 7-year-old children in İstanbul, Turkey. *Turk J Pediatr* 2014;56:31–40.
188. Sultész M, Katona G, Hirschberg A, Gálffy G. Prevalence and risk factors for allergic rhinitis in primary schoolchildren in Budapest. *Int J Pediatr Otorhinolaryngol* 2010;74:503–9.
189. Tamay Z, Akçay A, Ones U, Güler N, Kilic G, Zencir M. Prevalence and risk factors for allergic rhinitis in primary school children. *Int J Pediatr Otorhinolaryngol* 2007;71:463–71.
190. Thomsen SF, Ulrik CS, Porsbjerg C, Backer V. Early life exposures and risk of atopy among Danish children. *Allergy Asthma Proc* 2006;27:110–14.
191. Eldeirawi KM, Kunzweiler C, Atek A, Persky VW. Antibiotic use in infancy and the risk of asthma in Mexican American children. *J Asthma* 2015;52:707–14.
192. Simon MR, Havstad SL, Wegienka GR, Ownby DR, Johnson CC. Risk factors associated with transient wheezing in young children. *Allergy Asthma Proc* 2008;29:161–5.
193. Verhulst SL, Vael C, Beunckens C, Nelen V, Goossens H, Desager K. A longitudinal analysis on the association between antibiotic use, intestinal microflora, and wheezing during the first year of life. *J Asthma* 2008;45:828–32.
194. Awasthi S, Kalra E, Roy S, Awasthi S. Prevalence and risk factors of asthma and wheeze in school-going children in Lucknow, North India. *Indian Pediatr* 2004;41:1205–10.
195. Yoshida S, Ide K, Takeuchi M, Kawakami K. Prenatal and early-life antibiotic use and risk of childhood asthma: A retrospective cohort study. *Pediatr Allergy Immunol* 2018;29:490–5.
196. Örtqvist AK, Lundholm C, Kieler H, et al. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. *Bmj* 2014;349:g6979.
197. Almqvist C, Wettermark B, Hedlin G, Ye W, Lundholm C. Antibiotics and asthma medication in a large register-based cohort study - confounding, cause and effect. *Clin Exp Allergy* 2012;42:104–11.
198. Celedon JC, Weiss ST. Use of antibacterials in infancy: clinical implications for childhood asthma and allergies. *Treatments in Respiratory Medicine* 2004;3:291–4.
199. Myléus A, Hernell O, Gothefors L, et al. Early infections are associated with increased risk for celiac disease: an incident case-referent study. *BMC Pediatr* 2012;12:194.
200. Dawson-Hahn EE, Rhee KE. The association between antibiotics in the first year of life and child growth trajectory. *BMC Pediatrics* 2015;19:23.
201. Poulsen MN, Pollak J, Bailey-Davis L, Hirsch AG, Glass TA, Schwartz BS. Associations of prenatal and childhood antibiotic use with child body mass index at age 3 years. *Obesity (Silver Spring)* 2017;25:438–44.
202. Rogawski ET, Platts-Mills JA, Seidman JC, et al. Early Antibiotic Exposure in Low-resource Settings Is Associated With Increased Weight in the First Two Years of Life. *J Pediatr Gastroenterol Nutr* 2017;65:350–6.
203. Rogawski ET, Westreich DJ, Adair LS, et al. Early Life Antibiotic Exposure Is Not Associated with Growth in Young Children of Vellore, India. *J Pediatr* 2015;167:1096–102 e3.
204. Hviid A, Svanström H. Antibiotic use and type 1 diabetes in childhood. *Am J Epidemiol* 2009;169:1079–84.
205. Ahmadiyar F, Vijverberg SJH, Arets HGM, et al. Early-life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. *Allergy* 2018;73:971–86.

206. Aghaali M, Hashemi-Nazari SS. Association between early antibiotic exposure and risk of childhood weight gain and obesity: a systematic review and meta-analysis. *J Pediatr Endocrinol Metab* 2019;**32**:439–45.
207. Azad MB, Moossavi S, Owora A, Sepehri S. Early-Life Antibiotic Exposure, Gut Microbiota Development, and Predisposition to Obesity. *Nestle Nutr Inst Workshop Ser* 2017;**88**:67–79.
208. Lee E, Cho J, Kim KY. The Association between Autism Spectrum Disorder and Pre- and Postnatal Antibiotic Exposure in Childhood-A Systematic Review with Meta-Analysis. *Int J Environ Res Public Health* 2019;**16**.
209. Tsakok T, McKeever TM, Yeo L, Flohr C. Does early life exposure to antibiotics increase the risk of eczema? A systematic review. *Br J Dermatol* 2013;**169**:983–91.
210. Jordan S, Storey M, Morgan G. Antibiotics and allergic disorders in childhood. *Open Nurs J* 2008;**2**:48–57.
211. Netea SA, Messina NL, Curtis N. Early-life antibiotic exposure and childhood food allergy: A systematic review. *J Allergy Clin Immunol* 2019;**144**:1445–8.
212. Marra F, Marra CA, Richardson K, et al. Antibiotic use in children is associated with increased risk of asthma. *Pediatrics* 2009;**123**:1003–10.
213. Miller SA, Wu RKS, Oremus M. The association between antibiotic use in infancy and childhood overweight or obesity: a systematic review and meta-analysis. *Obes Rev* 2018;**19**:1463–75.
214. Murk W, Risnes KR, Bracken MB. Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. *Pediatrics* 2011;**127**:1125–38.
215. Penders J, Kummeling I, Thijs C. Infant antibiotic use and wheeze and asthma risk: a systematic review and meta-analysis. *Eur Respir J* 2011;**38**:295–302.
216. Rasmussen SH, Shrestha S, Bjerregaard LG, et al. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis. *Diabetes Obes Metab* 2018;**20**:1508–14.
217. Shao X, Ding X, Wang B, et al. Antibiotic Exposure in Early Life Increases Risk of Childhood Obesity: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)* 2017;**8**:170.
218. Baron R, Taye M, der Vaart IB, et al. The relationship of prenatal antibiotic exposure and infant antibiotic administration with childhood allergies: a systematic review. *BMC Pediatr* 2020;**20**:312.
219. Kołodziej M, Patro-Gołąb B, Gieruszczak-Białek D, et al. Association between early life (prenatal and postnatal) antibiotic administration and coeliac disease: a systematic review. *Arch Dis Child* 2019;**104**:1083–9.
220. Kamphorst K, Van Daele E, Vlieger AM, Daams JG, Knol J, van Elburg RM. Early life antibiotics and childhood gastrointestinal disorders: a systematic review. *BMJ Paediatr Open* 2021;**5**:e001028.
221. Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. *Scand J Gastroenterol* 2018;**53**:1–7.
222. Ungaro R, Bernstein CN, Geary R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. *Am J Gastroenterol* 2014;**109**:1728–38.
223. Siddiq S, Grainger J. The diagnosis and management of acute otitis media: American Academy of Pediatrics Guidelines 2013. *Arch Dis Child Educ Pract Ed* 2015;**100**:193–7.
224. Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavy J. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. *BMJ* 2001;**322**:336–42.
225. Spurling GK, Del Mar CB, Dooley L, Foxlee R, Farley R. Delayed antibiotic prescriptions for respiratory infections. *Cochrane Database Syst Rev* 2017;**9**:Cd004417.
226. Grammatico-Guillon L, Abdurrahim L, Shea K, Astagneau P, Pelton S. Scope of Antibiotic Stewardship Programs in Pediatrics. *Clin Pediatr (Phila)* 2019;**58**:1291–301.
227. Patrick DM, Sbihi H, Dai DLY, et al. Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies. *Lancet Respir Med* 2020;**8**:1094–105.
228. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota. *Journal of Infection* 2019 Published online.
229. Zimmermann P, Curtis N. Effect of intrapartum antibiotics on the intestinal microbiota of infants: a systematic review. *Arch Dis Child Fetal Neonatal Edition* 2019.
230. Zimmermann P, Messina N, Mohn WW, Finlay BB, Curtis N. Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: A systematic review. *J Allergy Clin Immunol* 2019;**143**:467–85.
231. Volery M, Scherz V, Jakob W, et al. Study protocol for the ABERRANT study: antibiotic-induced disruption of the maternal and infant microbiome and adverse health outcomes - a prospective cohort study among children born at term. *BMJ Open* 2020;**10**:e036275.
232. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. *Science* 2016;**352**:539–44.
233. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006;**55**:205–11.
234. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol* 2016;**12**:154–67.
235. Aarts E, Ederveen THA, Naaijen J, et al. Gut microbiome in ADHD and its relation to neural reward anticipation. *PLoS One* 2017;**12**:e0183509.
236. Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977–2013. *Am J Gastroenterol* 2015;**110**:1582–7.
237. Wilkins AT, Reimer RA. . Obesity, Early Life Gut Microbiota, and Antibiotics. *Microorganisms* 2021;**9**:413.
238. Shu SA, Yuen AWT, Woo E, et al. Microbiota and Food Allergy. *Clin Rev Allergy Immunol* 2019;**57**:83–97.
239. Sansotta N, Peroni DG, Romano S, Rugiano A, Vuilleumier P, Baviera G. The good bugs: the use of probiotics in pediatrics. *Curr Opin Pediatr* 2019;**31**:661–9.
240. Aghaali M, Hashemi-Nazari SS. Association between early antibiotic exposure and risk of childhood weight gain and obesity: a systematic review and meta-analysis. *Journal of Pediatric Endocrinology & Metabolism* 2019;**32**:439–45.